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GENERAL iNTROdUcTiON, AimS ANd OUTLiNE OF ThE ThESiS
Endoscopic ultrasound (EUS)-guided tissue sampling was introduced in the nineties and offers 
a minimal invasive and accurate modality for real-time tissue acquisition [1, 2]. Since Vilmann 
first described its performance in solid pancreatic lesions, the technique has considerably 
evolved [3]. Today, its use is continuously growing, with an expanding role of tissue analysis 
in the era of patient tailored medicine [4]. Although EUS-guided tissue sampling can indeed 
provide a tissue diagnosis with a high level of diagnostic accuracy, its outcome strongly depends 
on the skills and experience of the performer, the sampling tools and techniques, and the way 
the tissue is handled and processed [5]. Consequently, EUS-guided tissue sampling has been 
subject to numerous innovations.
Adjusting and improving the design of EUS-needles has been and still is a major focus of 
innovation. Traditionally, tissue sampling was performed using fine needle aspiration (FNA) 
devices, which mainly harvest loose target cells for cytologic evaluation. Unfortunately, its 
yield depends on rapid on-site tissue evaluation (ROSE) by a dedicated pathologist, which is 
not generally available in most EUS-centers [6-9]. Furthermore, cytology is suboptimal for the 
identification of tumor invasion or the diagnosing and staging of specific diseases that require 
additional (immunohistochemical and molecular) testing, such as auto-immune pancreatitis, 
submucosal or stromal lesions, and neuro-endocrine tumors [10-12].
Fine needle biopsy (FNB) devices were introduced to overcome these limitations by offering 
the possibility to harvest histologically intact tissue fragments rather than loose target cells. 
Although the first devices, the TruCuttm (Travenol Laboratories, 1980) and Quick-Core® (Cook 
Medical, 2003) needles achieved acceptable diagnostic accuracy rates, their use was hampered 
by a rigid design, and somewhat difficult deployment of the cutting and firing system [13-15]. 
Consequently, the ProCore reversed bevel needle (Cook Medical, Ireland) was introduced in 
2012. This needle has a reverse bevel located at the lateral side near the tip, which collects 
tissue when the needle is moved in a retrograde motion. However, the diagnostic performance 
of the ProCore needle was not convincingly better than the conventional FNA needles [16-20].
As a response to this, several novel FNB needles were designed and introduced. The first 
was an adjusted ProCore needle, only available as 20-gauge (diameter), which has a forward 
facing rather than a reversed bevel, and a more flexible design (Cook Medical, 2015). Secondly, 
the Fork-tip or SharkCore needle (Medtronic, 2016) was introduced, which has a characteristic 
prominent long tip-edge and an opposing beveled tip-edge with a total six distal cutting-edge 
surfaces. Last, the Franseen or Acquire needle (Boston Scientific, 2017) was launched, which 
has a large crown-tip with three cutting edges and a long insertion length. Due to the relatively 
recent introduction of the newest ProCore, Acquire and SharkCore needle, evidence on their 
performance is limited.
Parallel to these needle design innovations, EUS-sampling techniques evolved. One adapta-
tion is the application of negative pressure. With the ‘slow pull technique, the stylet is slowly 
12 Chapter 1
removed during sampling to create negative pressure at the tip of the needle, which should 
promote the harvest of tissue. Another way to increase negative pressure is through suction 
applied by using a vacuum syringe at the proximal end of the sampling device. So far, there is 
no convincing evidence for the benefit of either technique, or superiority of one over the other 
[21]. In addition, the ‘fanning technique’ was introduced, which is named after the fan-like-
movement that is made with the needle within the lesion, allowing the lesion to be targeted 
from different angles, and collecting tissue from different areas of the target lesion. This tech-
nique has been proven to increase the diagnostic accuracy of EUS-guided tissue sampling, and 
is recommended by the European Society for Gastroenterology (ESGE) [22].
Another field of interest is EUS-tissue preservation and processing. Traditionally, specimens 
were collected with FNA-needles, and handled using the so-called ‘smear technique’. Here, the 
collected material is smeared onto a glass slide and stained for pathological analysis. Unfor-
tunately, smears are sensitive to preparation and contamination artifacts, causing suboptimal 
diagnostic accuracy rates [23, 24]. Obviously, it would be ideal to assign a dedicated pathologist 
to handle this on-site, but, as previously mentioned, many centers lack this service due to 
reimbursement and cost issues [6-9].
A way to bypass the vulnerable smear-preparation is to collect the sample in a liquid-based 
medium, the so-called liquid-based cytology (LBC) technique, i.e. ThinPrep, SurePath, Cellprep 
plus, and cell block. LBC makes samples less vulnerable to contamination or artifacts, since 
debris, blood and exudates can easily be removed from the collected tissue sample [25]. 
Furthermore, it allows for ancillary tissue tests, such as immunohistochemistry or molecular 
testing, that could previously only be performed on histological samples. Although these LBC 
tissue preparation techniques have proven their value in other specialties, such as gynaecology, 
its diagnostic benefit in gastroenterology remains to be established [24, 26-35].
Although innovations have evolved rapidly, the number of well-conducted studies to assess 
their value are running behind. Some adaptations may impact others. For example, if the new 
generation FNB needles turn out to outperform FNA, LBC preparations may become redundant.
AimS ANd OUTLiNE OF ThE ThESiS
This thesis explores if and how technical factors can improve the diagnostic outcome of EUS-
guided tissue sampling, by
1. gaining insight in the current practice of the endosonographer community
2. searching for the optimal EUS-sampling device
3. exploring ways to improve EUS-specimen preparation and handling
Part one focuses on the current clinical practice. Although EUS-guided tissue sampling is globally 
established, little is known about intercontinental practice variations. It is also unknown how 
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practice guidelines are locally implemented, especially since they lack firm scientific evidence. 
Therefore, chapter 2 describes the practice patterns of EUS-guided tissue sampling in today’s 
endosonographic community. An online questionnaire was sent out to 400 endosonographers 
from the United States (US), Europe, and Asia to identify differences and concordances be-
tween practice patterns, and to assess how they match the recommendations expressed in the 
guidelines of the American and European Society of Gastroenterology (ASGE and ESGE).
Part II aims to identify the optimal EUS-sampling device by focusing on the diagnostic 
performance of FNA and FNB needles. chapter 3 compares the diagnostic performance of a 
new FNB needle, the 20G ProCore FNB needle, to a conventional FNA needle, the 25G EchoTip 
Ultra device, in terms of diagnostic accuracy, tissue core yield, sample quality, the number of 
needle passes, and the number of adverse events in patients with a solid gastrointestinal lesion. 
A randomized controlled trial, the ASPRO study (Aspiration versus PROcore), was performed in 
13 EUS-centers in the US, Asia, Australia, Europe, and the Middle-East.
Ideally, the performance of a diagnostic device is reproducible in expert and non-expert 
hands. chapter 4 compares the diagnostic agreement on the samples obtained in the above-
mentioned trial amongst academic and non-academic pathologists. In addition, we assess if, 
and to what extent, the experience of the pathologist and the characteristics of the specimen 
influence diagnostic accuracy.
Instead of choosing one EUS-needle over the other, some advocate the use of FNA and FNB 
consecutively (dual needle sampling). chapter 5 therefore explores the yield of combined use 
of the 20G ProCore FNB and the 25G FNA needle in patients with a suspicious solid gastrointes-
tinal lesion, and assesses the indication, the optimal needle order, and safety of this strategy. 
chapter 6 aims to identify the optimal sampling device, by providing an updated meta-analysis 
on the diagnostic performance of FNA compared to the new generation of FNB needles, includ-
ing the ProCore reversed and forward facing bevel, the SharkCore, and the Acquire needle.
The third and final part of this thesis focusses on the optimization of the tissue samples that 
are collected through EUS-guided tissue sampling. It is known that the traditional, so called, 
smear-technique, harbors a high artifact rate. Since most EUS-centers do not have the re-
sources for a dedicated, on-site pathologist to handle and prepare the collected tissue (ROSE), 
chapter 7 explores if a one-day-hands-on tissue preparation training for endoscopy staff can 
improve sample quality and thus diagnostic accuracy. chapter 8 continues to find a solution to 
the suboptimal FNA-sample quality in centers lacking ROSE, by assessing the diagnostic benefit 
of tissue collection using LBC, with the ThinPrep and cell block technique.
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Although Endoscopic Ultrasound (EUS)-guided tissue sampling is widely used, the optimal 
sampling strategy remains subject of debate. We evaluated practice patterns within the inter-
national endosonographic community.
methods
An online questionnaire was sent to 400 endosonographers from the United States (US), Eu-
rope, and Asia.
Results
A total of 186 (47%) endosonographers participated: US 54 (29%), Europe 85 (46%), and Asia 
47(25%). European (75%) and Asian (84%) respondents routinely check coagulation status, 
whereas US respondents only check on indication (64%, p=0.007). While propofol sedation is 
standard in the US (83%), conscious sedation is still widely used in Europe (52%) and Asia (84%, 
p<0.001). Overall, the 22G needle is most commonly used (52%). For FNA of solid pancreatic 
lesions, 22G (45%) and 25G (49%) needles are used equally. For FNB of solid masses, the 25G 
device is less favored than the 22G FNA device (49% versus 21%). The 19G needle is generally 
used for FNB of submucosal masses (62%). Rapid on-site pathological evaluation (ROSE) is uti-
lized more often by US (98%) than by European and Asian respondents (51%, p<0.001). CytoLyt 
(52%), formalin (15%) and alcohol (15%) are used for FNA specimen preservation in the US and 
Europe, while saline (27%) and alcohol (38%) are widely used in Asia (p<0.001).
conclusion
EUS-guided tissue sampling practices vary substantially within the international endosono-
graphic community and differ considerably from recommendations expressed in guidelines. 
As the clinical relevance of these variations is largely unknown, the outcome of this survey 
prompts for further studies.
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iNTROdUcTiON
Endoscopic ultrasound (EUS) guided tissue sampling is a safe and accurate modality to diagnose 
and stage lesions in and around the gastrointestinal tract [1]. It enables clinicians to obtain a 
tissue diagnosis during real-time imaging, using fine-needle aspiration (FNA) or fine-needle bi-
opsy (FNB). The diagnostic accuracy of these sampling techniques ranges from 52 % – 98 % and 
is influenced by several factors including target lesion characteristics, operator skills, needle 
size and type, sampling techniques, presence of an on-site pathologist, and specimen handling 
and processing [2-9].
To provide endosonographers with some guidance, both the American and European Soci-
ety of Gastrointestinal Endoscopy (ASGE and ESGE) issued a set of guidelines [10-16]. In 2011, 
the ESGE published practice guidelines on EUS-guided tissue sampling, covering its indications, 
learning phase, techniques, complications and results [11,12]. They were updated in 2013, add-
ing two new techniques; elastography and contrast enhanced ultrasound [16]. The ASGE has is-
sued practice guidelines concerning sedation, antibiotic prophylaxis, and prevention of adverse 
events. In addition, the Papanicolaou Society of Cytopathology, one of the leading societies in 
cancer cytopathology, published guidelines addressing EUS cytology techniques, terminology, 
ancillary studies, and post procedure management [17,18]. Table 1 compares their most im-
portant recommendations. Unfortunately, due to the limited number of well-conducted studies 
in this field, many of these recommendations lack firm scientific evidence. As a result, today’s 
practice mainly relies on local hospital protocols, expert opinions, and personal preferences.
Although EUS-guided tissue sampling is globally established, little is known about intercon-
tinental variations in clinical practice. It is also unknown how available practice guidelines are 
implemented in current local sampling routines. The purpose of this study was therefore: 1) to 
map the practice patterns in EUS-guided tissue sampling in today’s endosonographic commu-
nity, 2) to identify differences and concordances between endosonographers from the United 
States (US), Europe and Asia, and 3) to compare the current practice patterns to the guidelines 
of the ASGE and ESGE.
mEThOdS
Selection of study subjects
An online questionnaire was sent out per e-mail to endosonographers from the US, Europe, and 
Asia. Registered endosonographers were selected by 1) using the personal network of the re-
search team, which consists of national and international experts in the field, and 2) performing 
a PubMed literature search to identify authors who have published on the topic of EUS-guided 
tissue sampling in the last 10 years. Not only first authors but all listed authors were approached. 
Consent to participate in the study was inferred from voluntary completion of the survey.
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Questionnaire
The survey consisted of a maximum of 65 multiple-choice questions and was designed to take 
less than 10 minutes to complete (Appendix 1). The survey was divided in four sections. The 
first part focussed on demographics including gender, age, country of residence, type and size 
of current practice, years of experience, training and familiarity with EUS and EUS-guided tissue 
sampling. The second part included questions regarding peri-procedural use of anticoagulants, 
Table 1. Recommendations for EUS-guided tissue sampling from the ASGE, ESGE, and Papanicolaou Society 
of Cytopathology.




•  EUS-FNA of solid lesions can 
be performed in patients on 
aspirin or NSAIDS, but not in 
patients on Thienopyridines.
•  Check coagulation status in 
patients with personal or 
family history suggesting 
bleeding disorder or with a 
clear clinical indication.
•  EUS-FNA of solid lesions can 
be performed in patients on 




•  Recommended before 
sampling of cystic lesions.
•  Recommended before 
sampling of cystic lesions.
Sedation •  Propofol provides more 
rapid onset of action and 
shorter recovery time. No 
proof of higher patient 
satisfaction or better safety. 
Cost-effectiveness for 
average-risk patients is not 
proven.
•  On site anesthesiologist 
suggested in presence of 
patient-related risk factors.
•  Propofol provides higher 
post procedural patient 
satisfaction, decreases 
time to sedation and 
recovery. No proof of cost-
effectiveness.
•  On site anesthesiologist 




•  19G, 22G and 25G needles 
have similar diagnostic 
yields and safety profiles.
•  19G should not be used for 
transduodenal puncturing.
•  Generally: 22G or 25G
•  Vascular mass: 25G
•  Lymph nodes: 25G
•  Mucinous cyst: 22G
•  Fibrotic stromal rich mass: 
19G
Number of  
passes
•  Cysts: 1
•  Solid pancreatic: ≥5
•  Lymph nodes: 3
•  Cysts: 1
•  Solid pancreatic: 5-7
•  Lymph nodes: <5
•  Stromal cell tumor: 3-5
Suction •  Applying continuous 
suction with a syringe is 
recommended in solid 
masses but not in lymph 
nodes.
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antibiotics, and sedation. The third part contained questions on preferred equipment and sam-
pling techniques and whether these preferences depend upon target lesion type (pancreatic 
solid or cystic mass, lymph node or submucosal mass). The final part of the survey examined 
practice patterns regarding tissue processing and analysis.
Questionnaire administration
All endosonographers were approached by e-mail with a study invitation and were provided 
with a personal, direct link to the survey. This link was inactivated once the survey was com-
pleted. A reminder was sent by e-mail, after two, four, and six weeks. Without effect within the 
next 4 weeks, a subject was considered to be a non-respondent.
Statistical analysis
Only completed surveys were used for data analysis. For comparison between continents, the 
Chi-squared or Kruskal Wallis test was applied. All reported p-values are two-sided and a value 
< 0.05 was considered to be significant. Data was analyzed with SPSS 22, Statistical Package for 
the Social Sciences, SPSS Inc., Chicago, Illinois.
RESULTS
Demographics
A total of 400 endosonographers were approached, of which 197 responded (49%). Eleven 
responses were discarded because they were incomplete, which resulted in 186 participants 
(47%): 54 from the US (29%), 85 from Europe (46%), and 47 from Asia (25%, Table 2, Appendix 
2). The majority of the respondents were male (90%) gastroenterologists (96%), working in an 




In preparation of the procedure, most European (75%) and Asian (84%) respondents report 
to ‘always check’ coagulation status, while their US colleagues generally do so on indication 
(Table 3, p=0.007). continuing Acetylsalicylic acid is generally continued (77%), but this differed 
between continents. US respondents always continue acetylsalicylic acid, as compared to 87% 
of European and 50% of Asian respondents (Table 3, p<0.001). Regarding the use of heparin, 
coumarin, and New Oral Anticoagulants (NOACs), there is little consensus. While heparin is dis-
continued by all US and most Asian respondents (94%), it is stopped by 75% of the Europeans 
(p=0.022). The opposite is true for coumarins, which are stopped more often in Europe (86%) 
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than in the US (46%) and Asia (59%, p=0.003). In analogy, European respondents less often 
perform tissue sampling in patients with an INR >1.5 (11%), as compared to non-European 
respondents (33%, p=0.008). Lastly, NOACs are discontinued by virtually all US (91%) and Euro-
pean (88%) endosonographers, as compared to 66% of Asian respondents (p=0.029).
Table 2. Demographics and practice details of survey respondents per continent.
Variables
All
n = 186 (100%)
US
n = 54 (29%)
Europe
n = 85 (46%)
Asia
n = 47 (25%)
Age, years [Median IQR] 46 (41-52) 44,5 (41-54) 47 (41-52) 43 (40-49)





































































Formal EUS-training 114 (61) 37 (69) 48 (57) 29 (62)
EUS, endoscopic ultrasound; FNA, fine-needle aspiration; IQR, interquartile range; US, United States.
Table 3. Anticoagulation and antiplatelet management for EUS-guided tissue sampling per continent.
Variables
All
n = 99 (%)
US
n = 11 (%)
Europe
n = 56 (%)
Asia
n = 32 (%)
p-value*
Routine coagulation check
    Always








  5 (16)
0.007
Anticoagulant stopped
   Acetylsalicylic acid
   Thienopyridines
   Heparin
   Coumarins


























US, United States; NOACs, new oral anticoagulants.
*A chi square test was used to compare the three continents.
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Antibiotic prophylaxes
In all continents, the majority of respondents use antibiotic prophylaxis for EUS-guided tissue 
sampling (77%); mostly depending on the indication (92%), but some use antibiotics routinely 
(8%). Of those endosonographers who report to prescribe antibiotics on indication, virtually 
all use it when sampling a cystic lesion (95%)[12]. A minority prescribes antibiotics for other 
indications, such as a prosthetic cardiac valve, vascular graft, previous infective endocarditis, 
or congenital heart disease (<39%, Table 4). US physicians reported the lowest use of antibiotic 
prophylaxis.
Sedation and anesthesia
Almost all endosonographers sedate their patients during EUS-guided tissue sampling (98%). 
Propofol is generally used in the US (83%), whereas conscious sedation is still used by 52% of 
European and 84% of Asian respondents (p<0.001). All US respondents who use propofol have 
anesthesia personnel in the endoscopy room (100%), compared to only 66% in Europe and 50% 
in Asia (p<0.001).
Sampling techniques and equipment
Target lesion size
While half of the respondents perform EUS-FNA, regardless of the lesion diameter, the other 
half has a preferred minimum size of 0.5 cm (32%), 1 cm (17%), or 2 cm (1%). For EUS-FNB, most 
respondents confine to a minimum size of 1 cm (59%). European respondents perform EUS-FNB 
in lesions <1 cm more often (51%) than non-European respondents (34%, p=0.014).
Needle size
The gross of respondents prefers a specific needle size for FNA (84%) and FNB (75%), depending 
on the position of the scope or the location of the target lesion (66%). Overall, the 22G needle is 
most popular (Table 5). However, for FNA of solid pancreatic lesions, 22G (45%) and 25G (49%) 
needles are used equally and for FNA of submucosal lesions, besides the 22G (44%), the 19G 
Table 4. Antibiotic prophylaxis for EUS-guided tissue sampling; the US, as compared to Europe and Asia.
All
n = 132 (%)
US
n = 38 (%)
Europe + Asia
n = 94 (%)
p-value*
Antibiotic prophylaxes
   Prosthetic valve
   Vascular graft
   History of IE
   History of CHD





















US, United States; IE, Infectious endocarditis; CHD, congenital heart disease; GI, gastrointestinal.
*A chi square test was used to compare Europe and Asia with the US.
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needle (49%) is frequently used. For FNB of submucosal masses, most respondents use the 19G 
needle (62%). Responses did not differ between continents.
Number of passes
Generally, respondents perform 2-3 needle passes for FNA (49%) and FNB (57%). Most respon-
dents adjust the number of passes according to the target lesion. In pancreatic cysts, a single 
pass is performed for FNA (81%) and FNB (76%). For FNA of solid pancreatic masses, 2-3 (46%) 
or >3 needle passes are performed (50%). For FNB of solid pancreatic masses most respondents 
report to carry out only 2-3 passes (70%). A minority reports to do more than 3 passes (26%). 
Asian respondents vary their number of needle passes less often (47%) than European (69%) 
and US respondents (63%, p=0.037).
Sampling technique
Fanning is the preferred needle motion technique for FNA (64%). For FNB, fanning (44%) and 
only moving ‘to and fro’ (46%) are favored equally. To increase the yield of EUS-FNA, most 
endosonographers apply suction with a syringe (47%) or use the slow-pull technique (42%). 
Most respondents use dry instead of wet suction (93%). Also, for FNB, most endosonographers 
use an additional technique to increase the yield (70%); slow pull (53%), suction (44%), or a 
combination (3%). Some respondents adjust the sampling technique according to the target 
lesion (38%). While the slow-pull technique is mostly used for solid pancreatic masses (58%) 
Table 5. Reported use of needle size for EUS-guided tissue sampling.
FNA All  n = 88 (%) FNB All  n = 72 (%)
Overall
   25G
   22G
   19G
Pancreatic cystic lesion
   25G
   22G
   19G
Pancreatic solid lesion
   25G
   22G
   19G
Lymph node
   25G
   22G
   19G
Submucosal mass
   25G
   22G



















































FNA, fine needle aspiration; FNB, fine needle biopsy.
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and lymph nodes (62%), suction is generally applied for pancreatic cysts (82%) and submucosal 
lesions (48%).
Tissue processing and analysis
After FNA, a majority of the endosonographers prepares glass slides (65%), which they fixate in 
alcohol (45%) or leave to air dry (43%). As for liquid-based cytology, CytoLyt is generally used to 
preserve FNA specimens in the US (50%) and Europe (53%), while in Asia both saline (28%) and 
alcohol (38%) are used (p<0.001). Formalin is mostly used to preserve FNB or histologic tissue 
specimens (62%). In order to increase the yield of sampling, most respondents additionally 
prepare and analyze tissue cores after FNA (73%) or cytological material after FNB (73%). Asian 
respondents more often look for tissue cores after FNA (96%) than European (68%) and US 
respondents (61%, p<0.001).
ROSE
Rapid on-site pathological evaluation (ROSE) is available to 65% of endosonographers. Virtually 
all US respondents use ROSE (98%), compared to only half of respondents from Europe (48%) 
and Asia (55%, p<0.001). Reasons for omitting ROSE included ‘limited pathology staffing’ (74%), 
‘disbelieve in its additive value’ (32%), ‘high costs’ (24%), and ‘additional procedure time’ (24%).
Ancillary techniques
The majority of respondents apply the cellblock technique (85%). In the US, almost all en-
dosonographers use cellblock (96%), while it is used to a lesser extent in Europe (85%) and Asia 
(70%, p=0.002). Immunohistochemical analysis is also available for most respondents (96%), 
and generally used for diagnosing and staging of submucosal masses (91%), solid pancreatic 
lesions (75%) and lymph nodes (70%).
diScUSSiON
To the best of our knowledge, no study has investigated the practice trends in EUS-FNA guided 
tissue sampling with respect to the current ASGE and ESGE guidelines. This survey identified 
substantial intercontinental differences in EUS guided tissue sampling. Interestingly, some 
routines vary considerably from the recommendations expressed in existing guidelines.
We found that sedation with propofol is custom in the US, but not in Asia and Europe. 
In the past conscious sedation was standard of care, but procedures have become lengthier 
and more complex, requiring higher doses of sedatives. Propofol is appreciated as an alterna-
tive, because it provides a deep level of sedation with a short recovery time. However, costs 
may be higher, due to the need of aneasthesiological assistance in most countries [13,19,20]. 
Since cost-effectiveness of sedation with propofol has not been established, the American and 
European Society of Gastroenterology do not take a stand on this subject [11,13]. Although 
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we did not ask participants to motivate their choice, previous studies have suggested that the 
increased use of propofol in the US is caused by 1) the believe that it improves the diagnostic 
accuracy of EUS-guided tissue sampling, 2) efforts to offset falling procedure reimbursements, 
and 3) marketing strategies of anaesthesiologists [13,21,22].
The second interesting finding involves differences in anticoagulation and antiplatelet 
management. While respondents from the US generally check coagulation status on indication 
only, European and Asian respondents do this more routinely. Interestingly, the practice of the 
US respondents, rather than that of the Europeans, seems to follow the ESGE guidelines, which 
recommend that coagulation status is only checked in selected patients, that is in those using 
anticoagulant or antiplatelet therapy or with a (family) history of a bleeding disorder. Both the 
ASGE and ESGE recommend not to discontinue acetylsalicylic acid, while all other anticoagula-
tion and antiplatelet therapy should be stopped [12,23]. In contrast to US respondents, not 
all European and Asian respondents adhere to this recommendation. One explanation might 
be that US physicians adhere to guidelines more promptly, possibly as a consequence of an 
increased chance for malpractice claims in the US. [24,25]. The relatively high number of Asian 
respondents who discontinue acetylsalicylic acid may reflect the fact that bleeding risks are 
weighted more heavily in Asia. It has been suggested that Asians are more susceptible to bleed-
ing complications, while Caucasians are more at risk for thromboembolic events [26]. However, 
the Japan Gastroenterological Endoscopy Society has recently revised their guidelines, empha-
sizing the thromboembolism risks of discontinuation of antithrombotic agents [27]. Therefore, 
a shift towards continuance of acetylsalicylic acid is to be expected.
Another interesting finding of this survey is that for solid pancreatic masses, endosonogra-
phers report to perform fewer needle passes with FNB than with FNA. This finding is line with 
recently published data about using FNB to establish a diagnosis in solid pancreatic masses 
[28-31]. The ESGE recommends performing at least 5 passes for FNA of solid pancreatic masses, 
in the absence of ROSE. Neither the ASGE not the ESGE recommend a minimum number of 
passes for FNB.
Also noteworthy is that, overall, most respondents reported to use the 22G needle more 
often than the 25G needle. This finding is especially interesting, since two recent meta-analysis 
found no differences between the two needles, with regard to diagnostic accuracy, the num-
ber of needle passes, or complications [8,32]. In fact, a trend towards better performance of 
the 25G needle for FNA of solid pancreatic masses was observed in these studies. The ESGE 
guideline states that, although there is no difference in diagnostic yield and safety profiles, 
the 25G needle performs somewhat better with regard to number of required needle passes, 
presumably due to its higher flexibility [12]. One of the leading societies in cancer cytopathol-
ogy, the Papanicolaou Society of Cytopathology, recommends adapting the needle size to the 
target lesion. For highly vascular lesions and lymph nodes they recommend a 25G needle, for 
mucinous cysts a 22G needle, and for fibrotic or stromal-rich lesions a 19G needle [17].
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Another important outcome of this survey is the intercontinental variation in use of rapid 
on-site pathological evaluation. Whereas virtually all US respondents use ROSE, only half of the 
European and Asian respondents do. Respondents who refrain from using ROSE state that they 
consider it too time consuming and that reimbursement for pathology services is too low. How-
ever, more than two thirds of our respondents also mention that they have doubts with regard 
to the added benefit of ROSE, which might be influenced by the recommendations of the ESGE 
which state that ROSE should only be implemented at sites where specimen adequacy rates 
are below 90% or during the learning curve of EUS-FNA [12,33]. In contrast, the Papanicolaou 
Society of Cytopathology recommends the use of ROSE whenever possible [17].
The last, but certainly not least remarkable finding concerns the preservation of the tis-
sue samples. After procurement, EUS-FNA specimens are susceptible to damage by colonizing 
bacteria and to autolysis by enzyme activity. To halt these processes, it must be placed in a 
fixative (e.g., formalin, CytoRich Red, CytoLyt) or physiologic solution (e.g., saline, Hanks’ salt 
solution). Although most of the respondents use formalin to preserve histologic samples, there 
is no consensus regarding preservation of cytological samples. While a majority of the Asian 
respondents store cytology in alcohol or saline, their European and US colleagues store it in 
CytoLyt. Although there are currently no guidelines on this topic, we did not expect to find such 
striking differences between the three continents. It would be interesting to investigate the 
influence of preservation methods on the specimen’s quality and diagnostic accuracy, as this 
aspect is under-investigated so far.
Our survey has some potential limitations. First, it seems conceivable that our results have 
been subject to a response bias, given our response rate of 47%. Although our response rate 
still falls at the high end of the spectrum of responses for online surveys amongst physicians 
[1-10], it might have caused a selection towards the more active, academic endosonographers. 
Although most respondents indeed reported to work in high volume academic centers, only 
61% had participated in a formal EUS training program. This could have accounted for the low 
adherence to the practice guidelines. Currently, the ESGE and ASGE advise that a dedicated 
fellowship should last 6-24 months [12,34]. However, they also acknowledge that there is a 
lack of sufficient EUS-training and training capacity in Europe and the US [35,36]. Since most 
respondents in the present study are EUS experts, the number of formal trained endosonog-
raphers and the adherence to the guidelines is likely to be even lower in non-academic, low 
volume centers. Last, a reporting or goodwill bias is likely to exist, since this is inevitable for 
retrospective surveys that are based on self-reporting. If respondents indeed gave an expected 
answer rather than a true answer, this would only strengthen our main conclusion that practice 
patterns for EUS-guided tissue sampling differ and are not congruent with the guidelines. 
In conclusion, this survey shows that there is considerable intercontinental variation in the 
practice of EUS-guided tissue sampling. Despite of the growing number of studies in the field 
of EUS-guided tissue sampling, the optimal sampling strategy remains subject of debate. More-
over, some routines vary considerably from recommendations stated in existing guidelines. 
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Further studies are required to determine the relevance and impact of various practices on 
outcome and safety. Pending these outcomes, cost-effectiveness studies may be required to 
support the implementation of a certain sampling strategies.
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APPENdicES 1 - 2
APPENdiX 1: The online survey
Background information
1. What is your gender?
 ⎕ Female
 ⎕ Male
2. What is your age?
 Please write your answer here: _________




4. in which year did you finish your training?
 Please write your answer here: _________
5. in what country are you currently working?
 Please write your answer here: _________
6. in what kind of hospital are you currently working? (more than one option possible)
 Please choose all that apply:
 ⎕ Community hospital
 ⎕ Academic/University hospital
 ⎕ Private hospital or independent endoscopy unit
 ⎕ Other, please specify: __________
7. how many EUS procedures do you perform each year?
 Please choose only one of the following:
 ⎕ < 100
 ⎕ 100-200
 ⎕ 200-300
 ⎕ > 300
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8. how many EUS-guided tissue-sampling procedures do you perform each year?
 Please choose only one of the following:
 ⎕ < 50
 ⎕ 50-100
 ⎕ 100-200
 ⎕ > 200
9.  did you have formal training in performing EUS guided tissue sampling? (Formal training 
is defined as a fellowship in a dedicated EUS training center for at least 3 months)
 Please choose only one of the following:
 ⎕ Yes
 ⎕ No
Preparation for EUS guided tissue sampling
10. do you use any type of sedation when performing EUS-guided tissue sampling?
 Please choose only one of the following:
 ⎕ Yes, conscious sedation, continue to 12
 ⎕ Yes, propofol
 ⎕ No, not as standard practice, continue to 12
11. is anesthesia personnel routinely present during the procedure?
 Please choose only one of the following:
 ⎕  Yes
 ⎕ No
12. do you use antibiotic prophylaxis when performing EUS-guided tissue sampling?
 Please choose only one of the following:
 ⎕ Yes, always, continue to 14
 ⎕ Yes, depending on the indication
 ⎕ No, continue to 14
2
Mapping international practice patterns in EUS-guided tissue sampling 35
13.  Please specify for which indication you use AB prophylaxis? (more than 1 answer 
possible)
 Please choose all that apply:
 ⎕ Cystic lesions
 ⎕ Prosthetic cardiac valve
 ⎕ Vascular graft
 ⎕ History of previous infective endocarditis
 ⎕ Congenital heart disease
 ⎕ Solid lesions of lower gastrointestinal tract
 ⎕ Other, please specify: __________
14. do you routinely check the coagulation parameters before EUS-guided tissue sampling?
 Please choose only one of the following:
 ⎕ Yes
 ⎕ No, continue to 18
15. Please specify when you check coagulation status? (more than one answer possible)
 Please choose only one of the following:
 ⎕ Always
 ⎕ In patients on anticoagulants
 ⎕ In patients with a (family) history of bleeding disorder
 ⎕  In both, patients on anticoagulants and patients with a (family) history of bleeding 
disorder
16.  Which of the following anticoagulants do you generally discontinue, prior to a 
puncture procedure? (more than one answers possible)
 Please choose all that apply:
 ⎕ Acetylsalicylic acid (aspirin, carbasalate calcium (Ascal), dipyridamole (Persantin))
 ⎕ Thienopyridines (Ccopidogrel (Plavix, Grepid, Iscover, Vatoud), prasugrel (Effient))
 ⎕  Coumarin derivatives (acenocoumarol (Sintrom), phenprocoumon (Marcoumar, 
Marcumar, Falithrom))
 ⎕  Heparin or derivatives (warfarin (Coumadin), dalteparin (Fragmin), nadroparin 
(Fraxiparin), tinzaparin (Innohep))
 ⎕  New Oral Anticoagulant drugs (NOAC) (rivaroxaban (Xarelto), apixaban (Eliquis), 
dabigatran (Pradax))
 ⎕ Other, please specify: __________
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17.  Up to which iNR value would you consider it safe to perform EUS-guided tissue 
sampling?
 Please choose only one of the following:
 ⎕ INR 1.0
 ⎕ INR 1.1 - 1.5
 ⎕ INR 1.6-2.0
 ⎕ INR > 2.0
This section contains questions about Fine Needle Aspiration
18. What is the minimum lesion diameter for you to consider FNA?
 Please choose only one of the following:
 ⎕ No minimum
 ⎕ 0.5 cm
 ⎕ 1 cm
 ⎕ 2 cm
19. do you have a preferred needle size for FNA?
 Please choose only one of the following:
 ⎕ Yes
 ⎕ No, continue to 21
20.  does your preferred needle size depend on scope position and/or location of target 
lesion?
 Please choose only one of the following:
 ⎕ Yes, continue to 22
 ⎕ No
21. Which needle size do you generally prefer?




22. Specify if your preferred needle size depends on: (more than one answer possible)
 Please choose all that apply:
 ⎕ Location of target lesion,
 ⎕ Scope position, continue to 24
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23. Please specify your preferred needle size for the following indications:
 Please choose the appropriate response for each item:
    19G 22G 25G
 Pancreatic solid mass ⎕ ⎕ ⎕
 Pancreatic cystic mass ⎕ ⎕ ⎕
 Lymph node  ⎕ ⎕ ⎕
 Submucosal mass ⎕ ⎕ ⎕
24. Please specify your preferred needle size for the following scope positions:
 Please choose the appropriate response for each item:
        19G 22G 25G
 Transgastric      ⎕ ⎕ ⎕
 Transduodenal D1 (Superior part/ Duodenal bulb)  ⎕ ⎕ ⎕
 Transduodenal D2 (Descending part)   ⎕ ⎕ ⎕
 Transduodenal D3 (Horizontal part)   ⎕ ⎕ ⎕
25. does your number of needle passes depend on the indication for FNA?
 Please choose only one of the following:
 ⎕ Yes
 ⎕ No, continue to 27
26. Please specify the number of needle passes per indication.
 Please choose the appropriate response for each item:
     1  2-3  > 3
 Pancreatic solid mass  ⎕ ⎕ ⎕
 Pancreatic cystic mass  ⎕ ⎕ ⎕
 Lymph node   ⎕ ⎕ ⎕
 Submucosal mass  ⎕ ⎕ ⎕
27. Please specify the number of needle passes you generally perform.
 Please choose only one of the following:
 ⎕ 1
 ⎕ 2-3
 ⎕ > 3
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28. What is your preferred needle movement technique during FNA?
 Please choose only one of the following:
 ⎕ To & Fro
 ⎕ Fanning
 ⎕ No preferred technique
29.  Which additional techniques do you employ to increase the yield of tissue sampling 
during FNA? Please choose only one of the following:
 ⎕ Slow pull
 ⎕ Syringe
 ⎕ Wet suction
 ⎕ Capillary technique
 ⎕ None
 ⎕ Other, please specify ___________
30.  how do you expel sampling material from the FNA needle? (more than one answer 
possible)
 Please choose all that apply:
 ⎕ Flushing with air
 ⎕ Flushing with saline
 ⎕ With stylet
31. do you use on-site pathological evaluation of the specimen?
 Please choose only one of the following:
 ⎕ Yes, always
 ⎕ Yes, sometimes
 ⎕ No, continue to 33
32. Please specify who performs on-site pathological evaluation.
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33.  Why are you not using on-site pathological evaluation? (more than one answer 
possible)
 Please choose all that apply:




 ⎕ No pathological personnel available
 ⎕ Other, please specify ___________
34. do you prepare glass slides after you performed FNA?
 Please choose only one of the following:
 ⎕ Yes
 ⎕ No, continue to 37
35. how do you fixate these smears?
 Please choose only one of the following:
 ⎕ Air dry
 ⎕ Direct fixation with alcohol
 ⎕ Other, please specify ___________
36. Which preservation medium do you use to collect cytology, obtained with FNA?
 Please choose only one of the following:
 ⎕ Saline
 ⎕ CytoLyt
 ⎕ A fixative (formalin)
 ⎕ Hanks
 ⎕ Alcohol
 ⎕ Other, please specify ___________
37. is the cell block technique applied in your center?




38. do you or your pathologist routinely look for tissue cores after FNA?
 Please choose only one of the following:
 ⎕ Yes, always, continue to 40
 ⎕ Yes, depending on the target lesion
 ⎕ No, continue to 44
39.  Please specify for which indication(s) you look for tissue cores after FNA? (more than 
one answer possible)
 Please choose all that apply:
 ⎕ Cystic pancreatic lesions (from solid components or cyst wall)
 ⎕ Solid pancreatic lesions
 ⎕ Lymph nodes
 ⎕ Submucosal lesion
40. Are these tissue cores processed differently compared to the cytological tissue sample?
 Please choose only one of the following:
 ⎕ Yes
 ⎕ No, continue to 44
41. They are collected in a separate vial?
 Please choose only one of the following:
 ⎕ Yes
 ⎕ No
42. They are collected in a different medium?
 Please choose only one of the following:
 ⎕ Yes
 ⎕ No
43. in what medium?
 Please choose only one of the following:
 ⎕ Saline
 ⎕ CytoLyt
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This section contains questions about Fine Needle Biopsy
44. What is the minimum lesion diameter for you to consider FNB?
 Please choose only one of the following:
 ⎕ No minimum
 ⎕ 0.5 cm
 ⎕ 1 cm
 ⎕ 2 cm
45. do you have a preferred needle size for FNB?
 Please choose only one of the following:
 ⎕ Yes, continue to 47
 ⎕ No
46. Which needle size do you generally prefer?




47.  does your preferred needle size depend on scope position and/or location of target 
lesion?
 Please choose only one of the following:
 ⎕ Yes, continue to 49
 ⎕ No
48. Which needle size do you generally prefer?




49. Specify if your preferred needle size depends on: (more than one answer possible)
 Please choose all that apply:
 ⎕ Location of target lesion
 ⎕ Scope position, continue to 51
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50. Please specify your preferred needle size for the following indications:
 Please choose the appropriate response for each item:
     19G 22G 25G
 Pancreatic solid mass  ⎕ ⎕ ⎕
 Pancreatic cystic mass  ⎕ ⎕ ⎕
 Lymph node   ⎕ ⎕ ⎕
 Submucosal mass  ⎕ ⎕ ⎕
51. Please specify your preferred needle size for the following scope positions:
 Please choose the appropriate response for each item:
        19G 22G 25G
 Transgastric      ⎕ ⎕ ⎕
 Transduodenal D1 (Superior part/ Duodenal bulb)  ⎕ ⎕ ⎕
 Transduodenal D2 (Descending part)   ⎕ ⎕ ⎕
 Transduodenal D3 (Horizontal part)   ⎕ ⎕ ⎕
52. does your number of needle passes depend on the indication for FNB?
 Please choose only one of the following:
 ⎕ Yes
 ⎕ No, continue to 54
53. Please specify the number of needle passes per indication.
 Please choose the appropriate response for each item:
     1  2-3  > 3
 Pancreatic solid mass  ⎕ ⎕ ⎕
 Pancreatic cystic mass  ⎕ ⎕ ⎕
 Lymph node   ⎕ ⎕ ⎕
 Submucosal mass  ⎕ ⎕ ⎕
54. Please specify the number of needle passes you generally perform.
 Please choose only one of the following:
 ⎕ 1
 ⎕ 2-3
 ⎕ > 3
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55. What is your preferred needle movement technique during FNB?
 Please choose only one of the following:
 ⎕ To & Fro
 ⎕ Fanning
 ⎕ No preferred technique
56.  do you use a special technique (slow pull or syringe) to acquire tissue with the FNB 
needle?
 Please choose only one of the following:
 ⎕ Yes, this depends on the indication
 ⎕ Yes, independent of the indication, continue to 58
 ⎕ No, continue to 59
57. Please specify per indication
 Please choose the appropriate response for each item:
  Slow pull Syringe Wet suction Capillary technique Other
 Pancreatic solid mass ⎕ ⎕ ⎕ ⎕ ⎕
 Pancreatic cystic mass ⎕ ⎕ ⎕ ⎕ ⎕
 Lymph node ⎕ ⎕ ⎕ ⎕ ⎕
 Submucosal mass ⎕ ⎕ ⎕ ⎕ ⎕
58. Please specify
 Please choose only one of the following:
 ⎕ Slow pull
 ⎕ Syringe
 ⎕ Wet suction
 ⎕ Capillary technique
 ⎕ Other, please specify __________
59.  how do you expel sampling material from the FNB needle? (more than one answer 
possible) Please choose all that apply:
 ⎕ Flushing with air
 ⎕ Flushing with saline
 ⎕ With stylet
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60. Which preservation medium do you use to collect the FNB specimen?
 Please choose only one of the following:
 ⎕ Saline
 ⎕ CytoLyt
 ⎕ A fixative (formalin)
 ⎕ Hanks
 ⎕ Alcohol
 ⎕ Other, please specify __________
61.  is immunohistochemical analysis performed in your center? (when sufficient sampling 
material is available)
 Please choose only one of the following:
 ⎕ Yes, depending on the indication
 ⎕ Yes, independent of the indication, continue to 63
 ⎕ No, continue to 63
62. Please specify (more than one answer possible)
 Please choose all that apply:
 ⎕ Solid pancreatic mass
 ⎕ Lymph node
 ⎕ Submucosal mass
63.  is a cytological sample also prepared and evaluated (i.e. glass slide, cyto spin), in 
addition to the histological tissue core specimen?
 Please choose only one of the following:
 ⎕ Yes
 ⎕ No, end of survey
64. does this depend on the needle size?
 Please choose only one of the following:
 ⎕ Yes
 ⎕ No, end of survey
65. Please specify for which needle size you look for additional cytological sample?
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APPENdiX 2: List of countries of respondents
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Several studies have compared EUS fine-needle aspiration (FNA) to biopsy (FNB) needles, but 
none has proven superiority. We performed a multicenter randomized controlled trial to com-
pare the performance of a commonly used 25-gauge FNA needle to a newly designed 20-gauge 
FNB needle.
dESiGN
Consecutive patients with a solid lesion were randomized in this international multicenter study 
between a 25-gauge FNA (EchoTip Ultra) or a 20-gauge FNB needle (ProCore). Primary endpoint 
was diagnostic accuracy for malignancy and the Bethesda classification (non-diagnostic, be-
nign, atypical, malignant). Technical success, safety, and sample quality were also assessed. 
Multivariable and supplementary analyses were performed to adjust for confounders.
RESULTS
608 patients were allocated to FNA (n=306) or FNB (n=302); 312 pancreatic lesions (51%), 
147 lymph nodes (24%), and 149 other lesions (25%). Technical success rate was 100% for the 
25-gauge FNA and 99% for the 20-gauge FNB needle (p=0.043), without differences in adverse 
events. The 20-gauge FNB needle outperformed 25-gauge FNA in terms of histological yield 
(77% vs 44%, p<0.001), accuracy for malignancy (87% vs 78%, p=0.002) and Bethesda classifica-
tion (82% vs 72%, p=0.002). This was robust when corrected for indication, lesion size, number 
of passes, and presence of an on-site pathologist (OR 3.53, 95% CI 1.55-8.56, p=0.004), and did 
not differ between centers (p=0.836).
cONcLUSiON
The 20-gauge FNB needle outperformed the 25-gauge FNA needle in terms of histological yield 
and diagnostic accuracy. This benefit was irrespective of the indication and consistent amongst 
participating centers, supporting the general applicability of our findings.
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iNTROdUcTiON
Endoscopic Ultrasound (EUS)-guided fine-needle aspiration (FNA) is a well-established tech-
nique for tissue acquisition of lesions in and around the gastrointestinal tract. However, FNA 
needles generally provide cytological rather than histological specimens. To optimize the 
efficacy, efforts have been made to ensure collection of histological specimens, as intact tis-
sue architecture enables a range of ancillary diagnostic tests, including immunochemical and 
biomolecular testing. As a result, dedicated EUS fine-needle biopsy (FNB) devices have been 
developed. Although these needles seem to generate good-quality specimens and provide a 
diagnosis in less passes than with FNA, some studies reported they did not so much improve 
the histological, but rather, the cytological yield [1-8]. Moreover, due to a more rigid design, 
their applicability is questioned in lesions that are difficult to sample from an angulated scope 
position, such as fibrotic pancreatic head masses [7, 9-11]. Lately, several novel FNB needles 
have been introduced, claiming to overcome this problem by having adapted their design to 
provide more flexibility.
Previous studies comparing FNA and FNB were retrospective, underpowered, did not 
include the whole range of indications, or were performed in a single center, which hampers 
their generalizability [3, 5, 7-9, 11-18]. So far, only one multicenter trial showed a benefit of 
FNB over FNA, but only in large pancreatic lesions [19]. Consequently, the authors of the latest 
2017 ESGE guidelines on technical aspects of EUS-guided sampling in gastroenterology lacked 
scientific ground to favor a specific technique or needle design [20, 21].
As the role of EUS-guided tissue acquisition is expanding in this era of personalized medi-
cine, identification of the optimal sampling technique bares even more relevance [22-25]. An 
EUS-needle device should be flexible, yet large enough to ensure ample representative tissue 
in as few passes as possible. Moreover, in the past FNA and FNB were regarded as separate 
entities, but this distinction seems less suitable nowadays. Although FNB needles incorporate 
specific design changes aimed to facilitate extraction of tissue cores, it has been shown that 
it is also possible to obtain tissue cores with FNA needles [7, 13, 19]. Moreover, the cell block 
technique allows for ‘histology like’ analysis of cytology material. Conversely, with FNB needles, 
besides true tissue cores, material for cytological analysis is also obtained.
We set up a  multicenter randomized controlled trial to compare the performance and diag-
nostic accuracy of a newly designed flexible 20-gauge FNB needle with a forward facing bevel to 
a more conventional 25-gauge FNA needle with a standard bevel, which is widely used amongst 




This investigator initiated, prospective randomized multicenter study was conducted in 13 EUS-
centers in the United States (Irvine, New Haven, New York), Europe (Leuven, Marseille, Milan, 
Rome, Rotterdam, Santiago de Compostela, and Stockholm), Australia (Adelaide), Asia (Osaka-
Sayama), and the Middle-East (Tel Aviv). Data were collected using online case record forms, 
which were accessible through a designated study website (www.aspro-study.com). The study 
was approved by the Institutional Review Boards of all participating centers and registered 
online, at ClinicalTrials.gov: NCT02167074. Financial support was provided by Cook Medical, 
Ireland (www.cookmedical.com), in the form of an unrestricted grant.
Patient selection
Consecutive patients with an indication for EUS-guided tissue acquisition of a solid pancreatic 
lesion, lymph node or other solid or submucosal lesion were prospectively enrolled from Febru-
ary 2015 to September 2016. Inclusion criteria comprised patient age ≥18 years, visualization of 
the target lesion during EUS, a lesion diameter ≥1 cm and signed informed consent. Both, virgin 
and previously sampled target lesions were included. Exclusion criteria were; increased bleed-
ing risk (a bleeding disorder that could not be corrected with co-fact or fresh frozen plasma) 
or anticoagulant use that could not be discontinued to guarantee an INR <1.5, a purely cystic 
lesion, previous inclusion in the current study, or pregnancy.
Allocation and blinding
Patients were randomized 1:1 by use of an online randomization tool assessable on-site, to 
tissue sampling with the 20-gauge ProCore® FNB needle (Figure 1) or the 25-gauge EchoTip® 
Ultra FNA needle (both Cook Medical, Ireland). Random block sizes were used for allocation 
concealment between groups. Patients were blinded as to which needle was used. Pathologists 
were only blinded if they were not present at the EUS-procedure.
Figure 1. Needle tip design and dimensions of the 20-gauge 
FNB needle with a forward facing bevel and a Menghini tip-
design.
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EUS-procedure and tissue acquisition
All participating endosonographers were experienced with a life-time performance of >1000 
EUS-guided tissue sampling procedures. They followed a standardized protocol, using a convex 
array echoendoscope (Pentax EG-3870UTK/3270UK, Olympus UTC 140/160/180/190/260 or 
UC140). If more than one lesion was identified, the most suspicious lesion was targeted. Each 
lesion was attempted to be punctured at least three times and tissue was obtained by a ‘to and 
fro’ movement. The number of ‘to and fro’ movements (gradual withdrawal of the stylet while 
moving the needle back and forth into the target), use of fanning, suction, or slow pull were 
left at the discretion of the endoscopist, as evidence on the superiority of these techniques 
is lacking [18, 20, 31]. Seven study sites had on-site pathological evaluation at their disposal 
(Irvine, Milan, New Haven, New York, Rotterdam, Santiago de Compostela, and Stockholm), 
and were allowed to use rapid on-site pathological evaluation (ROSE) according to their local 
protocols. After completion of the sampling protocol, the endoscopist was permitted to switch 
to another needle type and/or size, either during the same or a subsequent procedure, as long 
as specimens were analyzed separately.
Specimen processing
Specimens were collected in three vials to allow for analysis according to needle pass; one 
for the first pass, one for the second and third pass, and one for any subsequent passes. 
Samples were preserved according to local practice. Cytological samples from each vial were 
first smeared onto glass slides and stained with Diff Quick (Adelaide, Irvine, New Haven, Rot-
terdam, Santiago de Compostela, Stockholm, Tel Aviv), Hematoxylin and eosin staining (Milan, 
Osaka-Sayama, Rome), or PAP stain (New York). Two centers did not create glass slides (Leu-
ven, Marseille). Remaining material was collected in CytoLyt (Adelaide, Marseille, New York, 
Rome, Rotterdam, Santiago de Compostela, Stockholm), saline (Osaka-Sayama), alcohol (Tel 
Aviv), formalin (Irvine, Milan), CytoRich Red (Leuven, New Haven). Cytological cell suspensions 
were further processed using the ThinPrep technique (Leuven, Marseille, New Haven, New 
York, Rome, Santiago de Compostela, Stockholm) or the cell block technique, either the Cel-
lient™ automated cell block system (Hologic), the Agar technique, or Histogel (Irvine, Leuven, 
Marseille, Milan, New Haven, New York, Rotterdam, Santiago de Compostela, Stockholm, Tel 
Aviv). Adelaide and Osaka-Sayama did not further process cytology. Histology was collected in 
CytoLyt (Santiago de Compostela, Rotterdam) or formalin (Adelaide, Irvine, Leuven, Marseille, 
Milan, New Haven, New York, Osaka-Sayama, Rome, Rotterdam, Stockholm, Tel Aviv). Formalin 
samples were processed as paraffin blocks, sectioned at 3-4 microns and stained with Hema-
toxylin and eosin staining, PAP, or Giemsa for morphological evaluation.
Outcome measures and definitions
The collected vials were assessed according to the sampling order. The primary outcome 
measure was the diagnostic accuracy for malignancy and for the classification based on the 
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Bethesda nomenclature system (non-diagnostic, benign, atypical/suspect for malignancy, or 
malignant) [32]. Accuracy for malignancy was calculated from the correct number of cases 
that were defined as atypical/suspect for malignancy or malignant. Accuracy for the Bethesda 
classification was calculated from the number of cases that were correctly classified into 
the above-mentioned categories, according to the formula: (true positive + true negative) / 
all patients. The gold-standard diagnosis was either based on pathological evaluation of the 
surgical resection specimens or clinical follow-up for at least 9 months when surgical resec-
tion was not indicated because of a benign diagnosis or malignant advanced or metastasized 
disease. Consequently, alternative endpoints included a composite of outcomes including 
clinical follow-up, additional tissue collections, follow-up imaging investigations, and death. 
Gold standard diagnosis was recorded by the principal investigator of each of the participating 
centers. Serous cystadenoma (SCA) and leiomyomata were classified as benign. Lymphomas, 
solid-pseudopapillary neoplasms (SPN), and neuroendocrine (NET) and gastrointestinal stromal 
tumors (GISTs) grade 2 and 3 were classified as malignant [33, 34]. A sample was defined as 
non-diagnostic in case of absence or paucity of target cells.
Secondary outcome measures included the performance of the needles in terms of; 1) 
technical success rate (ability to obtain a sample), 2) procedural aspects (yield of the first pass, 
influence of on-site pathological assessment, safety), and 3) specimen specifics; i.e. sample 
quality (sufficiency for diagnosis or not), cellularity (</≥50% target cells present), and the pres-
ence of tissue cores. A tissue core was defined as a measurable microscopic cylinder, containing 
target organ cells with preserved histological architecture. As there are no uniform definitions 
to describe EUS-specimen quality and quantity, the definitions used in the current study were 
jointly created by the participating pathologists in this study.
Last, pathologists were asked to record if a sample diagnosis could be obtained from 
cytology, histology, or a combination. It was left at the discretion of the pathologist to assess 
cytology or histology first.
Sample size and statistical analysis
Sample size calculations for a two-side comparison of binominal proportions, with a power of 
90% and a type-1 error of 5%, showed that with 600 inclusions an 8% difference in diagnostic 
accuracy between the two needles could be detected, which was considered by the group 
to be a clinically relevant difference (SAS 9.3, Proc POWER TwoSampleFreq). Frequencies and 
percentages were calculated for categorical data, while continuous data were displayed as me-
dians with interquartile ranges (IQR). The chi-square test (with Yates’ correction when appro-
priate) or the Fisher exact test was used to compare the two needle types. Diagnostic accuracy, 
sensitivity, and specificity were assessed by means of an intention-to-treat (ITT) analysis. In the 
calculation of sensitivity and specificity, non-diagnostic samples were considered to be benign. 
Multivariable logistic regression analysis was applied to assess differences in diagnostic accu-
racy for malignancy between the two sampling devices, adjusted for the sampling indication, 
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lesion size, number of needle passes, and the presence of an on-site pathologist. Furthermore, 
an interaction term between sampling device and indication was included in the model, as 
differences between devices might differ per sampling indication.
As the reported diagnostic accuracy rates of EUS-guided tissue sampling in the literature 
varies significantly [5, 8-12, 14, 17, 29, 35-37), we performed a supplementary analysis to as-
sess the inter-center variation in diagnostic accuracy. For this, we used a logistic mixed model 
with the same fixed effect structure as our primary multivariable logistic regression model, 
but allowed for study center and needle specific effects by including random effects for these 
variables. An adapted likelihood ratio test was then used to determine if there was indeed sig-
nificant variation in diagnostic accuracy between the centers, and to assess its effect on needle 
accuracy [38]. Results from the multivariable analyses were expressed as odds ratios (OR) with 
95% confidence intervals. Statistical significance was defined as p<0.05 (two-tailed). Analyses 
were carried out using SAS version 9.3 (SAS Institute, Cary, NC, United States), SPSS version 
22, Statistical Package for the Social Sciences, SPSS Inc., Chicago, Illinois, and R (version 3.4.2).
RESULTS
Patient and target lesion characteristics
A total of 612 consecutive patients were randomized, of which four were lost to follow-up; one 
FNA and three FNB cases. Of the 608 remaining cases, 306 were allocated to the 25-gauge FNA 
needle and 302 to the 20-gauge FNB needle. Targets comprised 312 pancreatic lesions (51%), 
147 lymph nodes (24%), and 149 submucosal or other solid gastrointestinal tract lesions (25%). 
Baseline patient and target lesion characteristics are listed in table 1. After a median follow-up 
of 13 months (range 9-26), 463 malignancies were diagnosed (76%, table 2). There was no 
difference in final diagnoses between the needles (p=0.564). The gold standard diagnosis was 
obtained from surgical resection specimens in 135 cases (22%).
diagnostic performance
Technical feasibility and safety
Sampling was technically feasible in all FNA cases and all but four FNB cases (99%, p=0.043, 
table 3). Five minor adverse events occurred, three in the 25-gauge FNA group and two in the 
20-gauge FNB group. In the 25-gauge FNA group, a case of mild pancreatitis and a case of post-
procedural pain were managed conservatively. Also, one patient developed fever and positive 
blood cultures, for which antibiotics were given, after which the patient quickly recovered. In 
the 20-gauge FNB group, a minor bleeding was clipped during the same procedure and a case 
of mild pancreatitis was treated conservatively.
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male, n (%) 344 (57) 162 (54) 182 (60)
Age in years, mean ± Sd 66 ± 0.5 66 ± 0.7 66 ± 0.7
Lesion size, median mm (P25-P75) 28 (20-40) 29 (20-40) 27 (20-40)
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GIST: gastrointestinal stromal tumor, NET: neuroendocrine tumor, IPMN: intraductal papillary mucinous neoplasm, SCA: se-
rous cyst adenoma
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Tissue acquisition techniques
The slow pull technique was performed more often in the 20-gauge FNB than 25-gauge FNA 
group (27% versus 13%, p=0.001, table 3). Vice versa, fanning was applied more often with 
25-gauge FNA (85%) than 20-gauge FNB (68%, p<0.001). As for the number of needle passes, 
>3 passes were more frequently undertaken in the FNA group (p=0.002). On-site pathological 
assessment was performed in a minority of procedures (17%), also more often in the 25-gauge 
FNA group (24% versus 9%, p<0.001).
Specimens specifics
Although sample sufficiency and cellularity were equally good for the two needles, procure-
ment of histologically intact tissue cores was accomplished more often with 20-gauge FNB than 
25-gauge FNA (77% versus 44%, p<0.001, table 4, figure 2-5). In the same line, with 20-gauge 
FNB, the diagnosis was more often based on histology (29%) or histology and cytology com-
bined (30%), whereas with 25-gauge FNA, it was mostly based on cytology, processed as cell 
blocks (47%). Immunohistochemical staining was performed in similar percentages with a trend 
in favor of 20-gauge FNB (20-gauge FNB 46%, 25-gauge FNA 39%, p=0.090). The actual contri-
bution of immunohistochemical staining in establishing the final diagnosis was not assessed.








Technical success rate, n (%) 604 (99) 298 (99) 306 (100) 0.043
Number of passes
 1-3, n (%)








Stylet use, n (%)
 In place
 Withdrawn several cm
 Removed after needle insertion














Use of Fanning, n (%) 462 (77) 204 (68) 258 (85) <0.001
Additional techniques (per case), n (%)

















ROSE applied, n (%) 100 (17) 26 (9) 74 (24) <0.001
ROSE: rapid on-site pathological evaluation
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Diagnostic accuracy, sensitivity and specificity
Overall, 20-gauge FNB had a higher diagnostic accuracy for malignancy (87% versus 78%, 
p=0.002), with a higher sensitivity (90% versus 82%, p=0.008) and comparable specificity (96% 
versus 91%, p=0.229). After the first pass, the yield of 20-gauge FNB and 25G FNA was not sta-
tistically different but showed a trend in favor of FNB (72% versus 65%, p=0.069, table 5). The 
accuracy for classification according to Bethesda was better for 20-gauge FNB than 25-gauge 
FNA (82% versus 72%, p=0.002). Multivariable logistic regression analysis demonstrated this 
to be independent of indication, lesion size, number of needle passes, and presence of an on-
site pathologist (OR 3.53, 95% CI 1.55-8.56, p=0.004, table 6). Besides needle type, diagnostic 
accuracy was influenced by lesion type and number of needle passes. Lesions of pancreatic or 
lymphatic origin, and the performance of >3 passes were predictive of a correct final diagnosis 
(Table 6). Although the diagnostic accuracy varied between centers, for FNA between 56% and 
100%, and for FNB between 70% and 100%, this did not affect the difference in diagnostic 
accuracy between the two study needles (p=0.835) (Figure 6).
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LBC: liquid-based cytology. *Missing data is explained by the lack of sufficient pathological anatomical (PA) material for that 
particular diagnostic purpose.
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Figure 2. Endoscopic ultrasound image of a hy-
podense lesion of the pancreatic head, 2 cm in 
size, irregular borders.
Figure 3. Cytology collected with the 25-gauge FNA 
needle, showing a monotonous cell population, with 
enlarged nucleoli, and mucus producing cells (May 
Grunwald Giemsa stain).
Figure 4. Endoscopic ultrasound image of a hy-
podense pancreatic head lesion, 4cm in size, ir-
regular borders, and a close relation with SMA.
Figure 5. Histology obtained with the 20 FNB needle 
shows a well-differentiated adenocarcinoma with 
clear invasive groups of tumor cells, (hematoxylin-
eosin stain).
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Table 5. Sample diagnosis and performance characteristics for final diagnosis








































































Table 6. Multivariable analysis of factors influencing diagnostic accuracy for malignancy
















































ROSE: rapid on-site pathological evaluation, CI: confidence interval.
*Reference category. Interaction terms for needle type and target lesion were included in our model, but not displayed in 
this table.
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diScUSSiON
The results of this multicenter randomized controlled trial demonstrate that a novel 20-gauge 
FNB needle (ProCore design) outperforms a conventional 25-gauge FNA needle, in terms of di-
agnostic accuracy and histological yield. This equally applies for pancreatic and non-pancreatic 
lesions and is irrespective of lesion size, number of needle passes, and presence of an on-site 
pathologist. Moreover, despite inter-center differences, the benefit of the 20-gauge FNB needle 
was consistent amongst participating centers. Despite the notion amongst endosonographists 
that larger size needles are not as flexible and might fail to procure tissue in more difficult 
anatomical scope positions, this conception is contradicted by the results of the current study; 
the larger-bore 20-gauge FNB needle yielded better results than a small-bore 25-gauge FNA 
needle, which seems a relevant observation for EUS practice.
FNA needles are designed to procure cytological samples, which lack information on tissue 
architecture. This may hamper the diagnostic process, for instance in case of neuroendocrine 
tumors, well-differentiated carcinomas, or lymphomas [2, 39-42]. FNB can overcome this limi-
tation. An intact cellular arrangement facilitates establishing a diagnosis and allows for applica-
tion of a wide-range of diagnostic tests, including genetic profiling, needed for a personalized 
medicine approach. Furthermore, studies suggest that FNB facilitates interpretation by less 
experienced pathologists and obviates the need for ROSE [43, 44]. All this is achieved in less 
needle passes than FNA, thereby limiting traumatic injury and procedure time [7, 20]. However, 
if the larger diameter and subsequent stiffness of an FNB needle hinder maneuverability and 
hence impede procurement of tissue, all these benefits may be annulled.
Several studies have compared the performance of EUS-FNA to FNB, but they did not estab-






















Figure 6. Diagnostic accuracy per center for the 25G FNA and 20G FNB needle.
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did not entail the whole range of potential indications, or were performed in a single center or 
confined geographical region [5, 8, 9, 11-17, 19].  Although in the present study the diagnostic 
accuracy varied between the 13 centers, this did not affect the difference in diagnostic accuracy 
between both needles, affirming the general applicability of our results.
Recently, a randomised trial compared procurement of histological tissue core by 22-gauge 
FNB and FNA in 46 patients with a pancreatic mass. The yield of total and tumor tissue was 
quantified by specialized software and showed a benefit of FNB over FNA [45]. However, this 
study was not powered to establish the impact of needle type on diagnostic accuracy. Also, the 
software used for tissue quantification has not been validated. So far, only one multicenter trial 
from China included an adequate number of patients to compare the diagnostic accuracy of 
FNA and FNB [19]. This trial found a diagnostic benefit of FNB over an equally sized FNA needle 
(accuracy for diagnosis of 93% versus 82%), but this benefit was limited to pancreatic lesions.
The 20-gauge FNB needle used in the present study was designed to combine a large lu-
men with enhanced flexibility, to facilitate tissue acquisition, even from an angulated scope 
position. According to the manufacturers design specifications this was achieved by coating the 
sheet of the needle with a smooth and flexible material (Polytetrafluoroethylene). Also, the 
cutting edges of the needle were changed from a reversed to a forward-facing bevel, and from a 
Lancet to a Menghini tip-design, to decrease resistance during tissue traversing (Figure 1). With 
these design modifications, the technical success rate of the 20-gauge FNB needle reached 
99%, despite the fact that a significant number of lesions were sampled from an angulated 
scope position, including pancreatic head masses. In addition, with the 20-gauge FNB needle, 
diagnoses were more often based on histology, as compared to FNA, while the cytological yield 
of the two needles was comparable.
In accordance with existing literature, multivariable analysis demonstrated that overall ac-
curacy of both needles was higher for pancreatic lesions and lymph nodes than for submucosal 
and other solid lesions [46, 47]. Notably, this did not annul the diagnostic superiority of FNB 
over FNA. Whereas previous FNB needles particularly improved the diagnostic accuracy for 
large and submucosal lesions, the currently tested needle showed to be the better choice for 
all types of solid GI-lesions. Multiple needle passes increased the diagnostic accuracy, which 
is in accordance with previous reports [20]. However, with the 20-gauge FNB, needle a higher 
diagnostic accuracy was achieved in less passes. Beyond three passes, hardly any performance 
improvement was observed.
The present study has some limitations. First, inherent to a lack of evidence-based practice 
guidelines, there was a diversity in EUS-practices of the participating centers which were not 
all controlled for the purpose of the study [46, 48]. It is still unknown which method for EUS 
guided tissue acquisition and processing is superior [18, 20, 31, 49]. For example, the attributive 
value of ROSE has not been proven and seems to depend on user’s experience and the sampling 
indication [43, 44, 49, 50]. Particular sampling techniques such as ‘slow pull or suction’ recently 
was shown to have no impact on the diagnostic outcome [31]. Second, as ROSE was allowed the 
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pathologist could not be blinded for needle type in these cases. However, as ROSE was performed 
in a minority of the cases this effect is expected to be limited. Third, for 22% of patients who 
underwent surgery a pathological gold standard diagnosis from a surgical resection specimen was 
available while for the remainder of patients the gold standard diagnosis was based on clinical 
follow-up with a median time of 13 months. This is in line with other studies and inherent to 
the clinical application of EUS-FNA/FNB. Fourth, this study was performed in high volume expert 
centers. Ideally, our results should be affirmed and found equally good in lower volume centers 
and community practices. In the current multicenter set-up including 13 international centers, we 
found a somewhat lower accuracy rates compared to other, mostly single center, studies [51-55]. 
Although the diagnostic accuracy varied between centers, this however did not affect the differ-
ence in diagnostic accuracy between the two study needles affirming the general applicability 
of our results for clinical practice. Lastly, we investigated one specific FNB needle, in casu the 
20-gauge ProCore needle of Cook Medical. It should be noted that there is a continuously growing 
number of EUS FNB needles, designed to procure histological rather than cytological specimens, 
including the SharkCore (Medtronic-Covidien) and Acquire biopsy needle (Boston Scientific) [51-
55]. Future studies should evaluate and compare FNB needles with distinguished design features.
In conclusion, the 20-gauge FNB needle (ProCore design) consistently out-performed one 
of the most widely used 25-gauge FNA needles, in terms of histological yield and diagnostic 
accuracy, in pancreatic as well as non-pancreatic lesions and independent of the number of 
passes performed. The consistency of its diagnostic benefit amongst the 13 participating cen-
ters supports the general applicability of these findings.
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A recently performed randomized controlled trial demonstrated the benefit of a novel 20G 
fine needle biopsy (FNB) over a 25G fine needle aspiration (FNA) needle. The current study 
evaluated the reproducibility of these findings among expert academic and non-academic 
pathologists.
dESiGN
This study was a side-study of the ASPRO (Aspiration vs PROcore) study. Five centers retrieved 
74 (59%) consecutive FNB and 51 (41%) FNA samples from the ASPRO study according to 
randomization; 64 (51%) pancreatic and 61 (49%) lymph node specimens. Samples were re-
reviewed by five expert academic and five non-academic pathologists and rated in terms of 
sample quality and diagnosis. Ratings were compared between needles, expert academic and 
non-academic pathologists, target lesions, and cytology versus histological specimens.
RESULTS
Besides a higher diagnostic accuracy, FNB also provided for a better agreement on diagnosing 
malignancy (ĸ=0.59 vs ĸ=0.76, p<0.001) and classification according to Bethesda (ĸ=0.45 vs 
ĸ=0.61, p<0.001). This equally applied for expert academic and non-academic pathologists and 
for pancreatic and lymph node specimens. Sample quality was also higher rated for FNB, but 
agreement ranged from poor (ĸ=0.04) to fair (ĸ=0.55). Histology provided better agreement 
than cytology, but only when a core specimen was obtained with FNB (p=0.004 vs p=0.432).
cONcLUSiON
This study demonstrates that the 20G FNB outperforms the 25G FNA needle in terms of di-
agnostic agreement, independent of the background and experience of the pathologist. This 
endorses the use of the 20G FNB needle in both expert and lower volume EUS centers.
KEYWORdS
FNA, FNB, interobserver agreement, pathology
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iNTROdUcTiON
Traditionally, endoscopic ultrasound (EUS)-guided tissue sampling has been carried out using 
a thin and flexible fine-needle aspiration (FNA) needle, which mainly yields individual cells 
(cytology) rather than histologically intact tissue fragments. Although diagnostic accuracy rates 
of FNA are fair, intact tissue fragments are preferred to enable identification of tumor invasion 
and allow for ancillary immunological and molecular testing, for example in submucosal and 
neuro-endocrine tumors [1-9]. Furthermore, histology enables genetic profiling and a patient 
tailored approach, which is becoming increasingly relevant in this era of personalized medicine 
[10-14]. The growing need for histology resulted in the introduction of the fine needle biopsy 
(FNB) needles.
So far, most studies reported an equal performance of FNA and FNB needles [6-9, 15], 
but recently, two large randomized trials showed a significant diagnostic benefit of FNB [16, 
17]. One of these studies, the randomized controlled ASPRO (ASpiration vs PROcore) trial, 
was carried out in 13 EUS-clinics, worldwide [17]. This study showed a diagnostic benefit of a 
novel 20G FNB needle (ProCore, Cook Medical, Bloomington, IN, USA) over a widely used 25G 
FNA needle (EchoTip Ultra, Cook Medical), irrespective of lesion type, size, and the number of 
passes performed. However, general applicability of these findings cannot be warranted, as 
study participation was confined to expert centers only.
Ideally, the superiority of a diagnostic device is reproducible in expert and non-expert 
hands. Therefore, the present study compares the diagnostic agreement on samples obtained 




In the course of the ASPRO trial (ClinicalTrials.gov: NCT02167074), 13 EUS centers randomized 
608 consecutive patients with a solid pancreatic lesion, lymph node, or submucosal or other 
solid lesion to sampling with a 20G FNB (ProCore, Cook Medical) or 25G FNA needle (EchoTip 
Ultra, Cook Medical), between February 2015 and September 2016. Parameters regarding 
specimen characteristics and diagnostic accuracy were compared. Gold standard diagnosis was 
based on the prior ASPRO study [17] either on pathological evaluation of the surgical resection 
specimens or clinical follow up for at least 9 months when surgical resection was not indicated. 
Gold standard diagnosis was recorded by the principal investigator of each of the participating 
centers.
For the present side-study, the first 125 pancreatic and lymph node cases that were enrolled 
in the ASPRO study were included. The samples of these cases were reassessed by five expert 
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academic and five non-academic pathologists. Diagnosis of malignancy and quality scores were 
assessed, and agreement on these outcome measures was compared between the two needles 
and between academic and non-academic pathologists.
As our study was a clinical trial, all authors could access the study data and have reviewed 
and approved the final manuscript.
Center, pathologist and case selection
Aspiration versus PROcore study centers were invited to contribute to this study if they had col-
lected at least 20 solid pancreatic and lymph node samples by April 2016, and their pathologist 
was trained to read both cytology and histology. Five ASPRO study centers fulfilled these criteria 
(Milan, Osaka-Sayama, Rome, Rotterdam, and Santiago de Compostela). Each center was repre-
sented by the specialized ‘academic’ pathologist, who was also involved in the original ASPRO 
study. This academic pathologist invited a ‘non-academic’ colleague from a local community 
practice hospital with a general clinical profile to participate. Expert academic pathologists had 
reviewed between 3000 and 40 000 EUS samples, including both, FNA and FNB, during their 
career, whereas the non-academics had a sample review track record between 50 and 1000. 
Per case, the academic pathologists selected the minimum number of slides required to obtain 
a tissue diagnosis, including immunohistochemically stained slides, if available.
EUS-guided tissue sampling
Endoscopic ultrasonography procedures were carried out with a convex array echoendoscope 
(either Pentax EG-3870 UTK or EG-3270UK; Pentax, Tokyo, Japan, or Olympus UTC 140/180/26; 
Olympus, Tokyo, Japan) as is described in the ASPRO study [17]. Three study sites had on-site 
pathological evaluation at their disposal (Milan, Rotterdam, and Santiago de Compostela).
Specimen processing
Tissue samples were preserved according to local practice. Cytological tissue samples were 
smeared on to glass slides and stained with Diff Quick (RAL diagnostics) (Rotterdam and Santiago 
de Compostela) or Hematoxylin and eosin staining (HE) (Milan, Osaka-Sayama, Rome). Remain-
der of the cytological specimens were collected in CytoLyt (CytoLyt Solution, Marlborough, 
MA, USA) (Rome, Rotterdam, Santiago de Compostela), saline (Osaka-Sayama), or formalin 
(Milan). Cell suspensions were processed into cell blocks, using the Cellient™ automated cell 
block system (Hologic, Toronto, Canada) (Rotterdam) or Agar technique (Milan, Rome, Santiago 
de Compostela). Osaka-Sayama did not further process cytology. Histology was collected in 
CytoLyt (Santiago de Compostela and Rotterdam) or formalin (Milan, Rome, Rotterdam, Osaka-
Sayama). Samples collected in formalin were processed as paraffin blocks, sectioned at 3-4 
microns, and stained with HE for morphological evaluation.
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Review session
Cases were reviewed during a 2-day session at the Erasmus MC University Medical Center 
Rotterdam, the Netherlands in April 2016. Each expert academic pathologist presented the 
selected cases providing information on the patient’s gender, age and relevant medical history, 
type of target lesion (lymph node or solid pancreatic lesion) and a summary of the EUS report. 
Pathologists were blinded for the final clinical and pathological outcome. Slides were viewed 
simultaneously, using a multi-headed light microscope, but assessed individually. Slides, 
representative of a case, were presented, including immunohistochemically stained slides, if 
available. Each pathologist reviewed all cases, including their own.
Outcome measures and definitions
The primary outcome measure was to compare the diagnostic agreement on samples obtained 
with the two needles. First, samples were assessed for malignancy (yes/no) and classified ac-
cording to Bethesda (non-diagnostic, benign, atypical/suspect of malignancy, and malignant) 
[18]. Solid-pseudopapillary neoplasms were classified as malignant. Neuroendocrine and 
spindle cell tumors were classified malignant only if they harbored high-grade dysplasia or 
an invasive component. Secondly, we evaluated if diagnostic agreement for the two needles 
differed between expert academic and non-academic pathologists, between pancreatic and 
lymphatic lesions, and between specimens containing cytology and histology.
Furthermore, agreement on specimen quality parameters was assessed and compared 
between the two needles, and between expert academic and non-academic pathologists. The 
following quality parameters were scored: presence of artifacts, sample sufficiency, presence of 
target cells and tissue cores and suitability for additional analysis. Artifacts were subdivided in 
five categories; poor fixation or drying artifacts, thick smears, blood clots, contamination with 
other cells (mesothelial, liver, gastric or intestinal epithelium), and other. Sample sufficiency 
was defined as the presence of sufficient target cells to obtain or exclude a certain diagnosis. 
Target cells were classified as less or more than 50%. Presence of tissue core was defined as 
the presence of a measurable microscopic cylinder containing target organ cells with preserved 
histologic structure.
Last, we assessed if and to what extent, pathologist’s experience or specimen characteris-
tics influenced diagnostic accuracy.
Statistics
The sample size for this study was derived from Walter et al [19]. Given the availability of 
10 observers (5 academic and 5 non-academic pathologists), 50 samples are needed to be 
analyzed per needle type (50 x 2 = 100 in total), given a one-sided alpha of 0.05, a power 
of 80%, a minimally acceptable interrater reliability of 0.6 for agreement on the presence of 
malignancy, and a minimal deviation from the interrater reliability of 0.2 between the two 
needles, n=10. Inter-observer agreement was calculated by the use of kappa statistics Fleiss’ĸ-
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statistic and 95% confidence intervals (Cls). Kappa- statistics were interpreted according to the 
convention of Landis and Koch; <0, no agreement; 0-0.20, slight agreement; 0.21-0.40, fair 
agreement; 0.41-0.60, moderate agreement; 0.61-0.80, substantial agreement; and 0.81-1.0; 
almost perfect agreement. The chi-squared test was used to compare the diagnostic agreement 
between the two study needles, academic and non-academic pathologists, target lesion types, 
and cytological and histological samples. Although all 10 observers assessed the samples for 
each of the outcome parameters, we only report the average outcome per parameter. Last, uni-
variate logistic regression analysis was applied to assess if a pathologist’s expertise and sample 
quality influenced diagnostic accuracy. Outcomes of this analysis were expressed as odds ratio 
(OR) with 95% CI. Statistical significance was defined as p<0.05 (two-tailed). Analyses were 
carried out using SAS version 9.4 (SAS Institute, Cary, NC, USA), and SPSS version 22, Statistical 
Package for the Social Sciences (SPSS Inc., Chicago, IL, USA).
RESULTS
Target lesion and procedure characteristics
A total of 125 samples were reviewed, of which 74 were collected by FNB (59%) and 51 by FNA 
(41%), with a mean of 2.8 needle passes. Sixty-four were solid pancreatic lesions (51%) and 61 
lymph nodes (49%), with a mean size of 30.4 ± 1.3 mm. Table 1 shows the case and sampling 
specifics. Techniques intended to increase the sample yield were applied in 94% of cases; suc-
tion with a syringe in 74 (63%), the slow-pull technique in 50 (37%), and a combination of the 
two in five (4%). The gold standard diagnosis comprised 26 (21%) non-malignant cases, and 99 
(79%) malignant cases (Table 1). The gold-standard diagnosis was based on surgical resection 
specimens in 31 cases (25%).
Diagnostic accuracy and agreement
In line with the ASPRO study results, FNB samples provided higher accuracy than FNA for malig-
nancy (88% vs 77%, p=0.002) and classification according to Bethesda (76% vs 61%, p=0.002). 
Regarding the primary question of diagnostic agreement, FNB samples provided better agree-
ment on the presence of malignancy (ĸ=0.76 vs 0.59, p<0.001) and classification according 
to Bethesda (k=0.61 vs 0.45, p<0.001, table 2). This was true for both, expert academic and 
non-academic pathologists (Table 2).
Assessment per target lesion showed that for lymph nodes, FNB provided higher agreement 
on the presence of malignancy and classification according to Bethesda. However, in pancreatic 
lesions FNB only outperformed FNA for agreement on the Bethesda classification, not for the 
presence of malignancy (Table 3). When comparing histology to cytology, agreement on the pres-
ence of malignancy was better for histological samples, but agreement on the Bethesda classifica-
tion was better for histological samples if they had been obtained with the FNB needle (Table 4).
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Specimen quality and agreement
Compared to FNA, FNB samples contained fewer artifacts (52% vs 45%, p=0.007, table 2), but 
agreement was low for both FNB (ĸ=0.10; 95% CI 0.07-0.14) and FNA samples (ĸ=0.17; 95% CI 
0.13-0.21). Agreement did not differ between expert academic and non-academic pathologists 
for FNA (p=0.132) or FNB (p=0.212). Sample sufficiency for diagnosis, percentage of target cells, 
presence of tissue cores, and suitability for additional analysis were all better for FNB than FNA, 
but again, agreement on these parameters was poor (ĸ=0.04) to fair (ĸ=0.55, table 2). As for the 
collection of histology, FNB obtained histological samples more often than FNA (70% vs 36%, 
p<0.001, table 2). Agreement on all of the above-mentioned quality parameters was highest 
for the expert academic pathologists. Furthermore, agreement amongst the expert academic 
Table 1. Case and sampling specifics.
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 NET high grade
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FNB; fine needle biopsy, FNA; fine needle aspiration, mm; millimeter, SD; standard deviation, GIST; gastrointestinal stromal 
lesion, NET; neuroendocrine tumor.
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pathologists was higher for FNB than FNA specimens. In non-academic pathologist however, 
FNB only provided for better agreement than FNA for the identification of tissue cores (ĸ=0.26 
vs 0.04, p<0.001).
Table 2. Agreement on sample diagnosis and quality amongst the pathologist groups per needle type
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FNB; fine needle biopsy, FNA; fine needle aspiration, no.; number, κ; kappa statistic, CI; confidence interval.
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Factors affecting diagnostic accuracy
Besides the type of needle, other factors affecting EUS-sample diagnosis are shown in table 
5. A pathologist’s background (expert academic or non-academic) did not influence the diag-
nostic accuracy of either needle (p=0.250). The presence of artifacts did have an effect, as this 
resulted in a lower diagnostic accuracy (p=0.030). Last, the presence of tissue cores significantly 
improved diagnostic accuracy (p=0.003).
Table 3. Diagnostic agreement of FNA and FNB per target lesion.
Scored variables
























FNB; fine needle biopsy, FNA; fine needle aspiration, CI; confidence interval.
Table 4: Diagnostic agreement on cytological and histological specimens per needle type.
Agreement κ (95% ci) cytology histology p-value
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diScUSSiON
In addition to the previously reported diagnostic benefit of a novel 20G FNB over a commonly 
used 25G FNA needle, the present study shows that diagnostic agreement is also higher for 
the FNB than FNA samples. More importantly, agreement on FNB samples was higher amongst 
pathologists from different backgrounds (academic vs community practice) and with different 
levels of experience (high vs lower volume). The benefit of FNB equally applies to pancreatic 
and lymphatic target lesions. The finding that FNB samples were of better quality and harbored 
histology more often, likely contributed to their superior diagnostic performance.
Most studies on EUS-needle devices have been carried out in expert high-volume centers. 
However, EUS-guided tissue sampling is increasingly applied in lower-volume centers. So far, 
few studies have evaluated the reproducibility of EUS-FNA/FNB results. Moreover, most of 
these studies had a limited number of observers, concerned one type of target lesion, or were 
carried out in an academic practice only [20-24]. Previous studies reported diagnostic agree-
ment rates ranging from moderate to excellent for FNA (κ=0.45-0.89) and FNB (κ=0.61-0.94). 
Recently, a promising study aimed to validate a novel scoring system to further optimize diag-
nostic agreement amongst cytopathologists [24]. Unfortunately, despite the fact that observers 
were selected from tertiary centers, diagnostic agreement for pancreatic FNA specimens was 
still suboptimal (ĸ=0.56). Compared to these agreement rates, the 20G FNB needle performed 
well, especially when taken into account pathologists from all over the world were included, 
academics and non-academics alike. The 20G FNB needle may thus contribute to improve 
reproducibility of EUS-FNA/B diagnosis.
The first explanation for a better agreement on FNB samples is its high tissue core rate, as 
the collection of histology rather than cytology was positively associated with a higher agree-
ment. This is supported by the finding that the cytological yield of FNB was also higher than 
for FNA, but only availability of tissue cores for histology, and not cytology, contributed to 
a better diagnostic accuracy. The importance of tissue core samples over cytological ones to 
reach a correct diagnosis when using an FNB needle has been previously described by others 
[20]. Compared to other FNB needles, the cytological yield of the current 20G FNB needle 
was high as well [9, 20, 22, 25-31]. Whereas previous studies reported sufficient cellularity in 
19% to 52%, in the current study this was 68%. The only device that provides higher histol-
ogy and cytology rates is the 19G needle [22, 25], which obtains cores in 88% of samples and 
an adequate amount of loose target cells in 91%. However, the reported clinical applicability 
of being able to obtain tissue with the 19G FNB needle (81%) is much lower than the 20G 
FNB needle (99%). Although the increased flexibility of the 20G FNB needle is likely a major 
contributor to its better performance, other needle design adjustments may have improved the 
tissue acquisition rate too[32, 33].
Another quality parameter that may have contributed to the high diagnostic agreement on 
samples obtained with FNB is a low artifact rate. Although artifacts not necessarily decrease ac-
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curacy when abundant tissue is collected, previous studies have shown that they may hamper 
for example advanced genetic testing [34]. Interestingly, agreement on the presence of artifacts 
was low for both needles (although slightly better for FNB than FNA). This is in line with the fact 
that agreement on all sample quality parameters was rather low, similar to reports from others 
[21, 24]. This may result from a lack of EUS-sample quality definitions. In the current study, we 
tried to minimize this limitation by using the predefined scoring system, as proposed by the 
Papanicolaou Society of Cytopathology in 2014 [18].
There are several limitations to our study. First, each academic pathologist brought and 
presented his or her own slides. Although they too were blinded for the final outcome, we 
cannot exclude recall bias. However, this only applied to a few cases per pathologist. Secondly, 
pathologists assessed samples individually, while in daily practice, difficult cases are often 
discussed amongst colleagues. Therefore, interobserver agreements reported in the current 
study may underestimate real-life reproducibility. Thirdly, our study involved pathologists 
from 10 centers from around the world, while previous studies were confined to no more 
than five centers from the same geographical region. In the absence of uniform guidelines 
for EUS-guided tissue sampling and processing, it is inevitable that there are geographical and 
institutional differences in the work-up of specimens. These differences may have resulted in 
slight differences in the appearance of specimens, which may have hampered interpretation 
by pathologists not familiar with certain preparation techniques. Lastly, it must be considered 
that all samples were collected by expert endosonographers. For an ideal assessment of the 
reproducibility of the outcome of the ASPRO study, the study should be repeated in low volume 
centers, with less experienced endosonographers.
In conclusion, this study demonstrates that the novel 20G FNB needle outperforms the 25G 
FNA needle in terms of diagnostic agreement, as its diagnostic superiority is not limited by the 
expertise and experience of the reviewing pathologist. Better sample quality and presence of 
histology seem to be the responsible determinants for the better diagnostic performance of the 
20G FNB needle. Together with the favorable accuracy rates from the previous ASPRO study, 
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Instead of choosing one endoscopic ultrasound (EUS) needle over the other, some advocate the 
use of fine-needle aspiration (FNA) and fine-needle biopsy (FNB) consecutively. We explored 
the yield of combined use of 20-gauge (G) FNB and 25G FNA needles in patients with a suspi-
cious solid gastrointestinal lesion.
methods
Patients from the ASPRO (Aspiration vs PROcore) study who were sampled with both needles 
during the same procedure were included. The incremental yield of dual sampling compared 
with the yield of single needle use on the diagnostic accuracy for malignancy was assessed for 
both dual sampling approaches – FNA followed by FNB, and vice versa.
Results
73 patients were included. There were 39 (53%) pancreatic lesions, 18 (25%) submucosal 
masses, and 16 (22%) lymph nodes. FNA was used first in 24 patients (33%) and FNB was used 
first in 49 (67%). Generally, FNB was performed after FNA to collect tissue for ancillary testing 
(75%), whereas FNA was used after FNB to allow for on-site pathological assessment (76%). 
Diagnostic accuracy for malignancy of single needle use increased from 78% to 92% with dual 
sampling (p = 0.002). FNA followed by FNB improved the diagnostic accuracy for malignancy 
(p = 0.03), whereas FNB followed by FNA did not (p = 0.13).
conclusion
Dual sampling only improved diagnostic accuracy when 25G FNA was followed by 20G FNB and 
not vice versa. As the diagnostic benefit of the 20G FNB over the 25G FNA needle has recently 
been proven, sampling with the FNB needle seems a logical first choice.
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iNTROdUcTiON
Over the past decades, endoscopic ultrasound (EUS)-guided tissue sampling has become an 
important tool in the diagnosis and staging of lesions around the gastrointestinal tract. For 
this purpose, both fine-needle biopsy (FNB) and aspiration (FNA) devices are used. Whereas 
FNA needles are generally more flexible and easier to use from an angulated scope position, 
FNB needles are designed to collect histologically intact tissue samples, which enable ancil-
lary testing. As histology is indispensable in this era of personalized medicine, collection of 
samples for histological analysis has become more important. Recently, two randomized trials 
demonstrated that FNB needles produce a better diagnostic yield than FNA needles in this 
context [1,2].
Instead of choosing one needle over the other, some advocate the selective use of both 
needle types consecutively (dual needle sampling) [3–7]. As the number of passes only seems 
to improve diagnostic accuracy up to a certain number of passes, the benefit of dual sampling 
probably lies within the combination of two different needle designs [8]. For example, FNA can 
be applied to obtain an on-site diagnosis through rapid on-site tissue evaluation (ROSE) and may 
then be followed by FNB to harvest tissue cores. This sequence prevents costly ancillary testing 
of unrepresentative tissue. Others start with FNB and switch to FNA in case they are faced with 
a small or fibrotic lesion that is anatomically difficult to reach. Although endosonographers are 
confronted with this needle choice dilemma on a daily basis, few studies have addressed the 
yield of dual needle sampling, and those that have report inconclusive results [8–14].
Owing to scant data, there is no clarity on the indication for dual sampling, the optimal 
needle order, safety, or costs. The current study aimed to explore the incremental yield of 
combined needle use in patients requiring EUS-guided tissue sampling of a solid gastrointesti-
nal lesion. This was assessed for two sampling orders: sampling with a conventional 25G FNA 
needle followed by a 20G FNB needle, and vice versa.
mEThOdS
Study design and case selection
Patients from the ASpiration vs PROcore needle (ASPRO) study, which was approved by the 
institutional review boards of the participating centers, were included in the current study. This 
multicenter trial compared the diagnostic value of a 20G FNB needle (ProCore; Cook Medical, 
Limerick, Ireland) with a 25G FNA needle (EchoTip Ultra; Cook Medical) in patients undergoing 
EUS-guided tissue sampling of a solid pancreatic lesion, lymph node, or subepithelial or other 
solid lesion (ClinicalTrials.gov: NCT02167074). Patients were allocated to one needle, but the 
protocol allowed additional sampling with the other needle, as long as specimens were ana-
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lyzed separately. All patients who were sampled with both needles during the same procedure 
were included in the present side study (Figure 1).
EUS-procedure and tissue acquisition
The participating endosonographers were experts who performed at least 250 EUS-guided 
sampling procedures per year. They used Pentax (EG-3870UTK; Pentax, Tokyo, Japan) or Olym-
pus echoendoscopes (UTC 140/160/180/190/260 or UC140; Olympus, Tokyo, Japan) with color 
Doppler. In cases of multiple lesions, the most suspicious lesion was targeted. Lesions were 
punctured at least three times with the allocated needle, followed by one or more punctures 
with the alternative needle during the same procedure. For each needle, the number of passes 
was recorded. ROSE was available at four of the study sites (Irvine, Milan, New Haven, Rot-
terdam).
Specimen processing protocol
Cytological samples were smeared onto glass slides and stained with Diff-Quik (Adelaide, 
Irvine, New Haven, Rotterdam), or hematoxylin and eosin staining (HE) (Milan, Osaka-Sayama). 
The remaining material was collected in CytoLyt (Cytyc Corp., Marlborough, Massachusetts, 
USA) (Adelaide, Rotterdam), saline (Osaka-Sayama), formalin (Irvine, Milan), or CytoRich Red 
Figure 1. Flow chart of patient selection from the main ASPRO study.
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(Thermo Fischer Scientific, Kalamazoo, Michigan, USA) (New Haven). Cytological cell suspen-
sions were further processed using the ThinPrep technique (Hologic Inc., Marlborough, Mas-
sachusetts, USA) (New Haven) or cell block technique using the Cellient automated cell block 
system (Hologic Inc.), the agar technique or Histogel (Richard-Allan Scientific Co., Kalamazoo, 
Michigan, USA) (Irvine, Milan, New Haven, Rotterdam). Histological samples were collected in 
formalin, processed as paraffin blocks, and stained with HE or Giemsa. In Rotterdam, histological 
specimens were also collected in CytoLyt and processed according to the cell block technique.
Outcome parameters and definitions
The primary outcome was the incremental yield of dual sampling, compared with single needle 
use, on the diagnostic accuracy for malignancy for both sampling orders – FNA followed by FNB, 
and vice versa. A diagnosis of malignancy was confirmed (gold standard) by surgical resection 
specimens, when available, or, in nonsurgical patients, by a compatible clinical disease course 
during a 9-month follow-up period. To further specify the type of cases that were selected 
for the current study, we compared case characteristics of the current cohort with those of 
patients in the main ASPRO study.
Statistics
Categorical data were recorded as frequencies and percentages. Continuous data were dis-
played as means with standard error as medians with interquartile range. The student’s t test 
was used to compare normally distributed continuous variables, and the Fisher’s exact test or 
chi-squared test was used to compare categorical variables. An exact McNemar test was used 
to compare the diagnostic accuracy of single vs. combined needle use within the same patient. 
A chi-squared test was used to compare the accuracy between the two sampling orders, and 
between cases from the current study and the ASPRO study cohort (patients from the cur-
rent study were excluded from the ASPRO cohort). Statistical significance was established as 
P < 0.05 (two tailed). Analyses were carried out using SPSS version 22 (IBM Corp., Armonk, New 
York, USA).
RESULTS
Sampling order and reason for dual sampling
Six of the 13 ASPRO centers used dual sampling (Adelaide, Irvine, Milan, New Haven, Osaka-Saya-
ma, Rotterdam). In total, 73 of the 608 ASPRO patients (12%) were punctured by both needles; 
FNA was used first in 24 patients (33%) and FNB was used first in 49 patients (67%). According 
to the endosonographers, the rationale for performing additional sampling differed, depending 
on the allocated needle (P < 0.001, table 1); generally, after FNA, FNB was performed to collect 
tissue for ancillary testing (75%), whereas after FNB, FNA was used to allow for ROSE (76%).
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case characteristics
Target lesions included 39 (53%) solid pancreatic lesions, 18 (25%) submucosal masses, and 16 
(22%) lymph nodes. Figure 2 shows endoscopic images of EUS-guided tissue sampling of two 
cases with solid pancreatic lesions. Most pancreatic lesions were located in the head (64%), 
Table 1. Baseline characteristics.
Variables All cases
(n=73)







center of origin, n (%)

























Reason sampling alternative needle, n (%)
 To allow for ROSE













































































Lesion size (mm), median (iQR) 35.0 (20-41) 26 (21-40) 35 (25-43) 0.786
Total number of needle passes, mean ± SE
 Overall
 With randomized needle













Pathologist present, n (%)
 With randomized needle









FNA: fine needle aspiration; FNB: fine needle biopsy; USA: United States of America; ROSE: rapid on-site pathological evalua-
tion; n: number of cases; mm: millimeter; IQR: interquartile range; SE: standard error.
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most lymph nodes were located in the abdomen (94%), and submucosal lesions were mostly of 
gastric origin (44%). There were no significant differences in patient or target lesion character-
istics between cases sampled with FNA or FNB first (Table 1 and 2).
Figure 2. Endoscopic ultrasound images of hypodense lesions of the pancreatic head.
a  Lesion, 4 cm in size, irregular borders, and in close proximity to superior mesenteric artery, sampled with the 20G fine-
needle biopsy needle. 
b  Lesion, 2 cm in size, irregular borders, sampled with the 25G fine-needle aspiration needle.








malignant lesions, n (%) 59 (81) 18 (75) 43 (88) 0.16
 Adenocarcinoma 39 10 29
 GiST 7 2 6
 NET 3 2 2
 malignant lymphoma 4 1 3
 Squamous cell carcinoma 1 1 0
 malignant cyst 2 1 1
 Other malignant lesions 3 1 2
Benign lesions, n (%) 14 (19) 6 (25) 8 (16)
 Lymph adenopathy 4 2 2
 Leiomyoma 1 0 1
 GiST 1 0 1
 NET 2 0 2
 duplication cyst esophagus 1 1 0
 Benign schwannoma 1 1 0
 Other benign lesions 4 2 2
FNA: fine needle aspiration; FNB: fine needle biopsy; n: number of cases; GIST: gastrointestinal stromal tumor; NET: neuro-
endocrine tumor.
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Compared with the main ASPRO cohort, patients who were selected for combined needle 
use had larger target lesions (37.1 ± 2.54 vs. 32.0 ± 0.83 mm; p = 0.04, table 3), were more 
often sampled from a duodenal scope position (p = 0.04), and more often had a pathologist in 
the room during the procedure (p < 0.001). As expected, more needle passes were performed 
per case (p < 0.001). Interestingly, the diagnostic accuracy for single use of either randomized 
needle (FNA or FNB) was comparable for the cases from the main ASPRO study and the current 
cohort (Table 3).
incremental yield of dual sampling on diagnostic accuracy
Gold standard diagnosis demonstrated 59 malignancies (81%), of which 18 (25%) were diag-
nosed based on resection specimens (Table 2). Overall diagnostic accuracy for malignancy of 
single needle use was 78% (57/73), which increased to 92% (67/73) when both needles were 







male, n (%) 37 (51) 307 (57) 0.279












Lesion size (mm), mean ± SE 37.1 ± 2.54 32.0 ± 0.83 0.042








Total number of needle passes randomized needle
 1-3 passes, n (%)
 >3 passes, n (%)
Total number of needle passes overall
 1-3 passes, n (%)




























diagnostic accuracy, n (%)
 Randomized needle overall
 Randomized needle FNA










ASPRO: aspiration versus procore needle; FNA: fine needle aspiration; FNB: fine needle biopsy; n: number of cases; SE: stan-
dard error; GIST: gastrointestinal stromal tumor; NET: neuroendocrine tumor
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used (p = 0.002, table 4). The incremental yield of dual sampling over single needle use dif-
fered depending on which needle was used first: FNA followed by FNB resulted in a significant 
increase in accuracy (p = 0.03), whereas FNB followed by FNA did not (p = 0.13, table 4).
Of all 16 cases (22%) that were incorrectly diagnosed after single needle sampling, 10 (59%) 
benefited from the alternative needle (Table 5). Cases that benefitted comprised 6 of the 24 
cases in which FNB was used after FNA (25%), and 4 of the 49 in which FNA was applied after 
FNB (8%). FNA cases that benefitted from subsequent FNB sampling comprised a pancreatic 
adenocarcinoma, a metastatic lymph node, a benign schwannoma of the rectum, and three 
cases of benign lymphadenopathy. The four FNB cases that benefitted from subsequent FNA 
sampling included three pancreatic adenocarcinomas and a lymph node metastasis.
Table 4. No. of correctly diagnosed cases for single versus combined needle use per sampling regime.





Overall, n=73 57 (78) 67 (90) 0.002
FNA-FNB, n=24 18 (75) 24 (100) 0.031
FNB-FNA, n=49 39 (80) 43 (88) 0.125
FNA: fine needle aspiration; FNB: fine needle biopsy; n: number of cases, No: number.
Table 5. Specification of all cases that were incorrectly diagnosed after sampling with initial needle/could 






















Yes Atypical Non-diagnostic Malignant 
fibromatosis








3 Pancreas 11 Antrum No Non-
diagnostic
Non-diagnostic NET, Octreoscan 
confirmed
4 Pancreas 35 Corpus Yes Bile duct 
tissue only
HG IPMN HG IPMN
5 Submucosal 140 D2 Yes Benign Non-diagnostic Leiomyosarcoma
6 Lymph node 27 Rectum Yes Non-
diagnostic









Two recent large randomized controlled trials showed that FNB outperforms FNA in terms of 
histological yield and diagnostic accuracy [1,2]. The current study demonstrated that combined 
needle sampling only improves diagnostic accuracy when FNA is followed by FNB, but not vice 
versa. As stated above, the theory behind the benefit of a needle switch, or so called “dual 
sampling,” is that FNA and FNB are complementary. FNA needles collect cytological samples 
rather than material for histological analysis; their strength lies in their flexibility, which enables 
them to reach and traverse difficult target lesions, and the fact that they allow for on-site 
pathological evaluation. FNB devices, however, collect intact histological tissue cores, allowing 
for a wide range of diagnostic tests. Regarding the use of ROSE, the so-called “sample crush 
technique” may also allow for on-site specimen assessment of FNB samples [15,16].  However, 
the optimal method of performing ROSE on FNB samples has yet to be determined.
The explanation as to why FNB following FNA has incremental value and FNA following FNB 
does not is multifactorial. First, the 20G FNB needle was proven to be diagnostically superior 
to the 25G FNA needle in our previous study. Thus, this also explains why FNA followed by FNB 
results in a higher diagnostic accuracy than FNA alone and the limited value of the reversed 
Table 5. Specification of all cases that were incorrectly diagnosed after sampling with initial needle/could 


















10 D1 No Non-
diagnostic
Non-diagnostic NET on CT
9 Pancreatic 
head
20 D1 Yes Benign Non-diagnostic Adenocarcinoma
10 Pancreatic 
head
25 D1 Yes Benign Malignant Adenocarcinoma
11 Lymph node 26 Gastric 
corpus
No Insufficient Adenocarcinoma Metastasis
12 Pancreatic 
head
25 D2 No Few atypical 
cells
Adenocarcinoma Adenocarcinoma






14 Submucosal 29 Rectum No Insufficient Benign Schwannoma
15 Lymph node 15 Gastric 
corpus








FNA: fine needle aspiration; FNB: fine needle biopsy; n: number of cases; mm: millimeter; ROSE: rapid on-site pathological 
evaluation; NET: neuroendocrine tumor; HG: high grade; IPMN: intraductal papillary mucinous neoplasm; D1: superior duo-
denal part; D2: descending duodenal part; CT: computed tomography
5
Combined use of FNA and FNB 99
approach. Second, puncture with the more traumatic FNB needle poses a higher risk of blood 
contamination of subsequent specimens. In addition, the larger FNB needle may cause “track-
ing,” impeding the FNA needle from finding its own diagnostic route. Third, secondary FNA 
was mostly used to allow for ROSE. However, the incremental yield of ROSE is questionable 
[2,17]. Its impact on diagnostic accuracy has only been demonstrated for endosonographers in 
training or in centers with low accuracy rates [11]. The current study included only high-volume 
expert centers, in which the benefit of ROSE is expected to be limited.
The finding that one sampling order benefitted from dual sampling, whereas the other did 
not, cannot be explained by differences in case or procedure characteristics, as these did not 
differ between groups. However, we did observe that non-pancreatic lesions mainly benefitted 
from FNB following FNA. This may be explained by the fact that diagnosing and staging of 
lymphomas, smooth muscle tumors, and metastases require abundant histological tissue for 
ancillary testing [8,18–22]. In contrast, three out of four cases that benefitted from additional 
FNA concerned pancreatic lesions. As these lesions tend to be hard and fibrotic, they may be 
more easily sampled using a smaller FNA needle.
When comparing the current subgroup with the main ASPRO study cohort, endosonog-
raphers selected cases for dual sampling that were bigger in size and more often punctured 
from the duodenum. Although it was not reported, a larger lesion may have created a desire 
to harvest more tissue, in order to secure a diagnosis. The high frequency of duodenal punc-
tures seems to indicate that target lesions that were difficult to reach were selected for dual 
sampling. Interestingly, the diagnostic accuracy of combined needle use did not differ from our 
previously reported single use [2].
So far, only seven studies have reported on the incremental yield of dual sampling [8–14]. 
Four studies found a significant increase in diagnostic accuracy when both FNA and FNB were 
used during the same procedure. However, two studies used the TruCut needle and two used 
a reversed bevel ProCore device, thus hampering comparison with our results. Furthermore, 
no study assessed the needle order, and only reported the incremental yield of additional FNB 
or the combination of the two devices. Our study is the only available study that has looked 
at the “needle order,” and is hypothesis generating, especially with respect to studying the 
cost-effectiveness of different sampling strategies. Of the previous dual sampling studies, so far 
only one reported on cost-effectiveness; FNB alone was cost saving compared with FNA alone 
or FNA followed by FNB [12]. As only one study has reported on this, it would be interesting 
for future studies to assess the costs of the different sampling strategies, such as FNA with or 
without ROSE, FNA followed by FNB or FNB alone.
Obviously, this study has limitations. As mentioned earlier, cases were selected based on 
the endosonographers’ choice and not on predefined criteria. This may have introduced selec-
tion bias. A second limitation is that dual sampling was not compared with continuous sampling 
with the allocated needle. As harvesting more tissue alone may be responsible for a diagnostic 
benefit, this is of interest. Third, the diagnosis of the first needle may have encouraged the 
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pathologist to find the same diagnosis in the second sample. However, as needle sequence was 
randomly determined, the effect of this bias is negligible. Finally, we did not assess the impact 
of dual sampling on procedure time and costs.
In conclusion, for EUS-guided tissue sampling, the 20G FNB needle seems a logical first 
choice, as it was proven to be superior to the 25G FNA needle, and an incremental value of FNA 
following FNB was not demonstrated. FNA after FNB may be considered in fibrotic pancreatic 
lesions, or lesions that are too difficult to reach from an angulated score position. Some may 
still prefer to start with FNA to assess the accessibility and cellularity of a lesion and to prevent 
costly ancillary testing of unrepresentative tissue. There seems to be a role for FNB after a 
non-diagnostic attempt with FNA, especially for lesions of non-pancreatic origin.
5
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EUS guided tissue acquisition is extensively used, but the optimal sampling device is still a 
matter of debate. Since the last meta-analysis on this subject, a substantial number of studies 
have been published. Thus, an update was required.
mEThOdS
EMBASE, MEDLINE/PubMed, Web of Science, the Cochrane Library, and Google Scholar were 
systematically searched. We included randomized controlled trials that involved at least 50 
cases with a suspected solid gastrointestinal lesion and that compared one of the novel FNB 
needles (ProCore, SharkCore, and Acquire) to FNA. Outcome measures included diagnostic ac-
curacy, adequacy, number of passes, presence of tissue cores, and adverse events. Quality was 
assessed based on the QUADAS-2 tool.
RESULTS
We identified 18 RCT that compared 1046 FNA to 1004 FNB cases, and 648 cases that were 
sampled with both needles. All studies involved ProCore as FNB needle. The pooled diagnostic 
accuracy was higher for FNB (OR1.70 95%CI 1.19 to 2.41, p=0.003), as was the tissue core rate 
after sensitivity analysis (OR2.17, 95%CI 1.21 to 3.91, p=0.01). In addition, less passes were 
performed with FNB (MD -0.54, 95%CI -1.03 to -0.04, p=0.03). Complication rate was low and 
did not differ between FNA and FNB (p=0.80). These findings equally applied to solid gastroin-
testinal lesions and pancreatic lesions. Studies were sufficiently powered, well designed, and 
harbored a low risk of bias.
cONcLUSiON
The ProCore FNB needles outperform FNA in establishing a diagnosis of any type of solid 
gastrointestinal lesion. Moreover, they secure a higher tissue core rate, with comparable com-
plications.
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iNTROdUcTiON
Endoscopic ultrasound (EUS) guided tissue sampling is a well-established technique to provide 
a pathology-based diagnosis of lesions in and around the gastrointestinal tract [1, 2]. Also, 
it is increasingly used to enable pre-therapeutic tissue analysis for targeted treatment [3]. 
Traditionally, EUS-guided tissue sampling was performed with a fine-needle aspiration (FNA) 
needle, which mainly harvests loose cells or cytology. Apart from its limited ability to establish 
tumor invasion and diagnose certain conditions (i.e. auto-immune pancreatitis, submucosal or 
stromal lesions, and neuro-endocrine tumors [4-6], it strongly depends on rapid on-site tissue 
evaluation (ROSE) by a dedicated pathologist, which is not always available [7-10]. Also, it may 
not provide enough material for ancillary testing.
Fine-needle biopsy (FNB) devices were introduced to overcome these limitations, by 
harvesting histologically intact tissue fragments. The first devices, the TruCuttm (Travenol 
Laboratories) and Quick-Core® (Cook Medical) needles, were hampered by a rigid design and 
difficult deployment. Since then, several novel FNB devices have been introduced, including 
the ProCore reversed and forward facing bevel needles (Cook Medical, Ireland), the Fork-tip 
(SharkCore, Medtronic), and Franseen needle (Acquire, Boston Scientific).
Despite growing evidence on the diagnostic benefits of FNB over FNA, so far, just one meta-
analysis found a higher diagnostic accuracy for FNB, but only for pancreatic masses [11]. As 
several large studies have been published since then, we aimed to provide an updated review 
and meta-analysis of studies comparing FNA to the novel FNB needles, including ProCore, 
SharkCore and Acquire (Figure 1A-D).
mEThOdS
Study selection
EMBASE, MEDLINE/PubMed, Web of Science, the Cochrane Library, and Google Scholar were 
systematically searched to identify studies that had compared FNA to the new generation of 
FNB needles, including the ProCore reversed and forward facing bevel needles (Cook Medi-
cal, Ireland), and the Fork-tip (SharkCore, Medtronic) and Franseen needles (Acquire, Boston 
Scientific) for sampling of a solid lesion reachable from the gastrointestinal tract. A combina-
tion of subject headings and text words were used. The key search words were ‘endoscopic 
ultrasound’, ‘fine needle aspiration’, ‘fine needle biopsy’, ‘core biopsy’, ‘procore’, ‘sharkcore’, 
‘franseen’, ‘acquire’, ‘fork-tip’, ‘histology’ and ‘cytology’. The EMBASE search strategy was 
adapted for use in the other databases. The search focused on human studies without language 
restrictions. All searches were performed on April 8, 2019. Two independent authors (PvR and 
DC) systematically reviewed the title and abstract of every retrieved record. If this information 
suggested that inclusion criteria were met, available full text articles were read and evaluated. 
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Any disagreement between the reviewers was resolved by discussion with the third author 
(MB).
in- and exclusion criteria
We included randomized controlled trials (RCTs) that involved at least 50 patients and reported 
on at least two outcome measures. Studies were excluded if they lacked data to reliably extract 
the outcome measures. In case of multiple publications on the same population, the most 
recent publication was included. Conference abstracts were included from the year 2017, as 
they are still likely to be published as a manuscript.
Outcome measures: definitions and data extraction
Data was extracted on; 1) diagnostic accuracy, based on the final diagnosis (or confirmation 
of malignancy) obtained from a resection specimen or clinical follow-up period; 2) diagnostic 
adequacy, defined as the macroscopic sample sufficiency for diagnosis (yes/no) ; 3) presence 
of tissue cores, defined as a measurable microscopic cylinder, containing target organ cells 
with preserved histological architecture preserved tissue architecture, adequate for histologic 
Figure 1A. 22G ProCore FNB reversed bevel needle Figure 1B. 20G ProCore FNB forward facing bevel needle
Figure 1c. SharkCore FNB needle Figure 1d. Acquire FNB needle
6
The optimal EUS sampling-strategy: a meta-analysis 109
evaluation (yes/no); 4) the number of needles passes required for final diagnosis or diagnostic 
adequacy; and 5) procedure-related adverse events. In addition, general study, patient, lesion, 
sampling and tissue handling characteristics were recorded, as well as the definition of the gold 
standard diagnosis.
Assessment of methodological quality
Study quality and risk of bias were assessed using a scoring system based on the Quality Assess-
ment of Diagnostic Accuracy Studies (QUADAS-2) tool with the Cochrane Collaboration’s tool 
for assessing risk of bias [12]. Risk of bias was assessed based on; random sequence generation 
(selection bias), allocation concealment (selection bias), comparable study arms (patient and 
EUS-characteristics), statistical design (power analysis and data interpretation), blinding of 
participants and personnel (performance bias), blinding of the data analyst to the final out-
come (detection bias), coping with incomplete outcome data (attrition bias), selective reporting 
(reporting bias), the gold standard used (resection specimens, FNA/B or clinical follow-up), and 
whether the study design was single or multicenter. Any disagreement was resolved by discus-
sion with the third author (MB).
Statistical analysis
Categorical outcome measures were summarized as weighted proportions and 95% Confidence 
Interval (CI) for both needle types. The number of needle passes was summarized as the stan-
dardized mean difference (SMD) and 95% CIs. The meta-analysis was performed by pooling the 
estimates of effect of the included studies using the random effect Manzel-Haenszel method. 
P-values of < 0.05 were considered to be statistically significant. The degree of heterogene-
ity was calculated using the I2 index, and the presence of publication bias was assessed by 
examination of funnel plot asymmetry. Statistical analyses were executed by Review manager 
5.3 (The Cochrane Collaboration, Oxford, UK) and R (version 3.4.2).
To assess the influence of lower quality studies, those with a ‘high risk of bias’ in more 
than four QUADAS-2 categories were in turn removed from the analysis. In addition, to rule 
out small study effects and correct disparity of the underlying data, studies with a wide CI or 
a sample size of less than 100 were excluded in a sensitivity analysis. A wide CI was defined as 
more than five times the Odds ratio. Sensitivity analyses were only performed if at least three 
studies remained for analysis.
RESULTS
Results of the search
Our search identified 2841 titles, of which 1770 potential eligible studies were reviewed (Figure 
2). 1697 studies were excluded based on their title and/or abstract. Reviewing the full text 
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of the remaining 73 articles resulted in an additional 55 exclusions, as these studies met our 
exclusion criteria. This resulted in 18 full text articles on FNA versus FNB.
FNA versus FNB
Study and case characteristics
The 18 studies comparing FNA to an FNB device comprised 2698 patients [13-30]; 1046 al-
located to FNA and 1004 to FNB. The remaining 648 patients were alternately sampled with 
both needles. Study characteristics are presented in table 1-3. FNA was generally performed 
using the EchoTip Ultra needle (Cook Medical), mostly 22-gauge (G), followed by 25G and 19G. 
For FNB, all trials used a ProCore needle; 17 reversed and one forward-facing bevel. 12 stud-
ies assessed comparable needle sizes [14-16, 19-22, 24-27, 29] and three studies compared 
needles of different sizes [17, 28, 30]. One study varied needle size according to the target 
lesion location [23] and two left the decision up to the endosonographer [13, 18].
Eight studies concerned solid pancreatic masses [14, 15, 17, 21, 23, 25, 29, 30] and one 
subepithelial lesions [18]. The remainder 10 included any solid gastrointestinal lesion (Table 
1). The number of needle passes varied considerably, ranging from a single to more than six 
passes per target lesion (Table 2). ROSE was available in 11 of the 18 studies. Tissue handling 
differed greatly for FNA samples, ranging from processing as smears or liquid based cytology 
(LBC, comprising ThinPrep or cell block) to collection in formalin. FNB specimens were generally 
collected in formalin (Table 2).
Quality and risk of bias
The quality and risk of bias of the trials is summarized in figures 3A and B. Overall, more than 
75% of the studies harbored a low risk of selection, performance, detection, attrition, and re-
porting bias. Also, most studies were sufficiently powered, well designed and had comparable 
study arms for FNA and FNB. However, FNA or FNB diagnosis was used as the gold standard 
Figure 2. Flowchart of search and included studies.
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Figure 3A. Quality and risk of bias of studies comparing FNA to FNB based on the QUADAS-II and Cochrane 
Collaboration’s tool.
Figure 3B. Summary of quality and risk of bias in all studies comparing FNA to FNB based on the QUADAS-II 
and Cochrane Collaboration’s tool.
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diagnosis for malignancy in approximately 30% of the studies [13, 18, 24, 25, 29], which we 
considered to be suboptimal. Lastly, only seven out of 18 studies were multicenter trials [13, 
16, 20, 21, 24, 28, 29].
Outcome parameters of the included studies
The outcome measures of all individual studies from this meta-analysis are presented in table 
3 and will be discussed separately below.
Diagnostic accuracy
16 studies, involving 2528 patients, reported on the diagnostic accuracy [13-25, 27-29]. The 
pooled accuracy for sampling any solid lesion was significantly better for the ProCore FNB of 
than for the FNA needles (OR1.70, 95%CI 1.19 to 2.41, p=0.003, table 4 and figure 4A). Hetero-
geneity amongst the studies was moderate (I2=59%) and the funnel plot did not demonstrate 
signs of publication bias (Figure 4E). Sensitivity analyses did not change outcomes (Table 4 and 
figure 4B). Subgroup analyses for solid pancreatic target lesions demonstrated a similar out-
come, with a higher pooled diagnostic accuracy for FNB than FNA (Table 4, figure 4C), without 
change after sensitivity analysis (Table 4, figure 4D).




C: Pancreatic lesions only
D: Sensitivity analysis of pancreatic lesions
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Diagnostic adequacy
Seven studies concerning 1186 patients reported on diagnostic adequacy [13, 15, 19, 26-29], 
with moderate heterogeneity (I2=54%). There was no difference in sample adequacy between 
FNA and FNB (OR1.17, 95%CI 0.70 to 1.96, p=0.55, table 4, figure 5A), even after sensitivity 
analysis (Table 4, figure 5B). The same was true for pancreatic lesions (Table 4, figure 5C). 
Sensitivity analysis on this subgroup was not performed as this would leave less than three 
studies for analysis.
Figure 4E. Funnel plot of the diagnostic accuracy for all included studies.
Figure 5A-c. Forest plots comparing sample adequacy between FNA and FNB.
A: All studies
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Number of passes performed
Five studies reported on the mean or average number of passes performed to establish a 
diagnosis [14, 15, 24] or obtain an adequate sample according to the on-site pathologist [13, 
19]. The mean number of passes was lower for FNB than FNA needles (MD -0.54, 95%CI -1.03 
to -0.04, p=0.03, table 4, figure 6A). Heterogeneity was high amongst the studies (I2=94%). Sen-
sitivity analysis could not be performed, as this would involve less than three studies. Subgroup 
analysis for pancreatic lesions showed similar results, requiring fewer passes with FNB (Table 
4, figure 6B).
B: Sensitivity analysis
C: Pancreatic lesions only
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Presence of tissue cores
Ten studies reported on presence of tissue cores in 1537 patients [14, 15, 19-23, 27-29]. Het-
erogeneity amongst the studies was high (I2=83%). Before sensitivity analysis, a trend towards 
better tissue core yield for ProCore FNB was observed, with a pooled estimate rate of 77% 
(95%CI 75 to 80) for ProCore, and 63% (95%CI 61 to 68, table 4, figure 7A) for FNA. After sen-
sitivity analysis, this became a significant benefit (OR2.34, 95%CI 1.21 to 4.51, p=0.01, table 4, 
figure 7B). Similarly, subgroup analysis for pancreatic lesions demonstrated a trend towards a 
higher tissue core rate for FNB (Table 4, figure 7C), and a significantly higher yield after studies 
of suboptimal quality were removed (OR3.64 95%CI 1.85 to 7.13, p<0.001, table 4, figure 7D).
B: Pancreatic lesions only





All studies reported on the occurrence of procedure-related adverse events, which did not 
differ between FNA and FNB (OR 0.91, 95%CI 0.45 to 1.86, p=0.80, table 4, figure 8). The pooled 
estimate for complications was 0.9% (95%CI 0.5 to 1.4) for the ProCore and 1.1% (95%CI 0.6 
to 1.6) for the FNA devices. There was no heterogeneity amongst the studies for this endpoint 
(I2=0%).
C: Pancreatic lesions only
D: Sensitivity analysis of pancreatic lesions
Figure 8. Forest plot comparing the adverse event rate between FNA and FNB.
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diScUSSiON
The current meta-analysis is the first to demonstrate a convincing diagnostic benefit of the 
new generation FNB needles, specifically of the ProCore design, over FNA. The recent wave of 
publications enabled us to include a considerable number of new randomized controlled trials 
and limit our evaluation to high quality studies [11, 31-34]. Compared to FNA, FNB needles 
achieved a higher diagnostic accuracy and a higher tissue core rate, both in pancreatic and 
non-pancreatic lesions, with less needle passes. Complication rates were low and comparable 
for FNA and FNB. Since all of the included studies comprised ProCore needles, these results 
may not be straightly extrapolated to the other new FNB needles.
FNB outperformed FNA in several ways. First, the current meta-analysis confirmed their 
superior tissue core rate. Interestingly, sample adequacy did not differ between FNA and FNB. 
New preparation techniques such as ThinPrep and cell block enable pathologists to perform 
comparable tests on cytology and histology. However, these preparation techniques were 
widely applied in the current study population, yet diagnostic accuracy was still better for the 
ProCore FNB needles. The same applied for ROSE. The fact that most EUS-centers lack such 
Table 4: Summary of findings: pooled estimates of all outcome measures comparing FNA to FNB.
Outcome measure Pooled estimate % (95%ci) Pooled OR (95%ci) p-value
FNA FNB
diagnostic accuracy
   All studies
     Sensitivity analysis
   Pancreas only
    Sensitivity analysis
81 (79 - 82)
79 (76 – 82)
81 (78 – 83)
74 (71 – 78)
87 (86 - 89)
87 (85 - 89)
85 (83 – 88)
83 (80 – 86)
1.70 (1.19 - 2.41)
1.78 (1.19 - 2.66)
1.44 (1.03 – 2.21)






  All studies
     Sensitivity analysis
  Pancreas only
     Sensitivity analysis
82 (80 – 85)
79 (75 – 82)
88 (83 – 92)
Not performed
87 (84 – 89)
86 (83 – 88)
90 (85 – 93)
Not performed
1.17 (0.70 – 1.96)
1.56 (0.97 – 2.51)





mean no. of passes performed1
   All studies
   Pancreas only
-0.54 (-1.03 to – 0.04)
-0.71 (-1.10 to -0.31)
  0.030
  0.009
Presence of tissue cores
   All studies
     Sensitivity analysis
   Pancreas only
      Sensitivity analysis
64 (61 – 67)
57 (53 – 61)
63 (59 – 67)
54 (50 – 59)
78 (75 – 80)
77 (74 – 80)
79 (75 – 82)
80 (75 – 84)
1.69 (0.96 – 2.98)
2.34 (1.21 – 4.51)
1.96 (0.85 – 4.51)






   All studies 1.0 (0.6 – 1.6) 0.8 (0.5 – 1.4) 0.91 (0.45 – 1.86) 0.800
OR: Odds ratio, No. : number, NP: not performed.
1Standardized mean difference.
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additional techniques and services is another reason to endorse FNB sampling, especially in 
low-volume or non-academic centers.
Furthermore, FNB required less passes to obtain a diagnosis. Although the complication 
rate was comparable for FNA and ProCore, fewer passes will minimize the risk of traumatic 
tissue traversing. Furthermore, less passes will limit procedure time and costs. The single study 
that assessed procedure time and costs [13] found FNB cost saving, which is in line with two 
other reports [35, 36].
Despite the better diagnostic performance and other above-mentioned benefits of FNB over 
FNA needles, the significant heterogeneity amongst studies should not be overlooked. This has 
already been described in previous meta-analyses to results from a diversity in EUS-sampling 
protocols and inconsistent use of outcome definitions. Regarding diverse practice patterns, it 
is well known that EUS-guided tissue sampling and processing techniques vary substantially 
[10]. Although present EUS-guidelines offer some recommendations, solid evidence is scarce 
[7, 37-40]. On top of this, many recommendations are dated, and keep running behind on 
the latest innovations [7, 40]. The subsequent lack of uniformity in EUS-practice renders EUS-
device studies difficult to compare.
In addition, the lack of universal definitions for diagnostic outcome measures plays a role. 
The inconsistent use of terms for diagnostic accuracy, adequacy, and yield create confusion and 
hamper comparison of results. For example, diagnostic accuracy can refer to the accuracy in 
establishing a diagnosis or just accuracy in establishing presence of malignancy. Also, certain 
studies equate the diagnostic yield and diagnostic accuracy, whereas others use ‘diagnostic 
yield’ as a more subjective term, describing the presence of sufficient tissue for ROSE or patho-
logical analyses. In addition, presence of malignancy (as gold standard) is variably established 
from resection specimens or FNA/B specimens. Another confusing definition is that of ‘tissue 
cores’. It may be described as the presence of intact histologically tissue fragments or ‘whitish 
material’, the proportion or ratio of intact tissue fragments compared to the entire sample, or 
an intact ‘tissue core’ of a certain length and/or size.
Despite the fact that we selected large randomized controlled trials and removed studies 
of inferior quality in our sensitivity analyses, heterogeneity remained substantial. To improve 
the precision of our pooled estimates, we chose to perform a random rather than a fixed ef-
fect model for our analyses, as this model includes the variance within and between studies. 
The fact that this approach resulted in the inclusion of ProCore needles only (mainly with the 
reversed bevel design) results from the lack of trials that assessed SharkCore, Acquire, or the 
novel ProCore forward facing bevel design. As these needles are relatively new on the market, 
data on their performance is limited to small sized, single center, retrospective studies.
According to ClinicalTrials.gov, multiple studies comparing different design FNB needles 
are currently ongoing including two randomized controlled trials comparing FNA to Acquire 
(NTC02911974 and NTC0 3109639), two studies comparing FNA to SharkCore (NCT02678442 
and NTC0 3532347), one comparing SharkCore to FNA with ROSE (NTC03485924), one compar-
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ing a side-fenestrated needle to an Acquire needle (NTC03622229), one comparing SharkCore 
to Acquire (NTC03672032), and lastly one study that compares an unspecified core needle to 
FNA (NTC03435588). So far, no randomized controlled trials have compared ProCore to Shark-
Core. Unfortunately, two studies that aimed to do so were withdrawn, one because ProCore 
was no longer used in that clinic (NTC02766842), and another one because of a slow inclusion 
rate (NTC03011229).
In conclusion, this study demonstrates that the FNB ProCore needles outperform conven-
tional FNA needles in diagnosing any solid lesion surrounding the gastrointestinal tract. This 
observation is of paramount importance in light of the increased need of EUS-guided tissue 
acquisition for personalized medicine and targeted therapy. However, head to head compari-
son studies between each of the new generation of FNB devices are needed to further establish 
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In the absence of rapid on-side pathological evaluation (ROSE), endoscopy staff generally 
‘smears’ endoscopic ultrasound guided (EUS) fine-needle aspiration (FNA) specimens on a glass 
slide. As this technique is vulnerable to preparation artifacts, we assessed if its quality could be 
improved through a tissue-preparation-training for endoscopy staff.
mEThOdS
In this prospective pilot study, 10 endosonographers and 12 endoscopy nurses from 7 regional 
EUS-centers in the Netherlands were invited to participate in a EUS-FNA smear-preparation-
training. Subsequently, post training slides derived from solid pancreatic lesions were compared 
to pre-training ‘control’ slides. Primary outcome was to assess if the training positively affects 
smear quality and, consequently, diagnostic accuracy of EUS-FNA of solid pancreatic lesions.
RESULTS
Participants collected and prepared 71 cases, mostly pancreatic head lesions (48%). 68 con-
trols were selected from the pre-training period. The presence of artifacts was comparable 
for smears performed before and after training (76% versus 82%, p=0.363). Likewise, smear 
cellularity (≥50% target cells) before and after training did not differ (44% (30/68) versus 49% 
(35/71), p=0.480). Similar, no difference in diagnostic accuracy for malignancy was detected 
(p=0.998).
cONcLUSiON
In this pilot EUS-FNA smear-preparation-training for endoscopy personnel, smear quality and 
diagnostic accuracy were not improved after the training. Based on these results, we plan to 
further study other training programs and possibilities.
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iNTROdUcTiON
Since its introduction in 1992, endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA) 
is increasingly popular, due to its ability to sample difficult-to-reach target lesions at a low 
complication rate. Although the technique has gained global ground, diagnostic accuracy rates 
still vary from 68% to 98% [1-5], depending on patient characteristics, sampling techniques, and 
tissue handling and processing [6-14].
Historically, EUS-FNA tissue has been collected by spreading material on a glass slide, the 
so called ‘smear technique’. Although this technique is fast and cheap, its diagnostic value is 
easily hampered by contamination and preparation artifacts [15, 16]. In the absence of (cyto)
pathological assistance in the room (ROSE), specimens are prepared by the endoscopy staff, 
generally without formal training. There is limited data on their performance as compared to 
a specialized (cyto)pathologist. Although it seems that endoscopy staff is capable of assessing 
smear adequacy for diagnostic purposes [17-21], reports on their ability to prepare the smears 
themselves are conflicting [22-25]. We hypothesized that a tissue-preparation-training for 
endoscopy staff can improve smear quality and, thus, diagnostic accuracy of EUS-FNA.
mEThOdS
Study design
In this prospective pilot study, endosonographers and endoscopy nurses of seven regional EUS-
centers in the Netherlands were invited to participate in a one-day EUS-FNA-specimen prepara-
tion training, if they had not undergone formal tissue preparation training before. To assess the 
impact of the training, quality and diagnostic accuracy of smears were compared before and 
after the training. For this, all study samples were sent to the Erasmus MC University Medical 
Center Rotterdam for expert review. As the study did not intervene with routine patient care, 
the Medical Ethics Committee of the Erasmus University Medical Center of Rotterdam waived 
the need to comply to the Medical Research Involving Human Subjects Act (MEC-2016-022). 
This committee also specifically approved for the use of any tissue and fluid samples as a model, 
as the training location was restricted to a controlled area (biohazard) at the department of 
Pathology in the Erasmus University Medical Center in Rotterdam. 
Training program
The specifically designed training program comprised of a 2-hour theoretical and 2-hour practi-
cal ‘hands-on’ part. The training was provided by an expert pathologist and a group of cyto-
technicians from the Erasmus University Medical Center in Rotterdam. During the theoretical 
part, participants were educated on pancreas pathology, including solid and cystic pancreatic 
neoplasms, chronic pancreatitis, and focal inflammation. Furthermore, several examples of 
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normal pancreas cytology and histology were discussed, as was the Bethesda classification and 
common diagnostic pitfalls in pancreas (cyto)pathology. Next, participants were lectured on the 
different FNA tissue preparation techniques, including smears, and commonly encountered pit-
falls. The main focus of the training was optimal smear preparation. To prepare a good smear, 
participants were taught to apply the collected specimens 1cm from the edge of the glass slide. 
Then, they were told to place a second glass slide on top of the first glass slide that contained 
the drop of FNA material, and try to evenly distribute the tissue using the so-called sandwhich 
method. In addition, participants were explained to limit the amount of tissue per glass slide 
(only 1 drop!) to prevent thick cells layers or overlapping cells, and to avoid crushing artefacts 
by pressing the two glass slides too firmly. Last, they were instructed on the importance and 
timing of on-site fixation, staining and drying of the material. During the hands-on workshop, 
participants learned how to optimally smear and stain FNA-specimens, and how to avoid com-
mon pitfalls during preparation. Porcine pancreatic tissue was used as training specimens. 
FNA-sample selection
After the training day, each participating center prospectively included all consecutive cases, 
scheduled for EUS-FNA of solid pancreatic lesions between April 2016 and September 2017. 
Subsequently, an equal number of historical controls (prior to the training date) was selected 
for each center. We did not match our controls based on needle type or size or the sampling 
technique used, as there is there is limited evidence on the impact of these variables on 
diagnostic accuracy of EUS-FNA. Samples that were prepared by (cyto)pathologists and/or 
cytotechnicians were excluded.
EUS-guided tissue sampling and specimens handling
EUS-guided tissue sampling was performed according to a standard protocol, using a convex 
array echoendoscope (Pentax EG-3870 UTK, Pentax EG-3270 UK; Pentax, Tokyo, Japan, Olympus 
UTC 140/180, Olympus linear GF-UCT180; Olympus, Tokyo, Japan). Tissue sampling was done 
by endosonographers, who performed between 25 and 100 EUS-guided tissue sampling pro-
cedures annually. The optimal sampling position was determined by scanning the target lesion 
and its environment with color and pulsed Doppler. Patients were punctured using a 19, 22- or 
25-gauge FNA needle (EchoTip; Cook Medical, or Expect; Boston Scientific). Per target lesion, 
the trainees performed two smears from a single pass. All residual material was processed 
according to the standard protocols of the laboratories involved (Table 1). Furthermore, the 
number of passes, sampling strategy, and use of additional sampling techniques (e.g. applying 
negative suction with a syringe) was left at the discretion of the endosonographers. If available, 
ROSE, but only after the trainee had performed the study smears. In that case, the on-site 
(cyto)pathologist was not allowed to comment on in the glass slide preparation of the trainee.
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Outcome measures and definitions
The primary outcome measure was to assess if this one day ‘hands-on’ EUS-specimens-prepa-
ration-training improved the diagnostic accuracy of smears, in the absence of an on-site (cyto)
pathologist. Diagnostic accuracy for malignancy was calculated from the correct number of 
cases that were defined as atypical/suspect for malignancy or malignant. In addition, accuracy 
for the Bethesda classification was calculated from the number of cases that were correctly 
classified into the categories; non-diagnostic, benign, atypical/suspect for malignancy or ma-
lignancy, according to the formula: (true positive + true negative) / all patients. Gold-standard 
diagnosis was based on surgical resection specimens, or a clinical follow-up period of at least 1 
year for non-operated patients. 
Secondly, we assessed if the training improved sample quality, which was defined as sample 
artifacts (fixation, thick smear/clots, obscuring blood or inflammation, cytolysis, contamina-
tion, other) and cellularity (presence of </≥50% target cells). 
Statistics
Outcome measures were expressed as means ± standard deviations (SD) or as medians with 
interquartile ranges (IQR). Statistical significance was assessed with the use of Student’s t-test 
for normally distributed continuous data; either the chi-square test for categorical data (with 
Yates’ correction when appropriate) or Fisher exact test for categorical data; and the median 
test for non-normally distributed continuous data. Sample quality and diagnostic accuracy were 
compared between cases and controls using a logistic mixed effect model with a random inter-
cept for participating center [26]. The latter has been done to take into account the clustering 
structure of this multi-center trial, i.e., that observations from the same site may be correlated. 
Statistical significance was established as p<0.05 (two-tailed). Analyses were carried out using 
SPSS version 21, Statistical Package for the Social Sciences, SPSS Inc., Chicago, Illinois, and R 
(version 3.4.2).
Power calculation
To determine the power needed for this study, we assessed the impact of the introduction of 
ROSE in one of the participating centers as a substitute intervention for our smear-preparation-
training. To determine if smear accuracy had improved, an expert pathologist reviewed 20 
smears from the period before and 18 smears from the period after ROSE was introduced 
in that center. Smear accuracy improved with 30% since the implementation of ROSE. Based 
on this assumption, a two-group continuity corrected chi-squared test with a 0.05 two-sided 
significance level will have 80% power to detect the difference between a Group 1 proportion 
(results before training), π1 of 0.400 and a Group 2 proportion (results after training), π2, of 
0.670 (odds ratio of 3.045) when the sample size in each group is 60 cases [27].
7
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RESULTS
Endoscopy staff characteristics
A total of 10 endosonographers and 12 endoscopy nurses attended the EUS-specimens-prep-
aration-training. Participants were selected by the principal investigators of the participating 
centers, during a meeting in February 2016. If they had not received a formal EUS-sample-
preparation-training previously, the study coordinator invited the participants by e-mail. Table 
2 demonstrates the participants’ characteristics. Majority of the trainees was female, with a 
median age of 38 (range 22-49). As only one of the centers was an academic hospital, most 
were working at a community hospital (77%). Experience with EUS-FNA ranged from several 
months to years.  We consider our study population to be representative for, at least, the other 
regions in the Netherlands, since most regions in the Netherlands comprise an academic and 
several smaller hospitals. Furthermore, majority of today’s medical staff comprises young to 
Table 2. characteristics of EUS-tissue training participants
hospital Profession Age (years) Female
Experience with EUS-FNA 
(years)
No. of EUS-FNA 
procedures performed 
annually
1 Doctor 42 No 12 100
1 Doctor 39 Yes 4 30
2 Nurse 24 Yes 2 300
2 Nurse 33 Yes 6 300
2 Nurse 22 Yes 2 300
2 Nurse 23 Yes 0 25
2 Nurse 30 Yes 0 30
3 Doctor 38 No 3 10
3 Doctor 35 Yes 1 25
3 Nurse 48 Yes 3 25
4 Doctor 44 Yes 10 50
4 Doctor 42 Yes 8 50
4 Nurse 48 Yes 11 92
5 Nurse 37 Yes 8 60
5 Doctor 49 No 7 50
5 Nurse 31 Yes 7 50
6 Nurse 29 Yes 5 40
6 Nurse 29 Yes 5 40
6 Nurse 47 Yes 0 45
6 Doctor 36 Yes 2 50
7 Doctor 39 No 1 60
7 Doctor 44 Yes 10 25
FNA: fine needle aspiration, no.: number.
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center of inclusion, n (%)
    Albert Schweitzer
    Reinier de Graaf
    Erasmus MC
    Haga Hospital
    Ijsselland Hospital
    Maasstad Hospital
















Target lesion location, n (%)
    Head
    Uncinate process
    Neck
    Corpus
    Tail














Target lesion size (mm), mean ± Sd 28.7 ± 9.63 31.0 ± 1.37 n.s.
FNA needle size, n (%)
    19-gauge
    22-gauge








Number of passes, median (iQR) 3.00 (2.00-3.00) 3.00 (2.00-3.00) n.s.
N: number, mm: millimeter, SD: standard deviation, FNA: fine needle aspiration, n.s: non significant.
Table 4. diagnostic outcome of SmEAR samples from cases versus controls.





Presence of artifacts 54 (76) 56 (82) 0.363
Type of artifacts*
    Poor fixation
    Thick smear/clots











    <50%







    Impossible to determine
    Benign
    Atypical/suspect for malignancy











    Benign
    Atypical (NET, pancreatitis)








diagnostic accuracy for diagnostic classification Bethesda 51 (36) 47 (32) 0.667
diagnostic accuracy for malignancy % (n/n) 66 (47/71) 66 (45/68) 0.998
NET: neuroendocrine tumor, n: number, *more than one option possible, **generalized linear mixed model.
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middle-aged women, and exposure to EUS-FNA varied greatly, which corresponds well with 
exposure in the academic and non-academic centers.
Target lesion characteristics
71 cases and 68 controls were assessed (Table 3), with a mean lesion size of 31mm (SD± 
1.37mm). Pancreatic corpus and tail lesions were somewhat over-represented in the control 
group (p=0.003, table 3). Most case lesions were sampled with a 25G needle (61%), while 
controls were mostly targeted with a 22G needle.
Smear quality
The presence of artifacts was comparable for smears prepared before and after the training 
session (76% versus 82%, p=0.363, table 4), as were individual types of artifacts. Also, for smear 
cellularity, there was no difference between cases and controls (p=0.480).
Smear diagnosis and accuracy
After a median follow-up time of 24 months (range 21-32), 70 (50%) of the smears were scored 
as malignant, 25 (18%) as atypical or suspect for malignancy, and 2 (1%) as benign. Smears were 
considered non-diagnostic in 42 lesions (30%). Gold standard diagnosis revealed 125 (90%) 
malignant lesions, 8 (6%) atypical lesions or suspect for malignancy (one IgG-mediated pancre-
atitis, two pancreatitis, five neuroendocrine tumors), and 6 (4%) benign lesions (three chronic 
pancreatitis, one fibrotic lesion, two non-specified benign lesions). Similar to FNA sample qual-
ity, tissue-preparation-training did not result in a significant increase in the diagnostic accuracy 
for malignancy (p=0.998) or the Bethesda classification (p=0.667, table 4).
diScUSSiON
With this pilot study, we aimed to evaluate the efficacy of an EUS-FNA-smear-preparation-
training for endoscopy staff in centers lacking ROSE. Unfortunately, our training did not improve 
the smear quality or diagnostic accuracy in our regional EUS-working group. For this, several 
reasons may be found.
First of all, our training program may have been inadequate to achieve a significant im-
provement in the performance of the trainees. As official EUS-sample preparation-courses do 
not exist, we had to design our own program. We chose a comprehensive training, combining 
theoretical and practical hands-on elements. However, this program may have fallen short. It 
is, for example, well known that practical skills are better achieved after extensive training, and 
tend to grow with exposure. Therefore, it may have be more effective to intensify or repeat the 
training by one or more refresh sessions. In addition to this, the specimen collection period 
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may have been too short to allow trainees to gain sufficient experience, thereby improving 
their skills.
Secondly, it has been demonstrated that self-assessment and standardized feedback im-
proves the learning curve for colonoscopy of Gastroenterologists in training [28]. Therefore, 
implementing standardized self-assessment forms could have increased the training effect. 
In addition, we could have implemented frequent multidisciplinary meetings of the trained 
endosonographers with the (cyto)pathologists. Such off-site feedback moments may further 
improve the learning curve for smear preparation.
Thirdly, our results might be inherent to the nature of the smear technique itself, since it 
is a manual method that is sensitive to artifacts and is prone to heterogeneous preparations. 
In contrast, cytological examination using a liquid-based medium (LBC), such as ThinPrep or 
cell block, has several advantages including less contamination by red blood cells, less drying 
artifacts [8].
A limitation of our study is that our power calculation was based on the training effect on 
our regional EUS-working group. Therefore, we could not assess the impact of the training on 
an individual basis. This prevents us from identifying trainees who did benefit from the training. 
It is known, that a learning curve can vary greatly between trainees. This has been shown 
for endoscopy and endoscopic retrograde cholangiopancreatography (ERCP) learning [29], 
and seems to have led to a more competence-based training schedule rather than a threshold 
number-based training for Gastroenterology residents [30, 31]. As our group comprised of 
endoscopy staff (both physicians and nurses) from high, medium and low volume centers with 
different levels of experience, differences in learning curves seem inevitable. Previous studies 
found that endosonographers performed equally well as compared to cytopathologists, but 
endoscopy nurses did not [22-25]. We did not power our study to compare the smear quality 
and accuracy between doctors and nurses.
Another limitation, one that hampers most EUS-FNA studies, is the inter-center variability 
in practice protocols. As we report in table 1, our centers use a variety of sampling and tissue 
preparation techniques. Although this may introduce a bias, today, this is inevitable in multi-
center studies, as no consensus exists on the optimal sampling and tissue handling technique 
[15, 30, 32].
Furthermore, the endpoints that we used to measure EUS-FNA quality are not globally 
harmonized. The most important problem is that there are no uniform guidelines that advise 
on how to mark FNA sample diagnosis [33], and there is no consensus on how to describe 
sample quality. Therefore, quality definitions used in the current study were jointly created by 
the study group.
Taken all together, this pilot EUS-FNA smear-preparation-training for endoscopy personnel 
did not improve EUS-FNA smear quality or accuracy. Nevertheless, it stands to reason that 
endoscopy staff could benefit from some form of specimens-preparation-training, and perhaps 
an adjusted, more elaborate program will be more effective. However, optimization of smear 
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quality is only one link in the chain towards a higher diagnostic accuracy for EUS-FNA. There-
fore, we also need to explore other strategies to achieve this.
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The traditional ‘smear technique’ for the processing and assessment of endoscopic ultrasound 
guided fine-needle aspiration (EUS-FNA) is sensitive to artifacts. Processing and evaluation of 
specimens collected in a liquid medium, liquid-based cytology (LBC), may be a solution. We 
compared the diagnostic value of EUS-FNA smears to LBC in pancreatic solid lesions in the 
absence of rapid on-site evaluation (ROSE).
methods
Consecutive patients, who required EUS-FNA of a solid pancreatic lesion were included in seven 
hospitals in the Netherlands, and followed for at least 12 months. Specimens of the first pass 
were split into two smears and a vial for LBC (using ThinPrep and/or cell block). Smear and LBC 
were compared in terms of diagnostic accuracy for malignancy, sample quality, and diagnostic 
agreement between three (cyto)pathologists.
Results
Diagnostic accuracy for malignancy was higher for LBC (82% (58/71)) than smear (66% (47/71), 
p=0.04), but did not differ when smears were compared to ThinPrep (71% (30/42), p=0.56) 
or cell block (62% (39/63), p=0.61) individually. Artifacts were less often present in ThinPrep 
(57% (24/42), p=0.02) or cell block samples (40% (25/63), p<0.001) than smears (76% (54/71)). 
Agreement on malignancy was equally good for smears and LBC (ĸ=0.71 versus ĸ=0.70, p=0.98), 
but lower for ThinPrep (ĸ=0.26, p=0.01) than smears.
conclusion
LBC provides a higher diagnostic accuracy than the conventional smear technique for EUS-FNA 
of solid pancreatic lesions in the absence of ROSE. Therefore, LBC, especially in EUS-centers 
lacking ROSE, is a better alternative for handling FNA samples than the smear technique.
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iNTROdUcTiON
Pancreatic cancer is one of the most lethal solid tumors [1, 2], but individualized therapies have 
improved progression free survival [3, 4]. As these therapies depend on pre- therapeutic tissue 
analysis [5], endoscopic ultrasound (EUS) guided tissue collection is increasingly being used for 
this purpose.
Although EUS-guided tissue sampling can reach diagnostic accuracy rates over 90%, its 
outcome strongly depends on performer skills, sampling tools and techniques, and tissue 
processing [6]. Traditionally, fine-needle aspiration (FNA) needles have been used to collect 
cytological samples, which were smeared onto glass slides, the so-called smear technique. This 
technique is cheap, easy to use and available to the majority of the EUS-centers [7]. The down-
side of smears is that they are very sensitive to preparation artifacts [8, 9]. A dedicated on-site 
pathologist (ROSE) can improve smear quality and hence diagnostic accuracy. However, in many 
EUS-centers ROSE is not readily available due to costs and logistic issues [7]. As a result, FNA 
samples are often handled by the endoscopy staff, with varying diagnostic outcomes [10-13].
An alternative for ROSE is to collect FNA samples in a liquid-based medium, the so-called 
liquid-based cytology (LBC) technique. This technique makes samples less vulnerable to con-
tamination or artifacts, as debris, blood and exudates can easily be removed [14]. There are 
different LBC techniques, i.e. ThinPrep, Surepath, Cellprep plus, and cell block. LBC slides mimic 
the in situ 3-dimensional tissue architecture and provide a homogeneous cell dispersion. They 
also allow pathologists to perform ancillary tissue tests that could previously only be performed 
on histological samples.
Although, LBC is more accurate than the conventional smears for the cytological diagnosis 
of cervical, bile duct and gall bladder cancers [15, 16], its superiority for pancreatic cancer has 
not been proven. The outcome of studies that compared smear to LBC for pancreatic lesions 
vary greatly, and are difficult to compare due to heterogeneity in the used LBC techniques (i.e. 
ThinPrep, Surepath, Cellprep plus, and cell block) [9, 17-26]. As the ThinPrep and cell block 
technique are two commonly used LBC techniques, we compared the diagnostic performance 
of these techniques to the conventional smear technique for the processing of FNA specimens 
from solid pancreatic lesions, in the absence of an on-site pathologist.
mEThOdS
Study design and patient selection
This prospective multicenter study compared EUS- sample processing using the smear and LBC 
technique in terms of diagnostic accuracy, sample quality, and agreement on these parameters. 
Consecutive patients, scheduled for EUS-FNA of a suspected solid pancreatic malignancy were 
included in a tertiary referral center and six regional community hospitals in the Netherlands, 
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between April 2016 and September 2017. Patients were followed for at least 12 months, until 
September 2018. Prior to the study, the endoscopy personnel underwent a one-day EUS-FNA-
tissue-preparation-training, to optimize their knowledge and skills. All harvested and prepared 
FNA samples were collected and reviewed by an expert cytopathologist and two experienced 
cytotechnicians of the pathology department at the Erasmus MC University Medical Center in 
Rotterdam, the Netherlands. The Medical Ethics Committee reviewed the study and granted 
a waiver of consent as the protocol did not interfere with local EUS-FNA sampling protocols 
(MEC-2016-022).
EUS-guided tissue sampling
All EUS-FNA procedures were performed according to a standard protocol, using a convex array 
echoendoscope (Pentax EG-3870 UTK, Pentax EG-3270 UK; Pentax, Tokyo, Japan, Olympus UTC 
140/180, Olympus linear GF-UCT180; Olympus, Tokyo, Japan, table 1). Tissue sampling was 
performed by endosonographers who were formally trained for at least 1 year at a tertiary 
referral center, have had 1-20 years of EUS experience, and perform at least 25 EUS-guided 
tissue sampling procedures annually. Patients were sampled using a 19, 22- or 25-gauge FNA 
needle (EchoTip; Cook Medical or Expect; Boston Scientific). The number of passes, sampling 
technique, and use of additional techniques (e.g. applying negative suction with a syringe) were 
at the discretion of the performer.
Specimen handling
EUS-FNA specimens of the first pass were split into two smears (glass slides) and a vial that 
was processed as LBC. Smears were performed using the ‘sandwich method’ [27]. LBC was 
processed using thin layer preparation (ThinPrep®, (Hologic) and/or the cell block technique 
(Cellient™ automated cell block system (Hologic), the Agar technique, or Aalfix cell block, de-
pending on local tissue handling protocols (Table 1). Subsequent passes were handled according 
to local standards and not included in the study. Smears and LBC were prepared on-site, by the 
endoscopy personnel (endoscopy nurse or endosonographer). On-site pathological assistance 
was only allowed after the first pass, once study material was collected.
Sample reviewing
All study samples were anonymized and sent to the Erasmus MC University Medical Center in 
Rotterdam for review by an expert cytopathologist and two cytotechnicians who were special-
ized in pancreaticobiliary diseases. Reviewers were blinded for the final clinical and pathological 
outcome. Sample assessment and scoring were done individually by the reviewers. Case discus-
sion was not allowed. Smears, thin layer samples and cell blocks were analyzed consecutively.
8



















































































































































































































































































































































































































































































































































































































Endpoints, scoring variables and definitions
The primary endpoint was the comparison of the diagnostic accuracy of the conventional 
smear method to the LBC technique of FNA-specimens from solid pancreatic lesions. Sample 
diagnosis was based on the Bethesda classification, and scored as non-diagnostic, benign, 
atypical, or malignant [28]. The reviewing expert cytopathologist determined the final sample 
diagnosis. Gold standard diagnosis was based on the surgical resection specimens in operated 
patients, or on a compatible clinical disease course during a 12-month follow-up period. Solid-
pseudopapillary neoplasms (SPN) and NET grade 2 and 3 were classified as malignant [29, 30].
Secondly, we compared sample quality, defined as sample cellularity (< or >50% target cells) 
and presence of preparation artifacts, such as poor fixation, thick smear/clots, obscuring blood 
or inflammation, or cytolysis (no/yes). In addition, we compared the interobserver agreement 
on sample diagnosis and quality amongst the three reviewers between the two techniques.
Other parameters that were scored included needle size, target lesion characteristics (loca-
tion, size), the number of needle passes performed, type of LBC medium used, and procedure 
related complications (pancreatitis, infection, bleeding, other).
Statistics
Diagnostic accuracy and sample quality were compared between the smear and LBC technique, 
and were analysed using logistic mixed effects models [31] with subject and study center spe-
cific (random) intercepts. This method allows to take into account the clustering structure of 
this multicenter trial, i.e., that observations from the same study center may be correlated. 
Separate models were fitted for the comparison of SMEAR vs LBC and SMEAR vs ThinPrep vs 
cell Block. Statistical significance was established as p<0.05 (two-tailed).
Inter-observer agreement amongst reviewers was calculated using kappa statistics [Fleiss’ 
ĸ-statistic and 95% confidence intervals (Cls)]. ĸ- statistics were interpreted according to con-
vention of Landis and Koch; <0, no agreement; 0-0.20 slight agreement; 0.21-0.40, fair agree-
ment; 0.41-0.60, moderate agreement; 0.61-0.80, substantial agreement; and 0.81-1.0; almost 
perfect agreement. Because not all samples were evaluated for both LBC methods, ThinPrep 
and cell block, some of the ratings were missing. To compare agreement coefficients, the coef-
ficient was then calculated based on the samples for which all ratings of the methods in the 
current comparison were available. In settings where the agreement coefficients of three meth-
ods were compared, three pairwise tests were used and p-values were corrected for multiple 
testing using Holm’s procedure [32]. For this, the p-values presented in this manuscript have 
been multiplied by the number of comparisons. Analyses were carried out using R version 3.5.1 
[33], and SPSS version 23, Statistical Package for the Social Sciences, SPSS Inc., Chicago, Illinois.
Power calculation
To determine the power needed for this study, we first performed a pilot study to assess the 
diagnostic accuracy for malignancy for pancreatic EUS-FNA specimens prepared using the 
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smears and LBC method in het Erasmus MC University Medical Center. A difference in diagnos-
tic accuracy of 20% between smear and LBC was found, and considered clinically relevant. We 
estimated that to find such a difference, a sample size of 59-72 pairs will have 80% power to 
detect a difference in proportions of 0.250 when the proportion of discordant pairs is expected 
to be between 0.500-0.600 and the method of analysis is a McNemar’s test of equality of paired 
proportions with a 0.050 two-sided significance level.
RESULTS
Case characteristics
A total of 71 cases were included, of which lesion and sampling characteristics are listed in 
table 2. No procedure related complications were recorded. Final diagnosis comprised 64 (90%) 
malignancies, 3 (4%) atypical cases, including 2 NETs and 1 case of pancreatitis, and 4 (6%) 
benign cases. This diagnosis was based on resection specimens in 19 (29%), additional tissue 
biopsy (i.e. peritoneal, brain, lymph node biopsy) in 13 (20%), and follow-up in 33 (51%) cases.
Diagnostic accuracy and sample quality for smear versus LBC
Overall, diagnostic accuracy for malignancy of the first pass was 86% (61/71). Accuracy was 
higher for samples processed using LBC than with the conventional smear technique (82% 
versus 66%, OR 2.62 95% CI 1.13-6.79, p=0.03). Overall diagnostic accuracy based on Bethesda 
was 80% (57/71). For this classification, smears and LBC performed equally well (51% versus 
Table 2. case characteristics.
Variables cases
(n=71)
Target lesion location, n (%)
    Head
    Uncinate process
    Neck
    Corpus






Target lesion size (mm), mean ± Sd 31.0 ± 1.37
FNA needle size, n (%)
    19-gauge
    22-gauge




Number of passes, median (iQR) 3 (2 - 3)
Gold standard diagnosis
    Benign
    Atypical (NET, pancreatitis)




n: number, mm: millimeter, SD: standard deviation, IQR: interquartile range, NET: neuroendocrine tumor. 
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59%, OR 1.44 95% CI 0.73-2.92, p=0.30). Comparing the diagnostic accuracy for malignancy 
and the Bethesda classification of smears to both LBC techniques individually did not result in 
a significant difference in diagnostic accuracy (Table 3). Cell block had lower sample cellularity 
than smear (OR 0.39 95% CI 0.18-0.82, p=0.01, table 4), but there was no clear evidence of a 
difference between ThinPrep and smear (OR 0.51 95% CI 0.21-1.16, p=0.11). Sample quality, 
in terms of artifacts, was better for both LBC techniques as compared to the smears (Table 4).
Diagnostic agreement for smear vs LBC
The diagnostic agreement amongst the cytopathologist and the two cytotechnicians was 
equally good for identifying malignancy in smears (ĸ=0.71, 95% CI 0.57-0.84) and LBC samples 
(ĸ=0.70, 95% CI 0.55-0.86, p=0.98). The same was true for their agreement on the Bethesda 
classification (ĸ=0.70, 95% CI 0.57-0.83 vs ĸ=0.64, 95% CI 0.50-0.78, p=0.55). When ThinPrep 
(ĸ=0.26, 95% CI 0.04-0.48) and cell block (ĸ=0.79, 95% CI 0.66-0.92) were assessed separately, 
agreement on the presence of malignancy was comparable for cell block and smears (ĸ=0.79 
vs. ĸ=0.73, adjusted p=0.53, figure 1), but lower for ThinPrep than smears (ĸ =0.261 vs ĸ =0.640, 
adjusted p=0.04). Similar results were found for the Bethesda classification (Figure 1). Agree-
ment on the presence of artifacts was low for all processing techniques, and did not differ 
significantly between the processing techniques (Figure 2). Agreement on cellularity was high-
est for cell block (ĸ=0.64, 95% CI 0.48-0.81) and smears (ĸ=0.60, 95% CI 0.46-0.75), and lowest 
for ThinPrep (ĸ=0.35, 95% CI 0.14-0.56).











OR (95% ci) p-value
Overall (n=71) 61 (86) 57 (80)
Smear (n=71)  47 (66) 1.92 (0.75-4.83) * 36 (51) 1.03 (0.62-1.71) *
LBc (n=71) 58 (82) 2.62 (1.13-6.79) 0.03 42 (59) 1.44 (0.73-2.92) 0.30
   ThinPrep (n=42) 30 (71) 1.29 (0.52-3.26) 0.59 26 (62) 1.61 (0.74-3.76) 0.24
   cell block (n=63) 39 (62) 0.78 (0.78-1.69) 0.53 22 (35) 0.51 (0.24-1.03) 0.07
*reference category
Table 4. Sample quality per tissue processing technique, compared to smear.









Smear (n=71) 54 (76) 4.09 (1.54-15.16) * 35 (49) 0.97 (0.43-2.04) *
LBc (n=71)
  ThinPrep (n=42) 24 (57) 0.32 (0.12-0.82) 0.02 14 (33) 0.51 (0.21-1.16) 0.11
  cell block (n=63) 25 (40) 0.15 (0.05-0.35) <0.001 18 (29) 0.39 (0.18-0.82) 0.01
*reference category
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diScUSSiON
Liquid-based cytology using ThinPrep and cell block provides a higher diagnostic accuracy than 
and a comparable agreement compared to the conventional smear technique for FNA speci-
mens from solid pancreatic lesions in the absence of an on-site pathologist. LBC is therefore a 
good alternative for the smear technique in the absence of ROSE. The higher diagnostic agree-
ment for cell block than ThinPrep advocates for the implementation of the cell block technique 
for LBC.
The first explanation for the higher diagnostic accuracy of LBC than smear seems to be its 
lower artifact rate. It is generally accepted that smears are vulnerable to preparation artifacts, 
which induces interpretation errors, and may result in a lower diagnostic accuracy [25]. Despite 
the fact that the endoscopy staff in the current study participated in a smear-preparation-
Figure 1. Agreement on diagnostic accuracy of malignancy and the Bethesda classification for the smear, 
ThinPrep and cell block technique.
Figure 2. Agreement on sample cellularity and presence of artifacts for the smear, ThinPrep and cell block 
technique.
158 Chapter 8
training to optimize their performance before initiation of the study, 76% of the smears still 
contained artifacts. This was much higher than artifact rate for cell block (40%) and ThinPrep 
samples (57%).
Besides a low artifact rate, the histology-like look of cell block samples likely contributes 
to an easier interpretation and matching interobserver agreement. It has previously been re-
ported that pathologists prefer histology or cell block over conventional cytology preparation, 
as its appearance is much closer to the in situ tissue architecture [8]. Furthermore, LBC allows 
for additional testing, such as immunohistochemistry, which may be deciding in challenging di-
agnostic cases such as auto-immune pancreatitis, or the differentiation between metastatic or 
primary disease. Although agreement was higher for cell block than ThinPrep, it should also be 
taken into account that special training of cytotechnicians and pathologists is prerequisite for 
accurate interpretation of these different LBC techniques [8]. Therefore, choosing the optimal 
LBC technique will depend upon the preference and experience of the local pathologists.
The finding that sample cellularity was lower for LBC than smears does not seem to match 
with its high diagnostic accuracy and agreement. It may be explained by the more homogeneous 
cell dispersion of LBC samples. This allows for better assessment of cell morphology, but may 
give the impression of a less ‘cellular sample’. On the other hand, highly cellular smears may 
be scored as containing more than enough target cells, but if cells are packed in thick layers, 
this only hampers the interpretation. Despite the lack of a clear definition of ‘FNA sample cel-
lularity’, a higher cellularity has been associated with a higher DNA yield for molecular testing 
[14]. Therefore, it is crucial to determine the specific purpose of EUS-guided tissue collection in 
advance, and discuss this with the involved pathologist.
It is challenging to compare our findings to previous reports, since EUS-FNA protocols and 
tissue handling and processing techniques vary greatly. So far, 11 studies have compared the 
smear to the LBC technique for solid pancreatic lesions [9, 17-26]. Six of them reported a higher 
diagnostic accuracy for smears than LBC [9, 18, 21-23, 26]. Half of these studies used ROSE [18, 
21, 22]. Overall, only three of the eleven studies that compared smear to LBC were performed 
without ROSE [9, 20, 26]. Of these studies, two found a benefit of smear over LBC [9, 26], and 
one found a benefit of LBC, using another ThinPrep-like solution (Surepath)[20]. Each study 
used different ThinPrep solutions, limiting a direct comparison with our results. Of the studies 
that reported a diagnostic benefit for LBC, two out of three used the cell block rather than the 
ThinPrep technique, which seems to correspond with our findings [17, 24, 25]. Lastly, none of 
the above-mentioned studies assessed diagnostic agreement on the different techniques.
Compared to other studies, our overall diagnostic accuracy rate of 86% is rather high, con-
sidering the fact that material was collected from the first needle pass only. Previous studies 
mostly based their results on several passes. Moreover, we split the material from this first 
pass for smear and LBC. As a result, our samples likely contained less material as compared to 
other study settings. Therefore, our diagnostic accuracy rates underestimate the true diagnos-
tic accuracy rates in our practices. Furthermore, the diagnostic accuracy of each preparation 
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technique alone was somewhat, lower than LBC overall. The most likely explanation for this 
is that ThinPrep and cell block are complementary techniques, that provide samples with a 
different phenotype and diagnostic possibilities.
Our study has some limitations. An important limitation of studies on EUS-guided tissue 
sampling is the lack of uniform guidelines on the optimal sampling and tissue handling tech-
niques. Therefore, the resulting inter-center variation should always be considered, and may 
hamper general extrapolation of our findings. Secondly, we did not power our study to perform 
additional, subgroup analysis. Furthermore, although the participating endosonographers who 
performed the smears participated in a hands-on-FNA-tissue-preparation training, their experi-
ence cannot be explained to that of on-site pathologists. Therefore, this may have limited the 
diagnostic accuracy of the smears.  Another limitation is that the reviewing pathology staff 
could not be blinded for the processing technique, as their appearance differs accordingly. 
Furthermore, we did not perform a cost-effectiveness analyses, due to the differences in local 
EUS-protocols between the participating centers.
In conclusion, in the absence of an on-site pathologist, diagnostic accuracy of EUS-FNA of 
solid pancreatic lesions can be increased with the LBC technique as compared to the conven-
tional smear technique. As LBC provided for a higher diagnostic accuracy and a comparable 
interobserver agreement than smears, it should be routinely implemented in EUS-centers lack-
ing ROSE. The higher agreement for cell block advocates for the implementation of cell block 
rather than ThinPrep. However, providing the optimal EUS-tissue sampling depends on many 
factors, including experience and skills of the involved endoscopy and pathology team, and 
starts with the determination of the diagnostic or therapeutic purpose of tissue acquisition.
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GENERAL SUmmARY ANd diScUSSiON
This thesis explores how to improve the diagnostic outcome of Endoscopic ultrasound (EUS)-
guided tissue sampling. First, it gains insight in the current international practice patterns of 
endosonographers. Then, it focusses on the performance of different EUS-sampling devices. 
We compared the diagnostic performance of a fine needle aspiration (FNA) and fine needle 
biopsy (FNB) device, their diagnostic reproducibility, and the value of their combined use, 
in a prospective randomized manner. In addition, a meta-analysis was performed, mutually 
comparing FNA and the novel-generation FNB devices, comprising the ProCore (Cook Medical), 
SharkCore (Medtronic) and Acquire (Boston Scientific) needles. In the third part of the thesis, 
we explore if EUS-FNA tissue preparation techniques can be optimized by training endoscopy 
personnel and by comparing specimen processing with liquid based cytology (LBC) to the 
conventional glass-smear technique.
current practice in EUS-guided tissue sampling
EUS-guided tissue sampling is increasingly being used, due to its high diagnostic accuracy, 
minimal invasive character, and good tissue yield, which is of major importance in the current 
era of patient tailored medicine [1]. Because of its increased use, the technique is continuously 
evolving. This leaves the optimal sampling strategy a subject of debate, and clinicians with 
limited evidence for their daily practice [2-6].
In chapter 2, an online survey aimed to map the practice patterns for EUS-guided tissue 
sampling. We found considerable intercontinental differences and deviations from the guide-
lines. According to the questioned American endosonographers, their all-round use of propofol 
rather than conscious sedation may be explained by marketing strategies of anaesthesiologists 
[7-9]. If this practice pattern will spread to Europe, procedure costs are expected to rise [7, 10, 
11]. Another difference was the use of periprocedural acetylsalicylic acid, which was generally 
continued in the United States (US), according to the guidelines, in contrast to Europe and Asia. 
In Asia, this may be explained by the believe that Asians are more susceptible to bleeding com-
plications [12]. As for the use of rapid on-site pathological evaluation and preparation of the 
collected tissue (ROSE), our survey reported that it was used by virtually all respondents from 
the US, while in Europe and Asia, it was only available in half of the centers, due to cost issues 
and disbelief in its added value. Indeed, a recent meta-analysis could not proof its benefit and 
the European Society of Gastroenterology (ESGE) guidelines do not recommend its use [13].
Histology was uniformly stored in formalin. The preferred preservation fluid for cytological 
specimens, however, differed considerably. Asians generally use alcohol or saline, while Euro-
pean and US practitioners use Cytolyt. This reflects the lack of recommendations on preserva-
tion and specimen handling by the current guidelines. A practice pattern that did not differ 
between continents was the preferred needle size and number of passes. The survey identified 
the 22-gauge (G) needle as the preferred size for both FNA and FNB [14-17], and participants 
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reported to perform less passes with FNB than FNA. Although at the time of the survey, this was 
not yet recommended, the updated ESGE guidelines indeed advise to perform less passes with 
FNB [2-3] than FNA [3-4], in the absence of ROSE [13].
The optimal EUS-sampling device
As we discussed in the introduction of this thesis, EUS-needles are, and always have been a 
major target of innovation in EUS-guided tissue sampling. FNB devices were introduced to 
overcome the limitations of FNA, mainly by providing histological specimens rather than loose 
target cells. However, their diagnostic performance was not convincingly better than the FNA 
needles [18-22]. Some reported that FNB not so much harvested histological tissue fragments, 
but just improved the yield of loose target cells [18, 23-29]. Others claimed that histology can 
also be obtained with the conventional FNA needles [18, 30, 31]. Lastly, new tissue preparation 
techniques, such as cell block, allow for a ‘histology like’ analysis of cytological material.
The first FNB devices, TruCuttm (Travenol Laboratories) and Quick-Core® (Cook Medical), 
were hampered by a rigid design and difficult deployment. In response, several novel FNB 
needles have been introduced in the last years, including the ProCore reversed and forward fac-
ing bevel, SharkCore, and Acquire needles. As the design of these needles significantly differs 
from the first FNB devices and from each other, there is a growing interest in their diagnostic 
performance.
The 20G ProCore forward facing bevel needle was introduced first, in 2015, and its diagnos-
tic performance has been extensively assessed. The largest study available is the international 
multicenter trial that is presented in chapter 3. In this trial, the ASPRO study (ASpiration versus 
PROcore), we compared the ProCore forward facing FNB needle to a commonly used conven-
tional FNA needle, the 25G EchoTip Ultra Needle (Cook Medical), which was chosen because of 
its optimal flexibility and yield [2, 13].
We demonstrated that this 20G FNB needle achieves a higher diagnostic accuracy and tis-
sue core yield within less passes than FNA. These findings equally applied for pancreatic and 
non-pancreatic lesions, and were irrespective of target lesion size, number of needle passes, 
and presence of an on-site pathologist. Moreover, despite of inter-center differences, the 
benefit of the new FNB needle was consistent amongst all 13 participating centers, supporting 
the general applicability of these findings.
The better performance of the new 20G FNB needle seems related to its design adapta-
tions, which include a large diameter, a flexible needle sheet, a forward facing rather than a 
reversed bevel, and a Menghini rather than a lancet tip, which decreases resistance during 
tissue traversing. The fact that a large-bore FNB needle outperformed a thinner FNA needle is 
an important observation, because it counters the conception that the performance of larger-
bore needles is hampered by their suboptimal performance in an angulated scope-position.
The better overall performance of the FNB needle was shown to be center independent, 
but we were well aware that all participating centers were high volume centers. To assess the 
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reproducibility in non-expert hands, we performed a second study. As described in chapter 4, 
we compared the diagnostic agreement between academic and non-academic pathologists. 
The first 125 pancreatic and lymph node cases, enrolled in the original ASPRO trial, were re-as-
sessed by 5 academic and 5 non-academic pathologists from different countries. The diagnostic 
agreement on the final diagnosis was higher for FNB samples than for FNA, amongst expert 
academic as well as non-academic pathologists. Logistic regression analysis further showed 
that the pathologist’s provenance (academic or non-academic) did not influence diagnostic ac-
curacy. This endorses the use of the novel 20G FNB needle in academic as well as non-academic 
centers.
The most likely explanation for the better agreement on the FNB samples is their higher tis-
sue core rate, which was positively associated with a better diagnostic agreement. Furthermore, 
the cytological yield of FNB was also higher than for FNA, but only the availability of tissue 
cores, and not cytology, contributed to a better diagnostic accuracy. Another quality parameter 
that seemed to contribute to the high diagnostic accuracy and agreement on samples obtained 
with FNB is the low sample artifact rate. Not only did the present study show a decrease in 
accuracy when artifacts were present, previous studies have also reported that artifacts may 
hamper ancillary testing [32]. Interestingly, agreement on the presence of artifacts was low 
for both needles (although slightly better for FNB than FNA). This is in line with the fact that 
agreement on all sample quality parameters was low in the current study, similar to reports 
from others [33, 34]. This likely results from the lack of uniform outcome definitions regarding 
the performance of EUS-guided tissue sampling.
To further explore the optimal sampling approach, in chapter 5, the role of combined 
FNA and FNB use is assessed. The benefits of an FNA needle; optimal flexibility to reach a 
target lesion and the possibility to perform on-site cytological evaluation, may complement 
the benefits of FNB; collection of histological tissue cores to optimize the diagnostic yield and 
harvest enough tissue for ancillary testing. To explore the incremental diagnostic yield of dual 
sampling, all ASPRO cases that were sampled with both needles during the same procedure 
were included. This resulted in 24 patients who were first sampled with the 25G FNA needle, 
and 49 cases who were first sampled with the 20G FNB device. Interestingly, dual sampling only 
improved diagnostic accuracy for malignancy if FNA was followed by sampling with FNB and not 
vice versa. The previously reported diagnostic benefit of the FNB over the FNA needle may very 
well explain why FNA followed by FNB resulted in a higher diagnostic accuracy than FNA alone, 
and also explains the limited value of the reversed approach. However, FNB may have caused 
blood contamination of subsequent specimens, or “tracking” within the target lesion, impeding 
the FNA needle from finding its own diagnostic route. Last, secondary FNA was mostly used to 
allow for ROSE. However, since the incremental yield of ROSE is questionable in academic high 
volume centers, the benefit of FNA to allow for ROSE is expected to be limited [35-37].
In chapter 6 we zoom out from the diagnostic performance of the two specific needles 
and present an updated meta-analysis on the performance of all currently available EUS-FNA 
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and FNB needles. EMBASE, MEDLINE/PubMed, Web of Science, the Cochrane Library, and 
Google Scholar were systematically searched for studies comparing FNA to FNB. We included 
randomized controlled trials of at least 50 patients, and extracted data on diagnostic accuracy, 
adequacy, number of passes, presence of tissue cores, and adverse events. Study quality was 
assessed based on the QUADAS-2 tool.
The recent wave of publications enabled us to include a significant number of new trials 
that compare FNA to FNB, and limit our evaluation to studies of high quality, as compared to 
previous meta-analyses [18-22]. Our analysis is the first to demonstrate a diagnostic benefit of 
FNB over FNA for pancreatic as well as non-pancreatic lesions, in terms of diagnostic accuracy, 
the number of needle passes performed, and tissue core yield. The adverse event rate was 
equally low for FNA and FNB. Other than diagnostic accuracy, sample adequacy did not differ 
between FNA and FNB. Sample adequacy or cellularity may be of less importance for a cor-
rect diagnosis than the presence histological tissue cores. Despite the use of new cytological 
preparation techniques like ThinPrep and cell block and the abundant use of ROSE, diagnostic 
accuracy was still better for FNB than FNA.
With regard to the general applicability of our results, it should be noted that there was a 
significant heterogeneity amongst the included studies. This is mainly due to the diversity in 
EUS-sampling protocols, and the inconsistent use of outcome definitions. Consequently, the 
outcomes of EUS-device studies remain difficult to interpret and should be extrapolated with 
caution.
Although the current analysis showed that FNB convincingly outperforms FNA, all included 
trials used the ProCore needle for FNB. As the use of the other new FNB needles, such as the 
Acquire and SharkCore needle, is increasing, we eagerly await head to head comparison studies 
between different FNB devices. Preferably, these should be (international) multicenter random-
ized controlled studies. According to ClinicalTrials.gov, a significant number of interesting stud-
ies investigating the performance of the novel generation of FNB devices is currently running.
improving EUS-specimen preparation and handling
As mentioned in the previous section of this discussion, new FNA-tissue preparation techniques 
like ThinPrep and cell block increasingly enable pathologists to perform ancillary testing on 
cytological specimens. These techniques have been introduced to improve FNA-sample quality 
and accuracy, since the traditional, so called, smear-technique, is highly sensitive to prepara-
tion and contamination artifacts. Another way to solve this issue is to invest in a dedicated, 
on-site pathologist to handle the collected tissue. However, most centers omit this type of 
service. Therefore, EUS-FNA specimens are often prepared by the endoscopy staff, generally 
without a specialized training.
chapter 7 explores if a one-day-hands-on tissue preparation training for endoscopy staff 
could improve sample quality and thus diagnostic accuracy of EUS-FNA in centers lacking ROSE. 
We performed a prospective pilot study, for which we invited 10 endosonographers and 12 
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endoscopy nurses from 7 regional EUS-centers in the Netherlands. Participants were educated 
on pancreas pathology, common diagnostic pitfalls, and the cause and prevention of smear-
preparation-artifacts. Subsequently, they practiced smear preparation under the supervision of 
a team of academic (cyto)pathologists. After the training, 71 FNA-smears were prospectively 
collected from solid pancreatic lesions and compared to an equal number of pre-training ‘con-
trol’ slides.
Unfortunately, smear quality and diagnostic accuracy did improve after the training. The 
sample size did not allow us to assess individual results, to identify any trainees that did benefit 
from the training. There may be several reasons for the limited effect of our pilot-training. 
First, the training program may have been too short. As practical skills are better achieved 
after extensive training and tend to grow with exposure, it might have been more effective 
to intensify or repeat the training with one or more refresh sessions. In addition, the study 
period may have been too short to allow trainees to gain sufficient experience. Last, the lack 
of quality improvement may also be inherent to the nature of the smear technique itself, since 
it is a manual method that is sensitive to artifacts and prone to heterogeneous preparations. 
In contrast, cytological examination using LBC, i.e. ThinPrep and cell block, are associated with 
less contamination and drying artifacts [38].
chapter 8 compares the diagnostic benefit of LBC to the conventional smear technique for 
the diagnosis of solid pancreatic lesions. The participating EUS personnel had been trained in 
the course of the previously described study. Two smears and a vial for ThinPrep and/or cell 
block were prepared from the first FNA-pass, without use of ROSE, and compared in terms of 
diagnostic accuracy for malignancy, sample quality, and diagnostic agreement between three 
(cyto)pathologists. The diagnostic accuracy was higher with the LBC technique as compared to 
the smear technique. However, this was only true when the yield of ThinPrep and cell block 
were collated. Artifacts were less present in both LBC techniques. The diagnostic agreement 
was comparable for LBC and smears, with the highest agreement on cell block samples. Given 
its higher accuracy and comparable agreement, LBC could be an alternative for centers lacking 
ROSE, especially cell block.
Future perspectives and recommendations
The historical line between FNA and FNB is fading with the current pool of EUS-devices contain-
ing FNA and FNB needles of comparable sizes and flexibility. To complicate things even further, 
needle designs differ significantly within the FNA and FNB groups. Therefore, we propose to 
discard the distinctive nomenclature of FNA and FNB, and instead, focus on the performance of 
individual EUS-sampling devices.
The current thesis provides significant new information that may be used to improve EUS-
guided tissue sampling. However, there is room for further development, as the updated meta-
analysis in this thesis found that the diagnostic accuracy for traditional FNA ranged between 
67% and 100% and for FNB between 69% and 100%. This thesis states that an FNB needle 
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outperforms FNA, and should be the first-choice device for EUS-guided tissue acquisition, 
independent of the type of solid target lesion. However, before any specific needle FNB type or 
design can be recommended, newer generation FNB needles need to be assessed.
Ideally, one would want to compare each available EUS-sampling device head to head, but 
this is challenging. First of all, due to the many available FNA and FNB sizes and designs this 
will be time consuming but not impossible. Other complicating issues that make it difficult 
to compare the result are the heterogeneity in EUS-sampling protocols and lack of uniform 
outcome definitions. As long as there is no evidence which sampling strategy is optimal, it will 
be difficult to standardize practice patterns. To overcome some of the issues, uniform outcome 
definitions need to be created. For this there may be a role for the European and American 
Societies for Gastroenterology, as was the case for the diagnostic classification of pathology 
samples by the Papanicolaou Society.
In addition to the optimal EUS-needle design, this thesis also focused on the optimal tis-
sue preparation of FNA specimens. One may question if future research should continue to 
focus on this, since our study proved FNB to be superior to FNA. However, we did not directly 
compare FNA specimens in liquid-based cytology to FNB cores in formalin. It would be interest-
ing to compare this in an international multicenter setting. Furthermore, it should be noted 
that tissue collection for liquid preparation techniques is easy for the endosonographer, but 
requires a well-equipped pathology laboratory and trained personnel. Therefore, introducing 
and implementing novel techniques and innovations for EUS-guided tissue sampling should 
always be done in close cooperation with the pathology department.
Lastly, in light of ever-increasing burden of health-care costs, it is crucial that, before mak-
ing any recommendation regarding the most optimal EUS-guided sampling technique and tool, 
cost-effective analyses should be performed.
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NEdERLANdSE SAmENVATTiNG EN diScUSSiE
Dit proefschrift onderzoekt hoe de diagnostische opbrengst van endo-echografisch (EUS)-
geleide weefselafname kan worden verbeterd. EUS is een techniek waarbij men een inwendige 
echo maakt, middels een flexibele endoscoop met aan het uiteinde een echoapparaat. Via 
een speciaal kanaal kunnen instrumenten, zoals naalden of biopteurs, worden ingebracht. Dit 
maakt het mogelijk om – echogeleid – weefsel af te nemen van verdachte gebieden in organen 
rondom het maagdarmstelsel.
Het eerste deel van dit proefschrift geeft inzicht in de huidige toepassing van EUS-geleide weef-
selafname en welke hulpmiddelen en technieken hierbij worden gebruikt. Het tweede deel 
richt zich op de verschillende naalden voor weefsel afname. We vergeleken de diagnostische 
prestaties van een dunne ‘aspiratienaald’ (fine needle aspiration, afgekort FNA) en een dikkere 
‘biopsienaald’ (fine needle biopsy, afgekort FNB) in een prospectief gerandomiseerde studie. 
Ook bekeken we de reproduceerbaarheid van deze uitkomsten en de waarde van het gecom-
bineerd gebruik van beide naalden gedurende één procedure. In een meta-analyse vergeleken 
we vervolgens de prestaties van FNA met de nieuwe generatie EUS-FNB-naalden, waaronder 
de ProCore (Cook Medical), SharkCore (Medtronic) en Acquire naalden (Boston Scientific). In 
het derde deel van dit proefschrift onderzochten we of de kwaliteit van EUS-FNA-preparaten 
kan worden verbeterd door endoscopiepersoneel te trainen in het verwerken hiervan, en door 
het verkregen weefsel te verzamelen in een vloeibaar medium (liquid based cytology, afgekort 
LBC), in plaats van het uit te smeren op een dekglaasje (de conventionele ‘smear-techniek’).
EUS-geleide weefselafname in de huidige praktijk
EUS-geleide weefselafname wordt steeds vaker gebruikt vanwege de diagnostische nauw-
keurigheid, het minimaal invasieve karakter en de hoge weefselopbrengst. Dit laatste is extra 
belangrijk in het tijdperk van gepersonaliseerde geneeskunde [1]. Vanwege het groeiende 
gebruik evolueert de techniek voortdurend en staat de optimale strategie nog ter discussie. 
Door het gebrek aan wetenschappelijk bewijs moeten endo-echoscopisten terugvallen op hun 
eigen ervaring en aanbevelingen van experts uit veelal verouderde richtlijnen [2-6].
hoofdstuk 2 beschrijft de uitkomsten van een onlinevragenlijst die wij naar een internationale 
groep endo-echoscopisten uitstuurden, om de gebruikte technieken en materialen bij EUS-ge-
leide weefselafname in kaart te brengen. We vonden aanzienlijke intercontinentale verschillen 
tussen en deviaties van de geldende richtlijnen. Volgens de Amerikaanse endo-echoscopisten 
wordt sedatie met Propofol daar veel vaker gebruikt dan het zogenaamde roesje. Wanneer dit 
gebruik zich naar Europa uitbreidt, zullen de kosten van EUS-geleide weefselafname ook hier 
toenemen [7, 10, 11].
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Een ander verschil bleek het gebruik van acetylsalicylzuur rondom de procedure. Conform 
de geldende richtlijnen werd dit in de Verenigde Staten (VS) veelal gecontinueerd, terwijl het 
in Europa en Azië vaker gestaakt werd. In Azië kan dit worden verklaard door de overtuiging 
dat Aziaten vatbaarder zijn voor bloedingscomplicaties [12]. De reden dat Europese endo-
echoscopisten hier afwijken van de richtlijnen blijft onduidelijk. Wat betreft het inzetten van 
een patholoog voor ‘on-siteweefselbeoordeling’ en verwerking (ROSE), rapporteerden alle 
respondenten uit de VS hier gebruik van te kunnen maken, terwijl dit in Europa en Azië slechts 
in de helft van alle centra het geval was. Redenen hiervoor waren volgens de Europese en 
Aziatische respondenten hoge kosten en een beperkt geloof in de toegevoegde waarde. Deze 
bevindingen sluiten aan bij de resultaten van een recente meta-analyse die inderdaad geen 
toegevoegde waarde van ROSE liet zien. Het komt daarnaast ook overeen met de huidige 
Europese richtlijn, waarin het gebruik van ROSE niet wordt aanbevolen [13].
Histologie (intacte weefselfragmenten) werd in alle continenten verzameld en bewaard in 
formaline. Het weefselmedium voor cytologie (losse cellen) verschilde aanzienlijk. De meeste 
Aziaten verzamelden cytologie in alcohol of zoutoplossing. Europese en Amerikaanse artsen 
gebruikten hiervoor Cytolyt. Deze verschillen kunnen goed worden verklaard door het gebrek 
aan richtlijnen voor het bewaren en bewerken van EUS-weefsel. Een item dat niet verschilde 
tussen de continenten was de keuze van de naalddikte (gauge) en het aantal puncties dat werd 
verricht. De 22-gauge (G) werd het meest gebruikt, zowel voor FNA als FNB [14-17]. Deelne-
mers verrichten minder puncties van een verdachte laesie met een FNB-naald in vergelijking 
met een FNA-naald. Hoewel er op het moment van het uitsturen van de vragenlijst nog geen 
aanbevelingen werden gedaan, adviseren de huidige richtlijnen van de European Society of 
Gastroenterology (ESGE) inmiddels om inderdaad minder puncties te verrichten met FNB (2 tot 
3) dan FNA (3 tot 4), mits er geen patholoog aanwezig is tijdens de procedure [13]. In dat geval 
kan deze beoordelen of voldoende weefsel is afgenomen voor verdere diagnostiek.
de optimale EUS-naald
Zoals in de inleiding van dit proefschrift al genoemd, was en is het verbeteren van de EUS-
naalden een belangrijk doelwit van innovatie. FNB-naalden werden geïntroduceerd om de 
beperkingen van FNA te overkomen, voornamelijk door de collectie van histologie in plaats 
van cytologie. De diagnostische prestaties van de eerste FNB-naalden waren echter niet over-
tuigend beter dan die van de conventionele FNA-naalden [18-22]. Sommigen meldden dat FNB 
niet de histologische, maar slechts de cytologieopbrengst verbeterde [18, 23-29]. Anderen 
beweerden dat histologie ook verkregen kon worden met FNA-naalden [18, 30, 31]. Ten slotte 
maken nieuwe weefsel-collectie-media en bewerkingstechnieken, zoals de cell block techniek, 
een ‘histologieachtige’ analyse van cytologisch materiaal mogelijk.
De eerste FNB-naalden, waaronder de TruCuttm (Travenol Laboratories) en Quick-Core® 
(Cook Medical) naalden, waren relatief stug en lastig te hanteren, hetgeen weefsel afname 
vanuit een sterk gebogen endoscoop positie, zoals het duodenum, bemoeilijkte. Als reactie 
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hierop zijn de afgelopen jaren verschillende nieuwe FNB-naalden geïntroduceerd, waaronder 
twee typen ProCore naalden (reversed en forward facing bevel) en de SharkCore en Acquire 
naalden. Aangezien deze naalden qua ontwerp niet alleen aanzienlijk verschillen van de eerste 
generatie FNB-naalden, maar ook van elkaar, is er veel interesse in hun diagnostische prestaties.
De 20G ProCore forward facing bevel naald werd als eerste geïntroduceerd, in 2015, en de 
diagnostische prestaties zijn inmiddels uitgebreid onderzocht. De grootste studie is de inter-
nationale multicenterstudie (de ASPRO-studie; ASpiration versus PROcore), die in hoofdstuk 
3 wordt gepresenteerd. In deze studie wordt deze ProCore naald vergeleken met een veelge-
bruikte FNA-naald, de 25G EchoTip Ultra Needle (Cook Medical), gekozen vanwege zijn grote 
flexibiliteit en opbrengst [2, 13].
Onze studie demonstreerde een hogere weefselopbrengst en diagnostische nauwkeurig-
heid voor de 20G FNB-naald. Met FNB waren bovendien minder puncties nodig dan met FNA. 
Deze bevindingen golden zowel voor pancreas- als niet-pancreaslaesies en waren onafhankelijk 
van de afmetingen van de afwijking, het aantal verrichte puncties en de aanwezigheid van een 
patholoog. Bovendien presteerde de nieuwe FNB-naald consequent beter dan de FNA-naald in 
alle 13 deelnemende centra. Dit pleit voor de algemene toepasbaarheid van onze bevindingen, 
ook buiten de studiepopulatie.
De betere prestaties van de nieuwe 20G FNB-naald lijken te berusten op ontwerpaanpassin-
gen, waaronder een grotere naalddiameter, een nieuwe coating van de huls van de naald voor 
meer flexibiliteit, een naar voren in plaats van naar achteren gerichte inkeping voor weefselcol-
lectie aan de zijkant van de naald en gebruik van een Menghini in plaats van een lancetpunt. 
Dit laatste om de weerstand tijdens de punctie te verminderen. Het feit dat een FNB-naald met 
een grote diameter beter presteert dan een dunnere FNA-naald is een belangrijke observatie, 
omdat dit ingaat tegen het bestaande idee dat de opbrengst van naalden met een grotere di-
ameter wordt beperkt door hun suboptimale prestatie vanuit een gebogen endoscooppositie.
Hoewel de betere prestaties van de nieuwe 20G FNB-naald algemeen toepasbaar leken, 
namen alleen hoog volume of ‘expertcentra’ deel aan de studie. Om de reproduceerbaarheid 
van de bevindingen in minder ervaren handen te onderzoeken, werd een tweede studie uitge-
voerd. Zoals beschreven in hoofdstuk 4, vergeleken we de diagnostische overeenkomst tussen 
het oordeel van academische en niet-academische pathologen. De eerste 125 pancreas- en 
lymfeklierpuncties, vervaardigd tijdens de oorspronkelijke studie, werden herbeoordeeld door 
5 academische en 5 niet-academische pathologen uit verschillende landen. Monsters afgeno-
men met FNB gaven een hogere mate van overeenstemming voor het stellen van de diagnose 
dan de FNA-monsters. Dit gold zowel voor de academische als niet-academische pathologen. 
Logistische regressie toonde bovendien aan dat de diagnostische nauwkeurigheid van FNB 
niet werd beïnvloed door de achtergrond van de patholoog (academisch of niet-academisch). 
Dit ondersteunt het gebruik van de nieuwe 20G FNB-naald in zowel academische als niet-
academische centra.
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De meest waarschijnlijke verklaring voor de hogere mate van overeenstemming voor FNB-
monsters is dat deze vaker intacte weefselfragmenten bevatten. De kans dat pathologen het 
eens waren over de diagnose was namelijk groter voor histologische monsters. Hoewel ook de 
cytologische opbrengst voor FNB hoger was dan voor FNA, droeg alleen histologie bij aan een 
hogere diagnostische nauwkeurigheid. Een andere kwaliteitsparameter die de hogere diagnos-
tische nauwkeurigheid en overeenstemming van FNB-samples kan verklaren, is het minimaal 
aantal artefacten in de FNB-samples. Onze bevinding dat weefselartefacten de diagnostische 
nauwkeurigheid van EUS-monsters verlaagd, wordt ondersteund door eerder onderzoek, dat 
aantoonde dat artefacten aanvullende tests lastiger maken [32]. De overeenstemming over 
de aanwezigheid van artefacten was vrij laag voor FNA en FNB, hoewel iets beter voor FNB. 
Dit is in overeenstemming met het feit dat de pathologen het überhaupt weinig eens waren 
over weefsel-kwaliteitsparameters. Dit werd ook door anderen vastgesteld [33, 34] en lijkt het 
gevolg van het gebrek aan uniforme kwaliteitsparameters voor EUS-geleide weefselafname.
Om de optimale techniek voor EUS-geleide weefselafname vast te stellen onderzoeken we 
in hoofdstuk 5 de rol van het gecombineerde gebruik FNA- en FNB-naalden. De voordelen 
van een FNA-naald: optimale flexibiliteit om een  target laesie te bereiken en de mogelijkheid 
van cytologische evaluatie door een patholoog ter plaatse, zouden de voordelen van FNB 
kunnen aanvullen: het verkrijgen van histologisch weefsel om de diagnostische opbrengst 
te optimaliseren en genoeg weefsel over te houden voor aanvullende diagnostiek. Om de 
waarde van gecombineerd FNA- en FNB-gebruik, of ‘dual-sampling’, nader te onderzoeken, 
includeerden wij alle 73 ASPRO-casussen waarbij tijdens dezelfde procedure met beide naalden 
was gepuncteerd. Bij 24 patiënten werd eerst de 25G FNA-naald gebruikt en in 49 eerst de 
FNB-naald. Interessant is dat de diagnostische nauwkeurigheid voor het vaststellen van een 
maligniteit alleen toenam als een punctie met FNA werd gevolgd door FNB en niet andersom. 
Het eerder bewezen diagnostische voordeel van de 20G FNB- ten opzichte van de FNA-naald 
kan dit uiteraard goed verklaren. Een andere verklaring is dat eerst prikken met FNB mogelijk 
meer bloedcontaminatie veroorzaakt voor de daaropvolgende FNA-punctie, of dat de er door 
de grotere diameter van de FNB-naald “tracking” ontstaat, waardoor de diagnostische route 
van de FNA-naald negatief wordt beïnvloed. Tot slot werd een punctie met FNA na FNB meestal 
gebruikt voor ROSE. Aangezien de toegevoegde waarde van ROSE twijfelachtig is voor expert-
centra, was de meerwaarde van ROSE in de deelnemende centra waarschijnlijk beperkt [35-37].
In hoofdstuk 6 verlaten we de twee eerdergenoemde EUS-naalden en geven we in een 
meta-analyse een overzicht van de prestaties van alle gangbare EUS-naalden. Hiervoor voer-
den we een systematische zoekopdracht uit in EMBASE, MEDLINE / PubMed, Web of Science, 
de Cochrane Library en Google Scholar naar alle studies die FNA met de eerder genoemde 
nieuwe generatie FNB naalden vergeleken. We beperkten de selectie tot gerandomiseerde 
studies van ten minste 50 deelnemers en extraheerden hieruit gegevens over de diagnostische 
nauwkeurigheid, de weefselkwaliteit, de aanwezigheid van histologie in de samples, het aantal 
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verrichtte puncties en de kans op complicaties. Hiernaast werd de studiekwaliteit beoordeeld 
met behulp van de QUADAS-2-tool.
In vergelijking met eerdere meta-analyses maakte de recente golf aan publicaties het 
mogelijk een aanzienlijk aantal nieuwe studies te includeren en ons te beperken tot studies van 
hoge kwaliteit [18-22]. Voor het eerst werd een diagnostisch voordeel van FNB ten opzichte van 
FNA aangetoond, zowel voor laesies in als buiten de pancreas. FNB leverde een hogere diagnos-
tische nauwkeurigheid en monsters bevatten vaker intacte histologische weefselfragmenten. 
Bovendien waren hier minder puncties voor nodig dan met FNA. De kans op complicaties was 
laag voor zowel FNA als FNB en verschilde niet significant. Hoewel FNB vaker tot een correcte 
diagnose leidde, werden monsters niet vaker als voldoende geschikt bevonden voor diagnos-
tiek. Dit kan worden verklaard door het feit dat de mate van geschiktheid voor diagnostiek 
vaak wordt beoordeeld op basis van het aantal losse cellen, de cytologie. Mogelijk is dit minder 
belangrijk voor het stellen van een correcte diagnose dan de aanwezigheid van histologisch 
intacte weefselfragmenten. Zelfs ondanks het gebruik van nieuwe verwerkingstechnieken 
voor cytologie, zoals ThinPrep en cell block, en het gebruik van ROSE, was de diagnostische 
nauwkeurigheid beter voor FNB.
Bij het extrapoleren van onze bevindingen naar andere centra dient men rekening te 
houden met de significante heterogeniteit tussen de studies in de meta-analyse. Dit komt 
vooral door de diversiteit in EUS-weefselafnameprotocollen en het inconsistente gebruik van 
uitkomstdefinities. Dit maakt de resultaten van EUS-studies moeilijk te interpreteren. Hoewel 
de huidige meta-analyse aantoonde dat FNB overtuigend beter presteerde dan FNA, betrof dit 
alleen de ProCore FNB-naald, aangezien alle studies in de meta-analyse met deze FNB-naald 
waren uitgevoerd. Er zijn op dit moment nog geen studies van voldoende kwaliteit beschikbaar 
waarin één van de andere nieuwe generatie FNB-naalden, zoals de Acquire en SharkCore naald, 
is getest, alhoewel volgens ClinicalTrials.gov er enkelen onderzoeken lopen.
Verbeteren van EUS-weefselpreparatie en -verwerking
Zoals eerder vermeld, stellen nieuwe FNA-weefselpreparatietechnieken zoals ThinPrep en 
cell block pathologen in toenemende mate in staat om aanvullende testen uit te voeren op 
cytologische samples. Deze technieken zijn geïntroduceerd om de kwaliteit en nauwkeurigheid 
van FNA-monsters te verbeteren, aangezien de traditionele smear-techniek gevoelig is voor 
artefacten. Een andere manier om dit probleem op te lossen is investeren in de aanwezigheid 
van een patholoog tijdens de procedure om het verzamelde weefsel direct te beoordelen en te 
verwerken. In de meeste centra ontbreekt echter deze mogelijkheid. Daarom wordt de eerste 
bewerking van EUS-FNA-materiaal vaak door endoscopiemedewerkers gedaan, meestal zonder 
formele training in weefselcollectie en -preparatie.
hoofdstuk 7 onderzoekt of een eendaagse ‘hands-on’ EUS-weefselpreparatietraining voor 
endoscopiepersoneel de kwaliteit en dus de diagnostische nauwkeurigheid van FNA-monsters 
kan verbeteren in centra zonder ROSE. In een prospectieve pilotstudie volgden 10 endo-
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echoscopisten en 12 endoscopieverpleegkundigen uit 7 regionale EUS-centra in Nederland een 
training. Zij werden onderwezen in pancreaspathologie, algemene diagnostische valkuilen en 
de oorzaak en preventie van artefacten van weefseluitstrijkpreparaten. Vervolgens oefenden 
zij het maken van uitstrijkpreparaten onder supervisie van een team van academische (cyto)
pathologen. Na de training verzamelden we prospectief 71 FNA-weefseluitstrijken van solide 
pancreaslaesies en vergeleken we deze met een gelijk aantal ‘controleuitstrijkpreparaten’, 
welke waren vervaardigd voor de training.
Helaas verbeterde onze training de kwaliteit en nauwkeurigheid van de EUS-FNA-weef-
seluitstrijken niet significant. Door de beperkte steekproefomvang konden we de individuele 
resultaten niet analyseren en dus niet beoordelen of er individuen wel baat had van de training. 
Voor het beperkte effect van onze pilot-training zijn meerdere verklaringen denkbaar. Ten eer-
ste was de training zelf misschien te kort of was één training te weinig. Aangezien praktische 
vaardigheden over het algemeen beter worden na een uitgebreide training en verder verbete-
ren na frequente en repeterende oefening, was het wellicht effectiever geweest om de training 
te intensiveren of te herhalen. De studieperiode was daarbij mogelijk te kort om de deelnemers 
voldoende ervaring op te laten doen. Ten slotte kan het gebrek aan kwaliteitsverbetering ook 
inherent zijn aan de aard van de uitstrijktechniek zelf, omdat het een handmatige methode is 
die gevoelig is voor artefacten en heterogene preparaten. De eerdergenoemde alternatieve 
technieken: ThinPrep en cell block zijn hiervoor minder gevoelig [38].
hoofdstuk 8 vergelijkt de diagnostische prestaties van deze alternatieve cytologieverwer-
kingstechnieken, LBC, met de conventionele weefseluitstrijktechniek voor EUS-FNA van solide 
pancreaslaesies. Het EUS-personeel van de eerdergenoemde 7 regionale EUS-centra was voor 
het starten van deze studie reeds getraind in het uitstrijken van FNA-weefsel, volgens de trai-
ning beschreven in hoofdstuk 7. Voor deze studie vervaardigden de deelnemers van elke eerste 
FNA-punctie monsters twee weefseluitstrijkjes en een flesje met weefsel in een vloeibaar 
medium, ThinPrep en/of cell block. Er mocht hierbij uiteraard geen patholoog op de kamer 
aanwezig zijn. We vergeleken de diagnostische waarde van beide technieken op basis van de 
weefselkwaliteit, de diagnostische nauwkeurigheid voor maligniteit en de overeenstemming 
over de weefseldiagnose onder de drie (cyto)pathologen.
De studie liet zien dat de diagnostische nauwkeurigheid hoger was voor LBC dan voor de 
uitstrijktechniek. Dit was echter alleen waar indien de opbrengst van ThinPrep en cell block 
werden samengenomen. Artefacten waren minder aanwezig in beide LBC-technieken. De 
pathologen bereikten even vaak overeenstemming over de diagnose voor LBC en weefseluit-
strijkjes en waren het vaker eens over de cell block samples. Gezien de hogere nauwkeurigheid 
en vergelijkbare diagnostische overeenstemming onder de (cyto)pathologen, zou LBC een 
alternatief kunnen zijn voor centra zonder ROSE. Gezien de hoge mate van overeenstemming 
tussen de pathologen zou de cell block techniek de voorkeur hebben boven ThinPrep.
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Toekomstperspectieven en aanbevelingen voor de toekomst
De historische grens tussen FNA en FNB lijkt te vervagen doordat de naalden vrijwel niet meer 
op basis van hun design te onderscheiden zijn. Om de zaken nog verder te compliceren, zijn er 
beduidende ontwerpverschillen binnen de FNA- en FNB-groepen. Hieruit voortvloeiend zouden 
wij willen pleiten voor het verlaten van de huidige nomenclatuur van FNA en FNB, en in plaats 
hiervan de nadruk willen leggen op de prestaties van individuele EUS-naalden.
Dit proefschrift biedt belangrijke nieuwe informatie die kan worden gebruikt om EUS-
geleide weefselafname te verbeteren. Er is echter ruimte voor verdere ontwikkeling, aangezien 
onder meer de meta-analyse in dit proefschrift aantoont dat de diagnostische nauwkeurigheid 
voor FNA nog steeds varieert tussen 67% en 100% en voor FNB tussen 69% en 100%. Dit proef-
schrift stelt dat een FNB-naald beter presteert dan FNA, en dus de eerste keuze zou moeten zijn 
voor door EUS-geleide weefselafname, onafhankelijk van de soort afwijking (gelegen binnen de 
pancreas of daarbuiten). Voordat men echter één specifieke EUS-naald kan aanbevelen moeten 
de diagnostische prestaties van alle nieuwe generatie FNB-naalden in kaart worden gebracht 
en vergeleken.
Hoewel men idealiter elk type EUS-naald ‘head to head’ zou willen vergelijken, zal dit een 
uitdaging zijn. Allereerst is het een tijdrovende, maar niet onmogelijke klus vanwege de vele 
beschikbare FNA- en FNB-formaten en -designs. Andere complicerende factoren zijn de hetero-
geniteit in EUS-weefselafnameprotocollen en het ontbreken van uniforme uitkomstdefinities. 
Zolang er geen bewijs is voor de optimale EUS-geleide weefselafnamestrategie zal het moeilijk 
zijn om uniforme EUS-strategieën te implementeren. Makkelijker te bewerkstellen is het creëren 
van uniforme uitkomstdefinities. Hierin zouden de Europese en Amerikaanse verenigingen voor 
gastro-enterologie een belangrijke rol kunnen spelen, zoals ook de Papanicolaou Society (de 
internationale pathologievereniging) deed voor de diagnostische classificatie van EUS-weefsel.
Naast de optimale EUS-naald, focust dit proefschrift zich op de preparatie en verwerking 
van EUS-FNA-monsters. Men kan zich afvragen of toekomstig onderzoek zich hierop moet blij-
ven richten, aangezien wij aantoonden dat FNB beter is dan FNA. We hebben echter niet direct 
onderzocht of FNB-weefsel nog steeds beter presteert indien FNA-weefsel is verwerkt middels 
LBC. Het zou interessant zijn dit te onderzoeken in een internationale multicenterstudie. In dit 
kader is het belangrijk te benoemen dat weefselbewerking middels LBC gemakkelijk is voor 
de endo-echoscopisten, maar niet voor het pathologiepersoneel, aangezien men hiervoor een 
goed uitgerust pathologielaboratorium en getraind personeel nodig heeft. Om die reden zal het 
implementeren van nieuwe technieken en innovaties voor EUS-geleide weefselafname idealiter 
altijd moeten worden afgestemd met de pathologieafdeling. Ten slotte is het cruciaal dat, ge-
zien de toenemende kosten van de gezondheidszorg, kosteneffectiviteitsanalyses plaatsvinden 
voordat innovaties in de praktijk geïmplementeerd worden.
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